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A case report of one of our patients with postpartum psychosis
Mrs. B, a 28-year-old woman with no prior psychiatric history, delivered a healthy daughter 
after a first, normal pregnancy. During the first two days postpartum, she was breastfeeding 
her daughter with notably reduced sleep. By the third day postpartum, she became 
convinced that her husband wanted to kill their newborn. After her mother suggested 
that she discontinue breastfeeding, she became extremely violent, kicking her mother in 
the abdomen. Over the next 4 days, the family continued to struggle as Mrs. B became 
progressively more impulsive, irritable, and disorganized. 
 One week postpartum, she was admitted to the Mother-Baby Unit of the Erasmus MC. 
During the admission interview, she exposed her breasts while shouting: “Look at these!  My 
breasts are great! I want to breastfeed 24 hours non-stop!” She was diagnosed as manic 
with psychotic features (Young Mania Rating Scale 34). Physical examination and routine 
laboratory investigations were normal. She was treated with haloperidol and lorazepam. 
One week after admission, she remained actively manic with psychotic features, requiring 
the addition of lithium. On a combination of haloperidol, lithium, and lorazepam, her manic 
and psychotic symptoms went into remission over the next 3 weeks. She was discharged 
home from the hospital seven weeks after delivery, with close outpatient follow-up, lithium 
monotherapy, and mother-child interaction therapy.
 Three months postpartum, she was diagnosed with autoimmune thyroiditis and thyroxine 
replacement was started. Lithium therapy was discontinued after 9 months. During a follow-
up of two years she did not experience major psychiatric symptoms. 
During the outpatient follow-up period following discharge from the hospital, the following 
important questions were raised by the patient, of which the literature provided incomplete 
answers:
•  “What happened? What triggered this totally unexpected bizarre behavior right after 
having my baby?”
• “I got better with a lot of medication, do I really need all these pills?”
•  “My thyroid disease, was that coincidental or does it have anything to do with my 
psychosis?”
•  “What will happen to me in the future, will I become ill again?”
•  “What happens if we want to have another baby?”
Unfortunately however, there was insufficient evidence in the literature to provide Mrs. 
B with answers to these important questions, many of which are necessary to optimally 
guide her clinical care. Therefore, in 2005 we designed a postpartum psychosis study 
to examine both clinical as well as pathophysiological questions: the OPPER study 
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(Onderzoeksprogramma Postpartum Psychose Erasmus MC Rotterdam). Among the many 
reasons for the limited evidence base in the literature regarding postpartum psychosis is 
the relatively low incidence. Encouraging of the research potential, we treat postpartum 
psychosis on a relatively large scale because our psychiatric ward at the Erasmus Medical 
Center has the ability to admit postpartum patients together with their baby. Accordingly, 
over the past 7 years, the OPPER study has evolved into the largest prospective cohort in 
the world of patients with first-onset postpartum psychosis. We have defined several risk 
factors, aspects of phenomenology, neurobiology and longitudinal follow-up of patients 
with postpartum psychosis and no prior episode of mania or psychosis. In this thesis, we 
present the foundational results of our study, describing postpartum psychosis from both 
clinical (part I) and pathophysiological perspectives (part II). 
In Part I – Clinical perspective we try to answer the following research questions: 
- Is postpartum psychosis a distinct disease entity?
- What are risk factors?
- What is the most favourable treatment?
- What is the prognosis, how can we prevent further episodes?
Chapter 2 starts with a clinical review of postpartum psychosis. We describe diagnosis, 
history, phenomenology and the relation with bipolar disorder. At the end of chapter 2, 
our treatment algorithms for both postpartum psychosis and postpartum depression with 
psychotic features are introduced. 
The objective of Chapter 3 is to assess obstetric, neonatal, and lactational risk factors for 
postpartum psychosis in women with first-onset postpartum psychosis compared to a 
population-based cohort. We also describe phenomenological characteristics of our patients 
and treatment response. 
In Chapter 4, we have investigated prevention of postpartum psychosis and mania in 
patients at high risk: Patients with bipolar disorder and patients with a history of postpartum 
psychosis but no manic or psychotic symptoms outside the postpartum period.  
Part II aims to identify aspects of the biological pathophysiology of postpartum psychosis: 
- Does the rapid onset, proximity to childbirth, and dissociability from social factors give  
 us a clue about aetiology?
- Is there an immune related trigger underlying postpartum psychosis?
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In Chapter 5, we discuss the current prevailing hypotheses regarding the aetiology of 
postpartum psychosis and we comprehensively summarize previous neurobiological studies.
In Chapter 6, we have introduced a novel “immune theory of postpartum psychosis”, which 
led to the research described in Chapter 7 and 8. 
The aim of Chapter 7 is to determine the prevalence of autoimmune thyroid dysfunction in a 
consecutive series of primiparous women with postpartum psychosis, compared to healthy 
postpartum women.
In Chapter 8, we have investigated monocyte gene expression and T-cell activation in women 
with postpartum psychosis. Patients were matched to postpartum and non-postpartum 
healthy controls. 

Part I
Clinical perspecti ve
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A clinical review of postpartum psychosis
Parts of this chapter have been published:
Bergink V, Koorengevel KM. Postpartum depression with psychotic features
Am J Psychiatry. 2010 Apr;167(4):476-7.
Noorlander Y, Bergink V, van den Berg MP. Perceived and observed mother-child interaction at time 
of hospitalization and release in postpartum depression and psychosis. Arch Womens Ment Health 
2008;11(1):49-56.
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Epidemiology, phenomenology and diagnosis
After childbirth, women are vulnerable to the onset of serious psychiatric symptomatology. 
Women are approximately 22 times more likely to experience the onset of a manic or 
psychotic episode in the first month postpartum than at any other time in their lives. 
Postpartum psychosis is the most severe form of childbirth related psychiatric illness. The 
prevalence of postpartum psychosis in the general population is estimated as 1-2 per 1000 
childbirths (1-3).
In the majority of cases, the onset is rapid and within 2 weeks postpartum (4, 5). 
The early symptoms include insomnia, mood fluctuation, and sometimes obsessive 
concerns regarding the newborn, followed by more severe symptoms such as delusions, 
hallucinations, disorganized behavior, and serious mood symptoms (6, 7). The occurrence of 
these severe mood symptoms such as mania, depression, or a mixed state is very prominent 
in postpartum psychosis. Affective phenomenology seems to be a hallmark of the disease 
and is more prevalent in postpartum psychosis compared to non-postpartum psychosis (8). 
Apart from its prominent affective symptoms, postpartum psychosis is also famous for its 
curious delirium-like appearance. Women with postpartum psychosis sometimes exhibit 
atypical cognitive symptoms such as disorientation, confusion, perplexity, misrecognition 
of people, derealisation, and depersonalization (4, 8-10). Of note, there is a relatively low 
incidence of schizophrenia-like symptoms, such as “Schneiderian first-rank symptoms” (7-
10). Together, given that postpartum psychosis is generally considered a mood disorder and 
not a primary psychotic disorder, the term postpartum psychosis is therefore somewhat 
misleading.
By far, the most important risk factors of postpartum psychosis are a history of bipolar 
disorder or a previous episode of postpartum psychosis. In either case, the risk of 
postpartum psychosis is estimated as 25-50% following every (subsequent) delivery. A family 
history of postpartum psychosis or bipolar disorder is also a well-known risk factor. Several 
family studies have consistently reported familial aggregation of psychiatric (particularly 
affective) disorders for first degree relatives of women with postpartum psychosis (11). 
Previous studies have suggested a number of demographic and clinical variables that may 
be associated with postpartum psychosis, such as primiparity and complications during 
delivery (12). Indeed, primiparity has been repeatedly observed as a significant covariate 
in modeling the risk factors for postpartum psychosis. However, a recent large population-
based study in primiparous mothers without previous psychiatric hospitalization found no 
significant influence of delivery complications on the risk of postpartum psychosis (13). 
Furthermore, no significant evidence has ever implicated psychosocial factors.
Chapter 2
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Postpartum psychosis must be clearly differentiated from postpartum depression (Table 
1). In particular, postpartum depression refers to a non-psychotic depressive episode that 
affects approximately 10% of mothers after childbirth. Women with postpartum depression 
experience symptoms of misery, apathy, irritability, social isolation, anxiety, failure to cope 
and guilt, which are likely to have an impact on a mother’s relationship with her child. Like 
non-puerperal depression, this disease entity is highly heterogeneous: psychosocial risk 
factors, such as a poor social background, lack of support, and stressful life events, factor 
prominently in the risk and clinical manifestations. Postpartum depression has a markedly 
different onset from postpartum psychosis. The onset of postpartum depression is highly 
variable: often with symptoms during pregnancy (in almost half of the cases), as well as 
episodes of depression with their onset throughout the entire first year postpartum (14-16). 
Table 1 Mood Symptoms and Syndromes during the Postpartum Period
Estimated 
incidence
Onset Frequent symptoms Management
Maternity 
“blues”
50 % 3-5 days postpartum Emotional lability, 
moodswings, anxiety
Self-limited, emotional 
support
Postpartum 
depression
10 % Variable window: 
during pregnancy 
up to one year 
postpartum 
Low mood, feelings of 
guilt, impaired feelings of 
bonding with the child 
Psychotherapy, antide-
pressant medication, 
mother-baby therapy
Postpartum 
psychosis*
0.1-0.2% Within 4 weeks 
postpartum (usually 
within 2 weeks)
Agitation, irritablility,  
euphoric mood, 
depression, delusions, 
hallucinations, confusion, 
cognitive symptoms
Hospitalization, medical 
workup, lithium, 
antipsychotics, ECT
*including postpartum mania and postpartum depression with psychotic features
Although an early postpartum onset is typical for postpartum psychosis, prodromal 
symptoms of postpartum psychosis are sometimes difficult to distinguish from the normal, 
physiological maternity blues. About half of recently delivered mothers experience the 
maternity blues between day 3 and 5 postpartum. This term refers to the brief occurrence 
of dysphoria, irritability and mood swings. In contrast to postpartum psychosis, the duration 
of maternity blues ranges from a few hours to a few days, and for which the more severe 
symptoms that define postpartum psychosis are entirely absent (Table 1) (6).
 Understandably, most studies and scientific reviews have focused on postpartum blues 
and depression. The relatively low incidence, the clinical severity, and diagnostic uncertainty 
regarding the proper classification of postpartum psychosis have all contributed to the 
paucity of research. In moving forward with a comprehensive research program, the history 
of postpartum psychosis and changes in its definition over time are illustrative. 
A clinical review of postpartum psychosis
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Diagnostic classification of postpartum psychosis: a brief history
One of the initial case reports of postpartum psychosis arose from the autobiographical 
work of Margery Kempe who delivered her first baby in the United Kingdom in 1393 (17). 
In brief, she described that she became gravely ill after delivery and called for a priest. The 
priest was not a very sensitive person as he began to censure her before she could divulge 
her sins, and then left. Fearing eternal damnation, she fell into a delusional state, where she 
described seeing devils around her.  Because she tried to throw herself out of the window 
and tried to bite through the veins in her wrist, her husband John chained her in a storeroom. 
After six months, she saw Jesus sitting at her bed side; the effect was miraculous as she was 
suddenly sane. She went into a domestic brewing business and after two years she became 
the biggest beer-maker in town. 
 Later case reports from Germany, France and the United Kingdom describe similar 
cases: women with an acute onset of severe affective psychosis immediately postpartum. 
Importantly, some of these case reports described women with multiple postpartum 
episodes but none outside the postpartum period, which suggested the existence of a 
specific postpartum disease. Over time, several names have been given to this postpartum 
disease, such as: “mania lacteal”, “amentia”, “puerperal insanity”, “puerperal psychosis”, 
“puerperal mania”, “dreamlike delirium”, and finally “postpartum psychosis”. Since the 18th 
century, postpartum psychosis has been widely appreciated as a severe disease, requiring 
acute intervention (16, 18). 
 The first treatments described were cutting of hair, applying ice packs to the head, and/or 
application of leeches. In the 19th century, physicians focused on the control of excitement, 
guarding against suicide, and supportive management pending an expected spontaneous 
remission (16, 19). Remarkably, current treatments of postpartum psychosis do not have 
a substantially improved empirical basis than the treatments over the last centuries (20). 
Furthermore, in the second half of the 20th century, the diagnostic category of “postpartum 
psychosis” was abolished: the prevailing view from experts in the field has been that 
postpartum psychoses are not specific and fall mainly within the bipolar spectrum.
 Childbirth is considered a general stressor, which can trigger an attack of any kind of 
psychiatric illness. Accordingly, the widely used American psychiatric classification system 
(DSM-IV: Diagnostic Statistic Manual of Disease) does not have a specific category for 
postpartum psychosis. Further, in this regard the outcome of the upcoming fifth edition 
of the DSM is reported to be highly similar to the current edition, i.e. without a separate 
disease category for postpartum psychosis (personal communication, perinatal congress, 
Pittsburgh 2010).
 Meanwhile in the United Kingdom, the British psychiatric classification system ICD-10 
(International Classification of Disease) contains a specific section entitled “mental and 
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behavioral disorders associated with the puerperium”. Notably, however, the addendum to 
this section encourages a very cautious use of this category:
“Most experts in this field are of the opinion that a clinical picture of puerperal psychosis 
is so rarely (if ever) reliably distinguishable from affective disorder or schizophrenia that a 
special category is not justified. Any psychiatrist who is of the minority opinion that special 
postpartum psychoses do indeed exist may use this category, but should be aware of its real 
purpose”. 
 Despite these serious warnings, and while the term “postpartum psychosis” is officially 
excommunicated, there is an undiminished interest from researchers to understand this 
phenomenon. In particular, over the last decades clinical research has focused intensely on 
the strong link with bipolar disorder. 
Postpartum psychosis and bipolar disorder
Women with a diagnosed bipolar disorder are at very high risk (25-50%) for affective 
psychosis in the weeks following delivery (21). Importantly, however, the majority of women 
presenting with postpartum psychosis do not have a history of bipolar disorder.
In patients with first-onset postpartum psychosis, researchers have widely hypothesized 
a link between postpartum psychosis and bipolar disorder (for review see Chaudron and 
Pies (22)).  Cross sectional symptomatology, family history data, and the longitudinal illness 
course all support the notion of a strong link to bipolar disorder. First, most studies have 
shown a preponderance of manic symptoms in postpartum psychosis. Further, family studies 
of patients with postpartum psychosis have consistently found the risk for bipolar disorder 
to be higher than the risk within the general population. Lastly, a widely-held estimate is that 
after an incipient postpartum affective psychosis, a woman has between 40-80 % chance of 
developing an bipolar disorder (22).
Treatment
Postpartum psychosis is a psychiatric emergency that requires immediate medical attention 
and psychiatric referral. Inpatient psychiatric treatment is essential to ensure the safety of 
mother and baby. Within the UK, national guidelines (NICE) recommend that all women 
requiring postpartum admission are admitted with their infants to specialist Mother and Baby 
Units (MBU). There is some evidence that admission to a MBU is associated with improved 
satisfaction with care and reduced time to recovery. In the Netherlands, few psychiatric or 
general hospitals have an MBU: combined mother-baby admission is only possible within 
the Netherlands at Erasmus MC Rotterdam, RPC Woerden, and RGC Apeldoorn.
A clinical review of postpartum psychosis
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The initial clinical evaluation for postpartum psychosis requires a thorough history, physical 
and neurological examination and laboratory analysis to exclude known organic causes for 
acute psychosis. There are case reports on misdiagnosis of postpartum psychosis revealing a 
late-onset urea cycle disorder (23), paraneoplastic encephalitis (24), citrullinemia type I (25), 
and primary hypoparathyroidism (26). Differential diagnosis should further include infectious 
diseases, eclampsia, autoimmune diseases, metabolic diseases, vitamin deficiencies, stroke 
and drug-induced psychosis (27). Therefore, tests should include a complete blood count, 
electrolytes, blood urea nitrogen, creatinine, calcium, liver function tests, glucose and 
thyroid function. With proper indication, head CT or MRI scan, vitamins B1, B12 and folate, 
urinalysis and urine drug screen should also be performed.
 For any mother who presents with a postpartum mood disorder, the clinician must 
inquire about thoughts of harming herself or the infant. Delusional thoughts about harm to 
the infant or herself in postpartum psychosis are ego-syntonic and associated with psychotic 
belief. The urge to act on psychotic beliefs, combined with loss of reality testing, can quickly 
and easily lead to dangerous life-threatening situations. 
Pharmacotherapy
Little is known about what interventions are most effective for patients with postpartum 
psychosis, as research has been very limited and no randomized trials have been performed. 
In total, only 17 treatment studies of postpartum psychosis can be found in the recent 
literature (20). Sample sizes are very small:  9 are case reports describing a single patient and 
only 2 studies included more than 10 patients. These studies exclusively used a retrospective 
design and a wide variety of diagnostic criteria to determine study inclusion and intervention 
efficacy. Only one previous treatment study reported using standardized diagnostic criteria. 
 The effects of lithium, antipsychotics, ECT, hormones and propranolol were examined. 
Lithium and antipsychotic medication are commonly used in the treatment of postpartum 
psychosis, however the evidence to support these treatment options is scarce. Lithium was 
found to be effective in one case study where it was used as monotherapy (28), and in 
two studies where it was used as adjunctive therapy (29, 30). The effects of antipsychotics 
have been described in four case reports, for which treatment was reportedly successful on 
chlorpromazine, clozapine and pimozide (20).
 Three studies have explored the influence of ECT in the treatment of PP. In one case 
study, treatment with chlorpromazine was ineffective, while ECT treatment led to remission 
(31). Similarly, a case series of 5 women with treatment refractory PP described positive 
treatment outcomes with ECT (32). Furthermore, a retrospective study compared the 
clinical responses to ECT of women with postpartum psychosis to outcomes following ECT 
in women with non-postpartum psychosis. Notably, the postpartum group was found to 
have greater clinical improvement following ECT compared to the non-postpartum group 
Chapter 2
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(33). Three studies conducted by the same group have found beneficial effects of estrogen 
(34-36). The potential beneficial use of progesterone and hormonal replacement therapy 
have been described through case reports (37). Other case reports have provided support 
for propranolol (a beta-adrenergic blocker used to treat hypertension) as a treatment option 
for postpartum psychosis (38).
 In the Erasmus MC, treatment of postpartum psychosis is administered using the clinical 
guidelines for the treatment of mania in bipolar I disorder (39).  This algorithm is based on 
our clinical experience, guided by the larger literature for treatment of bipolar patients. 
Specifically, all patients are initially treated with benzodiazepines.  For those patients 
without a marked improvement on benzodiazepine monotherapy, antipsychotic medication 
is initiated within the first week of admission. After 2 weeks of combination antipsychotic/
benzodiazepine treatment, adjunctive lithium is initiated in those patients without a 
significant clinical response.
 Unfortunately, few treatment recommendations are available in the literature regarding 
the treatment of postpartum depression with psychotic features. According to DSM-IV 
criteria, postpartum depression with psychotic features does not constitute a bipolar 
depression. However based on our clinical experience, we have followed the view that early-
onset postpartum depression is likely to have a bipolar diathesis, particularly if psychotic 
features are present. Therefore, we followed the guidelines for treatment of bipolar II 
depression in patients with the acute onset of depression with psychotic features during the 
postpartum period, even in the absence of hypomanic symptoms immediately postpartum 
or of a history of hypomania (40).
 Of our patients (n=7) diagnosed with a major depressive episode with psychotic features 
and an onset of symptoms within 4 weeks of the postpartum period, six women were 
treated with lithium and antipsychotics and one woman refused treatment. For all except 
one woman, the depression went into complete remission. The one patient who did not 
respond to treatment with lithium and antipsychotics received ECT, and her depression 
subsequently remitted (40). 
 We do not know what would have happened if we had treated these seven women 
with antidepressants, but in our opinion antidepressant treatment could have put these 
patients at an unacceptable risk for exacerbation of symptoms. Similar to Sharma et al. (41, 
42), we also have the clinical experience that antidepressants should be used cautiously 
in the postpartum period. Over the last 4 years, eight postpartum patients were referred 
to our clinic as a result of a very unstable illness course (manic and psychotic symptoms) 
after treatment with antidepressants (Table 2). Future studies will need to be performed to 
define an optimal treatment algorithm for postpartum depression with psychotic features.
A clinical review of postpartum psychosis
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Table 2 Clinical and Treatment Characteristics of Women with an Unstable Disease Course after 
Receiving Antidepressants (AD) in the Postpartum Period.
Psychiatric 
history
Age
Years
Parity Postpartum 
diagnosis
Onset 
post-
partum
AD
treatment
Adverse 
effect 
treatment
1 Anorexia 
Nervosa
37 P3 Postpartum 
anxiety 
30 days citalopram psychosis Stop AD 
2 Postpartum 
depression
32 P3 Postpartum 
depression
2 days paroxetine mania Stop AD, 
Lithium
3 None 29 P2 Postpartum 
anxiety
7 days sertraline anxiety and
hallucinations
Stop AD
4 Depression
Cannabis 
use
31 P1 Postpartum 
depression
7 days citalopram psychosis Stop AD, 
lithium, 
haloperidol
5 Depression 29 P1 Postpartum 
depression
7 days clomipramine mania Stop AD, 
lithium
6 None 32 P1 Postpartum 
depression
18 days citalopram psychosis Stop AD, 
lithium
7 Psychosis 
NOS
31 P1 Postpartum 
depression
6 days sertraline psychosis Stop AD, 
lithium, 
olanzapine
8 None 27 P2 Postpartum 
depression
10 days citalopram mixed 
episode
Stop AD, 
lithium, 
olanzapine
AD= antidepressant
Mother infant bonding 
Interrupted development of a secure mother–infant bond can lead to long-term problems 
in a child’s emotional, cognitive and behavioral development (43). Importantly, severe 
postpartum psychiatric disorders, such as postpartum psychosis, represent a major 
challenge to maintaining the integrity of mother–infant bonding while symptoms persist. 
Two small studies have confirmed a deleterious influence of postpartum psychosis on 
mother–child bonding during the acute phase of the illness (44, 45).  Remarkably however, 
a recent study from our group demonstrated that women with a postpartum psychosis, in 
contrast to postpartum depression, experience hardly any difficulties establishing a bond 
with their child after discharge from the hospital (46). Therefore, a more comprehensive 
series of studies is required to define optimal treatment algorithms for specific postpartum 
psychiatric disorders based upon empirical evidence and long-term outcomes.
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Prevention of subsequent episodes
The strongest predictors for postpartum psychosis are a history of bipolar disorder and/or 
postpartum psychosis (3, 20, 22).  Consequently, guiding women at high-risk for psychosis 
through pregnancy and the postpartum period is a major challenge for mental health 
practitioners and obstetricians (47-49), for which safe and effective relapse prevention 
would be the optimal strategy. 
 Six studies have assessed the efficacy of various prophylactic treatments for prevention 
of postpartum psychosis in bipolar patients: lithium (3 studies) (50-52), estrogen, valproate 
and olanzapine (53-55).  In all 3 studies using lithium, bipolar women receiving prophylactic 
treatment had significantly lower rates of postpartum psychosis.  In contrast, both estrogen 
and valproate failed to demonstrate significant prophylactic benefits. Olanzapine prophylaxis 
was equivocal and therefore warrants further investigation. Notably, a major limitation 
of these studies was that they included both women who initiated prophylaxis during 
pregnancy and postpartum, without differentiating between these groups. However, the 
timing of onset for pharmacological prophylaxis is of paramount clinical importance given 
that the benefits of prophylaxis during pregnancy need to be carefully weighed against the 
risks for the fetus (56). 
A clinical review of postpartum psychosis
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Abstract
Objective: To prospectively characterize a cohort of patients for whom their first lifetime 
episode of psychosis occurs in the postpartum period.
Methods: Included in the study were 51 women admitted for postpartum psychosis and 
a population-based control group (n=6969). All patients received naturalistic treatment 
using the sequential addition of benzodiazepines, antipsychotics, and lithium. A clinician-
administered questionnaire and parallel history provided information about obstetric 
history, pregnancy, delivery, breastfeeding, neonatal outcomes, and onset of the disease. 
Clinical remission was defined as the absence of psychotic, manic and depressive symptoms 
for at least 1 week. The study was conducted from 2005 to 2009.
Results: Compared to the general population sample, women with postpartum psychosis 
had a significantly higher incidence of primiparity, but had no significant differences in 
delivery-related, lactational, or neonatal-related risk factors.  The median onset of psychiatric 
symptoms occurred at 8 days postpartum (IQR 5-14) and median duration of episode was 
40 days (IQR 23-69). Patients with prominent depressive symptoms had a significantly later 
onset (p=.01) of psychosis and a longer duration of episode (p<.01) than patients without 
depressive symptoms. Psychotic symptoms were mood-incongruent in 64.7% of patients. 
Conclusion: In contrast other findings related to postpartum psychosis in bipolar patients, 
no delivery-related, neonatal-related, or lactational risk factors could be identified. Further, 
our findings of a delayed onset and mood-incongruence of postpartum psychotic symptoms 
markedly contrasts with that of patients with a previous history of bipolar disorder. These 
results suggest that women with psychosis limited to the postpartum period might have a 
distinct risk profile and phenomenology. 
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Introduction
Postpartum psychosis is a rare but severe disorder. The incidence has been estimated as 1 
or 2 of 1000 deliveries (1). Phenomenologically, postpartum psychosis has been described 
as having the abrupt onset of manic or psychotic symptoms within 4 weeks of delivery. 
In addition, patients frequently experience insomnia, restlessness, irritability, and affective 
instability (2). Importantly, clinical symptoms vary widely and can often be overlooked in the 
early postpartum period. However, given the severity of the disorder with very high risks for 
suicide and infanticide, early recognition is of great importance.
 By far, the most important risk factor for postpartum psychosis is a history for bipolar 
disorder (3).  In women with bipolar disorder, the first symptoms of postpartum psychosis 
are often reported within 1 or 2 days following delivery (4, 5).  Indeed for women with 
bipolar disorder, careful monitoring during the postpartum period, prophylactic treatment, 
and prevention of sleep loss have been well-documented to improve clinical outcome (6).
 Although bipolar disorder is an important risk factor for postpartum psychosis, the 
majority of patients admitted with postpartum psychosis have no prior diagnosis of a 
psychiatric disorder (7). Therefore, the etiology of postpartum psychosis in patients with no 
prior psychiatric history remains unclear.  Further, the most commonly reported hypothesis is 
that their manifestation of postpartum psychosis results from an underlying bipolar diathesis 
(8-10).  Therefore, investigators have now begun to focus studies specifically on this distinct 
population: those patients with psychotic episodes limited to the postpartum period (11, 12).
 Accordingly, the present study was designed to examine prospectively the risk factors, 
phenomenology, mode of onset, and clinical course in women with psychosis exclusively 
limited to the postpartum period.  
Methods
Participants
This study was approved by the medical ethical committee of the Erasmus MC Rotterdam. 
All subjects provided written informed consent.
 The study was performed at the Mother-Baby Inpatient Unit of the Department of 
Psychiatry of the Erasmus Medical Centre (Rotterdam, the Netherlands). This 5-bed 
inpatient unit treats female patients with severe psychopathology in the postpartum period 
(0-6 months). Patients are given the option for admission together with their baby, in a fully 
staffed nursery adjoining the unit. 
 Every patient admitted to the Mother-Baby Inpatient Unit between August 2005 
and December 2009 was screened for study inclusion (n = 157), and diagnosed using 
the Structured Clinical Interview for DSM-IV axis I Disorders, Patient edition (SCID – 1/P) 
(13). Previous hypomanic and manic episodes were registered using the Mood Disorder 
Questionnaire (14).
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 Patients aged 18-45 years with a diagnosis of ‘postpartum psychosis’ were included into 
the study cohort. As ‘postpartum psychosis’ is not described as a distinct disease entity in 
DSM-IV-TR, we defined subjects as those patients in which the SCID interview generated 
any of the following DSM-IV-TR diagnoses, and required the specifier “onset postpartum”: 
depressive disorder with psychotic features, mania with psychotic features, mixed episode 
with psychotic features, psychotic disorder not otherwise specified (NOS), or brief psychotic 
disorder.  Importantly, the specifier onset postpartum requires that the onset of symptoms 
must occur within 4 weeks postpartum. Consequently, patients with a chronic psychotic 
disorder or psychosis with onset during pregnancy were excluded.
 Sixty-six patients fulfilled the criteria for postpartum psychosis. We excluded 15 patients 
because of a history of psychosis and/or mania occurring outside the postpartum period: 8 
patients had a history of bipolar I disorder, 5 patients had psychotic disorder NOS, 1 patient 
had schizoaffective disorder, and 1 patient had cannabis dependence. Fifty-one patients had 
psychosis limited to the postpartum period, of which 45 patients were experiencing their 
first psychotic episode while 6 patients each had a single previous episode of postpartum 
psychosis. Of these 51 women with psychosis limited to the postpartum period, 9 women 
reported depressive and anxiety symptoms in history, 6 women had previously seen a 
psychologist, and 1 woman had been treated with venlafaxine. None fulfilled criteria for a 
DSM-IV axis II personality disorder. 
 Since postpartum psychosis is widely considered as a bipolar-spectrum disease, 
treatment was administered using the clinical guidelines for bipolar I disorder (15). 
Specifically, all patients were initially treated with benzodiazepines.  For those patients 
without a marked improvement on benzodiazepine monotherapy, antipsychotic medication 
was initiated within the first week of admission. After 2 weeks of combination antipsychotic/
benzodiazepine treatment, adjunctive lithium was initiated in those patients without a 
significant clinical response. 
 The control group was included through the Generation R study, a population-based 
study conducted in the same catchment area, with delivery dates from April 2002 until 
January 2006 (16). This study is designed to identify early environmental and genetic 
determinants of growth, development, and health from fetal life until young adulthood. 
Study inclusion occurred during pregnancy for n=6969 women, with a follow-up of at least 
two months in the postnatal phase.  
Risk Factors and Precipitating Factors
All participants and their relatives were interviewed by a psychiatrist. A clinician-
administered questionnaire provided information about obstetric history, pregnancy, 
delivery, breastfeeding, and neonatal outcomes.  
 Phenomenology was quantified using the Bipolar Affective Disorder Dimension Scale 
(BADDS) (17). The BADDS is a dimensional rating scale intended for use in clinical samples 
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with a high incidence of bipolar spectrum illness. There are four identified dimensions, which 
measure the key domains of lifetime psychopathology: mania, depression, psychosis, and 
mood incongruence. The presence of psychotic symptoms (percentage of time) was defined 
based upon the comprehensive psychiatric team evaluations throughout the admission 
course. 
Onset of Symptoms and Clinical Course 
We defined the onset of psychiatric symptoms as the first date of having any of the following 
symptoms: delusions, hallucinations, euphoric mood, increased libido, obsessive thoughts, 
panic attacks, suicidal thoughts, anhedonia, or disorientation.  Further, the onset of 
prodromal symptoms was defined as the time point at which the patient, her partner, or 
family initially reported becoming concerned about the patient’s mental health, but prior 
to contacting a mental health provider or having a sufficient symptom burden to fulfill the 
diagnostic criteria for postpartum psychosis.
 Clinical evaluation of treatment was performed weekly using the Clinical Global 
Impressions-Severity Scale (CGI-S), the Young Mania Rating Scale (YMRS) (18), and the 
Edinburgh Postnatal Depression Scale (EPDS) (19). Clinical remission was defined as the 
absence of psychotic, manic and depressed symptoms for at least 1 week (including CGI-S 
score ≤ 3, YMRS score ≤ 8, and EPDS score ≤ 10) (20). Duration of episode was defined as the 
number of days, from the initial onset of psychiatric symptoms until remission. 
Statistical analysis
All analyses were performed using SAS, version 9 (SAS Institute, Inc., Cary, NC).  Categorical 
outcomes were examined using odds ratios (ORs) with corresponding 95% Confidence 
Intervals (CIs). Continuous variables were evaluated using using a 2-sample t-test. Control 
cases were matched for ethnic group and parity, drawn randomly from the Generation R 
population using the sample function in SPSS. Postpartum onset of symptoms was evaluated 
using Kaplan-Meier methodology and the log-rank test.  All hypotheses were tested with an 
alpha of 0.05 (2-sided).
Results
Demographics and obstetric outcomes
Table 1 shows the demographic, obstetric, and child outcome measures for the enrolled 
cohorts.  Overall, compared to the unmatched general population sample, women with 
postpartum psychosis were more frequently of Dutch origin (OR 6.68, 95% CI: 2.85-15.67), 
with post-secondary education (OR 2.37, 95% CI: 1.36-15.67), and living with a partner (OR 
0.27, 95% CI: 0.07-1.13). Further, women with postpartum psychosis had a higher incidence 
of primiparity (OR 2.90, 95% CI: 1.49-5.67) and primigravity (OR 2.74, 95% CI: 1.51-4.96). 
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Table 1. Demographic Information, Obstetric variables, and Neonatal Outcomes in Women with 
Postpartum Psychosis
Postpartum
Psychosis
(N = 51) a
General
 Population
(N = 6969) a        OR  (95% CI)
General Population
 (matched for ethnicity
 and parity) (n = 2847) a OR  (95% CI)
General demographics
Dutch ethnicity 88.2 52.9 6.68 (2.85-15.67) 88.2 1.00 (0.42-2.37)
Postsecondary education 52.9 32.2 2.37 (1.36-4.12) 40.5 1.65 (0.95-2.88)
Marital status 96.1 87.0 0.27 (0.07-1.13) 90.8 2.23 (0.54-9.21)
Primiparity 78.4 55.6 2.90 (1.49-5.67) 78.3 1.01 (0.52-1.98)
Primigravidity 68.6 44.4 2.74 (1.51-4.96) 65.0 1.18 (0.65- 2.14)
Age, Mean  (SD) 31.9 (4.5) 30.2 (5.1) NS 30.7 (4.5) NS
History of depressive
 symptoms
17.6 16.2 1.11 (0.54-2.28) 17.0 1.05 (0.51-2.16)
Pregnancy
Unplanned pregnancy 9.8 27.1 0.29 (0.12-0.74) 19.8 0.44 (0.17-1.11)
Continual smoking 9.8 10.8 0.90 (0.36-2.27) 10.6 0.92 (0.36-2.32)
Continual alcohol use 25.5 17.9 1.57 (0.83-2.96) 22.1 1.21 (0.64-2.28)
Blood loss 3.9 1.0 4.02 (0.96-16.87) 0.8 5.01 (1.15-21.85)
Growth retardation 2.0 1.6 1.22 (0.17-8.94) 1.6 1.25 (0.17-9.21)
Hypertension 3.9 3.6 1.09 (0.26-4.51) 4.7 0.83 (0.20-3.43)
(Pre)eclampsia 5.9 1.9 3.24 (0.97-10.53) 1.9 3.23 (0.98-10.70)
Diabetes gravidarum 0 0.7 NAb 0.7 NAb
Delivery
Home delivery 13.7 14.1 0.97 (0.44-2.16) 16.8 0.79 (0.35-1.76)
Fetal distress 7.8 15.4 0.47 (0.17-1.30) 10.3 0.74 (0.27-2.07)
Failure to progress/descend 11.8 16.3 0.69 (0.29-1.60) 21.3 0.51 (0.22-1.21)
Fluxus 3.9 5.4 0.72 (0.17-2.96) 6.4 0.59 (0.14-246)
Prolonged rupture of 
membranes 
2.0 6.0 0.31 (0.04-2.28) 6.6 0.28 (0.04-2.07)
(sub)total rupture 7.8 5.5 1.46 (0.53-4.08) 4.6 1.76 (0.63-4.97)
Elective Caeserean 2.0 4.7 0.40 (0.06-2.93) 5.5 0.34 (0.05-2.50)
Emergency Caeserean 7.8 7.5 1.05 (0.38-2.91) 8.8 0.89 (0.32-2.48)
Vacuum 9.8 13.6 0.69 (0.27-1.74) 17.5 0.51 (0.20-1.29)
Breastfeeding 88.2 87.8 1.04 (0.44-2.45) 87.0 1.12 (0.48-2.66)
Child
Premature birth < 37 weeks 7.8 5.6 1.44 (0.52-4.00) 6.4 1.23 (0.44-3.46)
Neonatal ward 19.6 16.7 1.22 (0.61-2.44) 18.9 1.04 (0.52-2.10)
Birth Weight mean (SD),g 3391 (818) 3412 (566) NS 3420 (569) NS
a Values shown are percentages unless otherwise stated 
b Odds ratio cannot be computed given the absence of diabetes gravidarum in postpartum psychosis
Abbrevations: NA= not applicable, NS=nonsignificant
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Of note, 11 of 51 patients had a previous delivery, prior to study enrollment.  Six of these 
multiparous women had previous postpartum psychosis.  In contrast, the other 5 patients 
had no significant psychiatric symptoms following their previous deliveries. Therefore, of the 
45 patients with only one episode of postpartum psychosis, 40 (88.9%) were primiparous.
 No differences were found in the rates of complications during delivery, nor in the 
frequency of Caesarean section, compared to controls.  Children from mothers with 
postpartum psychosis had the same mean gestational age, birth weight and no difference in 
neonatal admission in the first week postpartum was observed. There was no difference in 
the prevalence of breastfeeding in women with postpartum psychosis compared to controls.
 Given the demographic differences between the patients and the control sample, we 
subsequently matched the cohorts for ethnicity and primiparity, as these demographic 
factors might influence the development of postpartum symptoms (Table 1).  After 
matching for ethnicity and primiparity, there was a significant difference in blood loss 
during pregnancy (OR 5.01, CI 1.15-21.85), despite the low absolute incidence of blood loss 
during pregnancy in all groups. Further, the incidence of (pre)-eclampsia in 3/51 women 
with postpartum psychosis remained elevated and nearly reached statistical significance 
(OR 3.23, CI 0.98-10.70). However, there remained no significant differences in any other 
demographic, obstetric, or child outcome measures.
Phenomenology 
Table 2 shows the phenomenological characteristics of the presenting episode of postpartum 
psychosis.  Fifty-one women experienced a postpartum psychosis, of which 36 were without 
depressive symptoms.  Of these women, 32 of  36 had a combination of manic and psychotic 
features, while 4 of 36 had predominance of psychotic symptoms without a clear evidence 
of mania. 
 Fifteen women had a postpartum psychosis with prominent depressive symptoms. 
Among these 15 women with a postpartum psychosis and prominent depressive symptoms, 
7 patients had mood symptoms restricted to depression, while 8 patients fulfilled criteria for 
a mixed episode involving both manic and depressive symptoms. 
 Regarding psychotic symptoms, the majority of patients had a mood-incongruent 
psychosis (33/51, 64.7%). Of these patients with mood-incongruent psychotic symptoms, 
25 presented with manic features, 4 with mixed features and 4 with depressive features. 
Further, 4 of these 33 patients showed Schneiderian first-rank symptoms, of which all four 
patients presented with manic features.
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Table 2. Phenomenology of Patients with Postpartum Psychosis 
Variable
Postpartum Psychosis
N=51
n %
Phenomenology
Postpartum Psychosis
With manic psychotic features 32 62.7
With only psychotic features 4 7.8
With depressed psychotic features 7 13.7
With mixed (manic and depressed) features 8 15.7
Relation between mood symptoms and psychotic symptoms
Only mood-congruent psychotic symptoms 18 35.3
Presence if mood-incongruent psychotic symptoms 33 64.7
Balance between mood-congruent/mood-incongruent 14 27.5
Mood-incongruent psychotic symptoms 15 29.4
Presence of first rank symptoms * 4 7.8
Presence of psychotic symptoms % of time
Up to 25 % of episode 8 15.7
50 % of episode 11 21.6
75 % of episode 9 17.6
100 % of episode 23 45.1
* thought echo, insertion, withdrawal or broadcasting, passivity experiences, hallucinatory voices 
giving running commentary, discussing subject in third person or originating in some part of the body, 
bizarre delusions, or catatonia
Onset of Symptoms
The median onset of the initial psychiatric symptoms occurred at 8 days postpartum 
(Interquartile range [IQR] 5-14).  There was no difference in symptom onset between the 
45 women with first-onset postpartum psychosis and the 6 women with a second episode 
of postpartum psychosis.  In contrast, there were significant differences in onset stratified 
by phenomenological characteristics. Patients without depression had a significantly earlier 
onset of psychosis (median=7 days, IQR 4-10) than patient with prominent depressive 
symptoms (median=18 days, IQR 7-21) (Figure 1; log-rank P = 0.01).
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Figure 1. Survival curve of Time from Delivery to the initial Onset of Prominent Psychiatric Symptoms 
in Patients with Postpartum Psychosis
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The majority of women reported a history of prodromal symptoms, prior to the overt onset 
of postpartum psychosis (n=37, 72.5%). Of these 37 women, only 4 reported an onset of 
prodromal symptoms during pregnancy. In contrast, 33 women had a postpartum onset of 
symptoms, for which the prodromal phase lasted a median of 5 days (IQR 2-7), while the 
onset of postpartum psychosis occurred at a median 9.5 day postpartum (IQR 7-17). No 
prodromal phase was evident prior to the onset of postpartum psychosis in the remaining 14 
women (27.5 %), for which the median onset of their acute psychosis was at day 6 (IQR 4-9).
 No difference in the incidence of prodromal symptoms was found between patients with 
a first versus second episode of postpartum psychosis.  Similarly, the presence or absence of 
depressive symptoms was not significantly related to the incidence of prodromal symptoms.
Duration of episode
In our cohort, 47 of 51 patients (92.2%) achieved full remission prior to discharge (Figure 2). 
The majority of patients (n=34, 66.7%) achieved remission using the combination of lithium, 
antipsychotics, and benzodiazepines. Nine patients (17.6%) remitted with the combination 
of antipsychotic medication and benzodiazepines, whereas 3 patients (5.9%) achieved 
remission with benzodiazepines only. One patient ultimately required ECT treatment to 
achieve full remission.
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Figure 2. Treatment of Patients with Postpartum Psychosis
Four patients requested voluntary discharge from the hospital before achieving full 
remission, at a median 7 weeks after admission. These four patients showed a clear response 
to treatment, for which both manic and psychotic symptoms were absent for more than 
one week (1 patient used benzodiazepines and 3 patients used the combination of lithium, 
antipsychotics, and benzodiazepines). However, they did not fulfill criteria for complete 
remission at discharge because they still suffered from depressive symptoms or irritability. 
In the 47 patients (92.2%) who achieved full remission during their inpatient hospitalization, 
the median duration of episode was 40 days (IQR 23-69). Further, the duration of episode in 
patients with first-onset postpartum psychosis was similar to those experiencing a second 
episode of postpartum psychosis (p=0.81, Mann-Whitney test).
There were significant differences in duration of episode based on the current 
phenomenology. The clinical course of patients with manic/psychotic features compared to 
patients with depressed/psychotic features is shown in Figure 3. 
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Figure 3.  Duration of Disease Episode in Patients with Manic/Psychotic Features Compared to 
Patients with Depressed/Psychotic features
In the 35 women with a predominance of manic/psychotic symptoms, the median duration 
of episode was 34 days (IQR 19-48).  In contrast, the 12 women with postpartum psychosis 
and depressive symptoms had a significantly longer median duration of episode (77.5 days 
[IQR 31-117]; p<0.01, Mann-Whitney test). This difference was particularly influenced by the 
median duration of episode in 6 women with psychotic depression (115 days), compared to 
6 patients with a mixed episode (54 days).
Discussion
In this prospective study, we examined risk factors, phenomenology, mode of onset, and 
clinical course in women with psychosis exclusively limited to the postpartum period.
Primiparity is a highly predictive covariate for postpartum psychosis
Primiparity has been previously observed as a significant covariate, predictive of 
postpartum psychosis (6).  Indeed, our data strongly confirm this finding.  Specifically, we 
find that the initial episode of postpartum psychosis occurs predominantly following a 
primiparous delivery.  Together, these data support a model whereby delivery represents a 
‘neurobiological stress test’, for which a primiparous delivery without psychiatric sequelae 
is highly predictive of subsequent deliveries.  Accordingly, if a woman’s initial delivery does 
not trigger a postpartum psychosis, then the likelihood becomes substantially lower that a 
subsequent delivery will cause a postpartum psychosis.
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Bloodloss and Pre-eclampsia as Riskfactors for Postpartum Psychosis?
Even after correction for ethnicity and parity, we found a higher incidence of blood loss and 
pre-ecclampsia during pregnancy in women who later developed postpartum psychosis. 
Accordingly, further research in larger naturalistic cohorts should be used to confirm these 
findings and to investigate their pathophysiological underpinnings.  Importantly however, 
the low absolute incidence of blood loss or pre-ecclampsia in the PP cohort precludes that 
either of these factors has a major influence on the general population rates of postpartum 
psychosis.
No Identified Delivery-related , Neonatal -related, or Lactational Risk Factors
Previous studies in bipolar patients have identified complications during delivery that were 
associated with postpartum psychosis (6). However, in contrast to these findings with 
bipolar patients, a recent population-based Swedish study in primiparous mothers with no 
previous psychiatric hospitalization found no significant influence of delivery complications, 
such as perinatal death, congenital malformations, preterm birth, or caesarean delivery 
(12). Similarly, our prospective cohort in non-bipolar patients with no previous psychiatric 
history also identified no obstetrical or neonatal-related risk factors that were predictive of 
postpartum psychosis.  
 To the best of our knowledge this is the first study of postpartum psychosis to evaluate 
the influence of lactation. In theory, the dramatic postpartum changes in the hormonal 
environment, followed by the cyclical neuroendocrine responses governing lactation, could 
be associated with the abrupt onset of postpartum psychosis. The principle hormones 
involved in lactation, prolactin and oxytocin, have each been independently associated with 
disturbances in mental state (21) (22). Importantly in our cohort, the rate of breastfeeding 
was equivalent in patients and controls. Based on these data we find no evidence of an 
association between breastfeeding and postpartum psychosis, though prolactin and 
oxytocin cannot be ruled out as possible factors in the aetiology of postpartum psychosis.
Demographic Characteristics
The patient cohort had a higher likelihood of being ethnically Dutch, having post-secondary 
education, and being married or living with a partner.  Notably however, no significant 
demographic differences remained after matching for ethnicity.  The higher frequency of 
ethnically Dutch patients could be due to the widely observed difference in psychiatric 
services utilization between native and immigrant residents (23). Consequently, some 
immigrant women and their relatives may not have contacted primary care services for 
serious mental health problems in the postpartum period. Accordingly, substantial efforts in 
the Netherlands have been increasingly focused on effective solutions for improving ethnic 
disparities in mental health services utilization (24).
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Phenomenology and Family History in Accordance With the Literature 
The majority of women suffered from mania (n=32).  Less frequently, we observed mixed- 
episode symptoms (n=8), depression with psychotic features (n=7), or psychosis in the 
absence of discernible affective symptoms (n=4). As extensively described in the literature, 
we indeed find that the majority of patients have bipolar symptoms.  By the specific DSM-
IV criteria, postpartum depression with psychotic features does not constitute a bipolar 
depression. However, several investigators have more recently advanced the perspective 
that early-onset postpartum depression is likely to have a bipolar diathesis, especially if 
psychotic features are present (25).
 Importantly, the increased prevalence of mood-incongruent psychosis is similar to 
that reported in previous studies.  In addition, the low incidence of Schneiderian first-rank 
symptoms has also been described previously (26-29). 
 One limitation of the current study is the absence of formal cognitive testing.  Previous 
studies of postpartum psychosis have included a detailed description of cognitive symptoms, 
which include disorientation, confusion, perplexity, misrecognition of people, derealisation, 
and depersonalization (26, 28-30). 
Delayed Onset of Psychiatric Symptoms in the Postpartum Period
The median onset of postpartum psychosis in our study was at 8 days following delivery. 
Indeed, multiple studies examining naturalistic cohorts of postpartum psychosis, including 
both bipolar and first-onset patients, have documented the predominant time of symptom 
onset between 3-10 days postpartum (27, 31).  However, these findings of a delayed onset of 
overt psychotic symptoms contrasts with that of bipolar women for whom the onset of acute 
psychosis is often immediately postpartum (4, 5).  Furthermore, an important confounding 
factor may be the relative preparedness of women with no prior psychiatric history versus 
those with bipolar disorder to recognize the emerging symptoms of postpartum psychosis. 
Additionally from a neurobiological perspective, the threshold for manifesting clinical 
symptoms of postpartum psychosis might be substantially reduced in bipolar patients as a 
consequence of previous mood episodes, a phenomenon termed the “kindling hypothesis 
of mood disorders”(32).
Duration of Episode Appears Similar to Those Observed for Bipolar Disorder
In this study, we report on the duration of episode while patients received naturalistic 
treatment using the sequential addition of benzodiazepines, antipsychotics, and finally 
lithium. Our treatment algorithm was based on our clinical experience, guided by the larger 
literature for treatment of bipolar patients.  Importantly, this treatment algorithm also 
included patients with postpartum psychotic depression based upon the findings of Sharma 
and colleagues (33, 34) . 
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 Indeed, few treatment recommendations are available in the literature documenting 
the duration of episode or response to treatment in non-bipolar patients with postpartum 
psychosis. Accordingly, future studies will need to be performed to define the optimal 
treatment algorithm for new-onset postpartum psychosis.
 Of note, the median duration of episode appears similar in patients with postpartum 
psychosis and predominantly manic features (5 weeks) compared to the duration of 
manic episodes previously reported for bipolar patients (7 weeks) (35). Furthermore, we 
observed a significantly longer duration of episode  in patients with postpartum psychosis 
and depressive features (11 weeks), analogous to the longer median duration of episode in 
bipolar depression (15 weeks) (35). As expected, patients with a mixed episode exhibiting 
both manic and depressed features showed a median duration of episode intermediate 
between the manic and depressed groups (8 weeks).  
Psychosis Limited to the Postpartum Period: a Distinct Disease Entity?
Previous studies have clearly described the unusual symptom presentation of patients with 
postpartum psychosis (26, 28-30) (36).  Our data confirm that women with psychosis limited 
to the postpartum period have a unique risk profile and phenomenology. In particular, and 
in addition to the clear absence of any manic or psychotic symptoms outside the postpartum 
period, these patients demonstrate a significantly delayed postpartum onset, the absence of 
obstetric complications as a significant risk factor, and a prominence of mood-incongruent 
psychosis, compared to bipolar patients with postpartum psychosis.  
 Most longitudinal studies have suggested that PP is frequently the initial presentation 
of an underlying mood disorder within the bipolar spectrum (10, 27, 37-42).  Accordingly, 
the first episode of postpartum psychosis may in retrospect be appreciated as the incipient 
clinical presentation of bipolar disorder. Further, previous studies have suggested that long-
term outcomes are more favorable when bipolar disorder has a postpartum onset  (37, 43, 
44).  Indeed, for some women the occurrence of a postpartum episode of affective psychosis 
will remain exclusively limited to the postpartum period (10, 27, 37-42).  Therefore, an 
independent status for psychosis limited to the postpartum period might be justified. 
Further research efforts to distinguish these populations at the time of their first-onset of 
psychosis will greatly enhance clinical prognosis and treatment.
Acknowledgements: We greatly appreciate Siska Verploegh, Jeroen Vervoort, Karin 
Burgerhout,  Sanne de Vries and  Andre Wierdsma for their assistance.
First-onset psychosis occurring in the postpartum period: a prospective cohort study
43
Ch
ap
te
r 3
References
1. Spinelli MG. Postpartum psychosis: detection of risk and management. Am J Psychiatry. 2009;166(4):405-8.
2. Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Womens Health (Larchmt). 2006;15(4):352-
68.
3. Jones I, Craddock N. Familiality of the puerperal trigger in bipolar disorder: results of a family study. Am J 
Psychiatry. 2001;158(6):913-7.
4. Heron J, McGuinness M, Blackmore ER, Craddock N, Jones I. Early postpartum symptoms in puerperal 
psychosis. BJOG. 2008;115(3):348-53.
5. Heron J, Robertson Blackmore E, McGuinness M, Craddock N, Jones I. No ‘latent period’ in the onset of bipolar 
affective puerperal psychosis. Arch Womens Ment Health. 2007;10(2):79-81.
6. Blackmore ER, Jones I, Doshi M, Haque S, Holder R, Brockington I, et al. Obstetric variables associated with 
bipolar affective puerperal psychosis. Br J Psychiatry. 2006;188:32-6.
7. Oates M. Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. Br Med Bull. 
2003;67:219-29.
8. Chaudron LH, Pies RW. The relationship between postpartum psychosis and bipolar disorder: a review. J Clin 
Psychiatry. 2003;64(11):1284-92.
9. Wisner KL, Peindl KS, Hanusa BH. Psychiatric episodes in women with young children. J Affect Disord. 
1995;34(1):1-11.
10. Benvenuti P, Cabras PL, Servi P, Rosseti S, Marchetti G, Pazzagli A. Puerperal psychoses: a clinical case study 
with follow-up. J Affect Disord. 1992;26(1):25-30.
11. Hay PJ. Post-partum psychosis: which women are at highest risk? PLoS Med. 2009;6(2):e27.
12. Valdimarsdottir U, Hultman CM, Harlow B, Cnattingius S, Sparen P. Psychotic illness in first-time mothers with 
no previous psychiatric hospitalizations: a population-based study. PLoS Med. 2009;6(2):e13.
13. First MB SR, Gibbon M, Williams JBW, editor. Structured Clinical Interview for DSM IV Axis I Disorders, Patient 
Edition (Nederlandse Versie). Lisse, Nederland: : Swets & Zeitlinger, BV; 1999.
14. Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry. 2001;62 
Suppl 14:5-9.
15. Sharma V. Treatment of postpartum psychosis: challenges and opportunities. Curr Drug Saf. 2008;3(1):76-81.
16. Jaddoe VW, van Duijn CM, van der Heijden AJ, Mackenbach JP, Moll HA, Steegers EA, et al. The Generation R 
Study: design and cohort update until the age of 4 years. Eur J Epidemiol. 2008;23(12):801-11.
17. Craddock N, Jones I, Kirov G, Jones L. The Bipolar Affective Disorder Dimension Scale (BADDS)--a dimensional 
scale for rating lifetime psychopathology in bipolar spectrum disorders. BMC Psychiatry. 2004;4:19.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J 
Psychiatry. 1978;133:429-35.
19. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh 
Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-6.
20. Hirschfeld RM, Calabrese JR, Frye MA, Lavori PW, Sachs G, Thase ME, et al. Defining the clinical course of bipolar 
disorder: response, remission, relapse, recurrence, and roughening. Psychopharmacol Bull. 2007;40(3):7-14.
21. Caldwell HK, Stephens SL, Young WS, 3rd. Oxytocin as a natural antipsychotic: a study using oxytocin knockout 
mice. Mol Psychiatry. 2008.
22. Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Marechal P, Pequeux C, et al. Plasma oxytocin levels and 
anxiety in patients with major depression. Psychoneuroendocrinology. 2007;32(4):407-10.
23. Fung K, Dennis CL. Postpartum depression among immigrant women. Curr Opin Psychiatry. 2010;23(4):342-8.
24. Hesselink AE, Verhoeff AP, Stronks K. Ethnic health care advisors: a good strategy to improve the access to 
health care and social welfare services for ethnic minorities? J Community Health. 2009;34(5):419-29.
Chapter 3
44
25. Sharma V, Burt VK, Ritchie HL. Bipolar II postpartum depression: Detection, diagnosis, and treatment. Am J 
Psychiatry. 2009;166(11):1217-21.
26. Wisner KL, Peindl K, Hanusa BH. Symptomatology of affective and psychotic illnesses related to childbearing. 
J Affect Disord. 1994;30(2):77-87.
27. Klompenhouwer JL, van Hulst AM. Classification of postpartum psychosis: a study of 250 mother and baby 
admissions in The Netherlands. Acta Psychiatr Scand. 1991;84(3):255-61.
28. Dean C, Kendell RE. The symptomatology of puerperal illnesses. Br J Psychiatry. 1981;139:128-33.
29. Brockington IF, Cernik KF, Schofield EM, Downing AR, Francis AF, Keelan C. Puerperal Psychosis. Phenomena 
and diagnosis. Arch Gen Psychiatry. 1981;38(7):829-33.
30. Klompenhouwer J, van Hulst A, Tulen J, Jacobs M, Jacobs B, Segers F. The clinical features of postpartum 
psychoses. Eur Psychiatry. 1995;10(7):355-67.
31. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662-73.
32. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance 
phenomena. Neurosci Biobehav Rev. 2007;31(6):858-73.
33. Sharma V. A cautionary note on the use of antidepressants in postpartum depression. Bipolar Disord. 
2006;8(4):411-4.
34. Bergink V, Koorengevel KM. Postpartum depression with psychotic features. Am J Psychiatry. 2010;167(4):476-
7; author reply 7.
35. Solomon DA, Leon AC, Coryell WH, Endicott J, Li C, Fiedorowicz JG, et al. Longitudinal course of bipolar I 
disorder: duration of mood episodes. Arch Gen Psychiatry. 2010;67(4):339-47.
36. Munoz RA. Postpartum psychosis as a discrete entity. J Clin Psychiatry. 1985;46(5):182-4.
37. Robling SA, Paykel ES, Dunn VJ, Abbott R, Katona C. Long-term outcome of severe puerperal psychiatric illness: 
a 23 year follow-up study. Psychol Med. 2000;30(6):1263-71.
38. Rhode A, Marneros A. Postpartum psychoses: onset and long-term course. Psychopathology. 1993;26(3-
4):203-9.
39. Schopf J, Rust B. Follow-up and family study of postpartum psychoses. Part III: Characteristics of psychoses 
occurring exclusively in relation to childbirth. Eur Arch Psychiatry Clin Neurosci. 1994;244(3):138-40.
40. Pfuhlmann B, Franzek E, Beckmann H, Stober G. Long-term course and outcome of severe postpartum 
psychiatric disorders. Psychopathology. 1999;32(4):192-202.
41. Davidson J, Robertson E. A follow-up study of post partum illness, 1946-1978. Acta Psychiatr Scand. 
1985;71(5):451-7.
42. Videbech P, Gouliaev G. First admission with puerperal psychosis: 7-14 years of follow-up. Acta Psychiatr 
Scand. 1995;91(3):167-73.
43. Serretti A, Olgiati P, Colombo C. Influence of postpartum onset on the course of mood disorders. BMC 
Psychiatry. 2006;6:4.
44. Colom F, Cruz N, Pacchiarotti I, Mazzarini L, Goikolea JM, Popova E, et al. Postpartum bipolar episodes are not 
distinct from spontaneous episodes: implications for DSM-V. J Affect Disord;126(1-2):61-4.
Chapter 4
Prevention of postpartum psychosis 
and mania in women at high risk
 
Veerle Bergink, Paul F. Bouvy,  Jeroen S.P. Vervoort, Kathelijne M. Koorengevel, 
Eric A.P. Steegers, Steven A. Kushner
Am J Psychiatry. 2012;169(6):609-15.
Chapter 4
46
Abstract
Objective: Women with a history of bipolar disorder or postpartum psychosis are at 
extremely high risk of relapse postpartum.  Although lithium prophylaxis has demonstrated 
efficacy in reducing postpartum relapse, the timing of prophylaxis remains controversial 
given the balance of risks and benefits for the mother and fetus.  The authors compared 
lithium use during pregnancy compared to its initiation postpartum in women at high risk 
for postpartum psychosis. 
Method: Between 2003 and 2010, 70 pregnant women at high risk for postpartum psychosis 
were referred to the authors’psychiatric outpatient clinic.  Women who were initially 
medication-free were advised to start lithium prophylaxis immediately postpartum.  Women 
already taking maintenance lithium during pregnancy were advised to continue treatment.
Results: All women with a history of psychosis limited to the postpartum period (n=29) 
remained stable throughout pregnancy despite being medication-free.  Of the women with 
bipolar disorder (n=41) 24.4 % relapsed during pregnancy, despite prophylaxis use by the 
majority throughout pregnancy.  The postpartum relapse rate was highest in women with 
bipolar disorder who experienced mood episodes during pregnancy (60.0 %).  In contrast, 
none of the 20 women with postpartum psychosis using postpartum prophylaxis relapsed, 
compared to 44.4% of postpartum psychosis patients who declined prophylaxis.
Conclusions: The authors recommend initiating prophylactic treatment immediately 
postpartum in women with a history of psychosis limited to the postpartum period, to 
avoid in utero fetal exposure to prophylactic medication.  Patients with bipolar disorder 
require continuous prophylaxis throughout pregnancy and the postpartum period to reduce 
peripartum relapse risk. 
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Introduction
Psychotic episodes during the postpartum period are life-threatening psychiatric emergencies, 
occurring after nearly 0.1% of all deliveries.  The strongest predictor for postpartum 
psychosis is a history of bipolar disorder and/or postpartum psychosis (1-3).  Consequently, 
guiding women at high-risk for psychosis through pregnancy and the postpartum period is a 
major challenge for mental health practitioners and obstetricians (4-6).  Although immediate 
treatment of affective instability or psychosis is clearly warranted, relapse prevention is 
widely viewed as the most desirable strategy.  Indeed, previous studies in high-risk women 
provide strong support for the benefits of lithium prophylaxis during pregnancy and the 
postpartum period (7-12).  However, the benefits of medication for relapse prevention need 
to be carefully weighed against risks for the fetus during pregnancy, neonatal complications 
following delivery, and for breastfeeding in the postpartum period (13). 
 Previous studies of peripartum relapse have largely focused upon women with a history 
of bipolar disorder.  Viguera et al. provided clear evidence that discontinuation of medication 
leads to very high rates of relapse in bipolar women during pregnancy (7, 8).  Further, four 
studies with smaller study groups have shown that prophylaxis with lithium is protective 
for relapse postpartum (9-12).  In all four studies, lithium was continued during pregnancy, 
started in the last trimester of pregnancy, or started immediately postpartum. 
 While lithium has been demonstrated to be effective in substantially reducing the risk 
of peripartum relapse, the precise timing of when to initiate lithium prophylaxis, during 
pregnancy or immediately postpartum, remains unclear.  An urgent need exists for clinical 
data that can be used to adequately weigh the risks and benefits of prophylaxis throughout 
the entire peripartum period. 
 Accordingly, we now describe the clinical outcomes of a Peripartum Prevention Program, 
designed to reduce the incidence and severity of peripartum relapse in women with a history 
of bipolar disorder, postpartum psychosis, or both.  Pregnant women already on maintenance 
regimen of lithium were advised to continue this prophylactic treatment during pregnancy 
and the postpartum period.  High-risk women who were clinically stable and medication-free 
at the time of evaluation were advised to start lithium prophylaxis immediately postpartum. 
These standardized clinical guidelines provided us the opportunity to examine the benefit 
of lithium prophylaxis during pregnancy compared to immediately postpartum, in women at 
high-risk for perinatal psychosis. It is important to note that although postpartum psychosis 
is widely considered as a new episode of bipolar disorder, some studies have indicated that 
postpartum psychosis is distinct from bipolar disorder (3, 14-17).  Therefore, we investigated 
the clinical outcomes of women with a history of psychosis limited to the postpartum period 
and of those with a history of bipolar disorder.
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Method
Participants
Between January 2003 and December 2010, a total of 618 referrals to the outpatient clinic 
of the Peripartum Prevention Program at the Department of Psychiatry, Erasmus Medical 
Center (Rotterdam, the Netherlands), were evaluated.  Requests for evaluation and clinical 
management during pregnancy and the postpartum period were made by obstetricians, 
psychiatrists, and general practitioners.  This study was approved by the Institutional Review 
Board of the Erasmus Medical Center.
 Psychiatric diagnosis was obtained through semistructured interviews by a psychiatrist 
and review of clinical records.  We included women with bipolar I disorder and bipolar 
II disorder with only non-puerperal episodes and those with both puerperal and non-
puerperal episodes. Further, we also included women with a history of postpartum psychosis 
but without any manic or psychotic symptoms outside the postpartum period.  Since 
‘postpartum psychosis’ is not described as a separate disease entity in DSM-IV, we defined 
‘postpartum psychosis’ as a history of any of the following DSM-IV diagnoses: psychotic 
disorder not otherwise specified, brief psychotic disorder, or mood disorder (manic, mixed, 
or major depressive episode) with psychotic features, all requiring the specifier “with 
postpartum onset” (≤ 4 weeks after delivery).  Women with chronic psychotic disorders 
such as schizophrenia or schizoaffective disorder were excluded.
 In total, 75 pregnant women fulfilled the inclusion criteria.  Five women were lost to 
follow-up during pregnancy (Figure 1).   Therefore, in total we included 70 pregnant women 
at high risk for postpartum psychosis.  Of this number, 29 women had a history of postpartum 
psychosis but without any manic or psychotic symptoms outside the postpartum period. 
Conversely, we included 41 women with a diagnosis of bipolar disorder, based on a history 
of non-puerperal episodes with or without puerperal episodes.  For women who had more 
than one delivery during the study inclusion period, we included only the most recent 
pregnancy in the main analysis. 
Peripartum Prevention Program
The Peripartum Prevention Program at the Erasmus MC was designed to provide standardized 
evidence-based clinical care for women at high-risk for peripartum relapse (18).  Women 
enrolled in the program received their full obstetric care through the department of 
Obstetrics and Gynaecology, and peripartum psychiatric care through the department of 
Psychiatry.
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Figure 1. Flowchart of inclusion for women at high risk for postpartum psychosis.
Women with bipolar 
disorder (N=41)
High-risk women evaluated (N=70)
Women visiting a psychiatric 
outpatient clinic in 2003–2010 
screened for inclusion (N=618)
Women without bipolar disorder 
or a history of postpartum 
psychosis excluded (N=543)
Women lost to follow-up (N=5)
With bipolar disorder (N=3)
With a history of postpartum 
psychosis only (N=2)
Women with a history of affective 
psychosis included (N=75)
 Women with a 
history of postpartum 
psychosis only (N=29)
We advised women who were using a mood stabilizer at the time of evaluation to continue 
pharmacologic treatment during pregnancy. Given that lithium monotherapy has the largest 
evidence base in the peripartum period as an effective mood stabilizer, this was our primary 
pharmacological recommendation (2, 19). We also informed women about teratogenic risks 
of lithium during early pregnancy and the elevated rate of neonatal complications of lithium 
(20, 21).
 We attempted to reduce the incidence of polypharmacy by recommending mood 
stabilization with a single medication. Further, we advised against the use of valproate 
during the peripartum period because of high teratogenic risks during pregnancy and the 
lack of efficacy for postpartum prophylaxis shown in a single study (22, 23). However given 
the potential risks of switching medications, our treatment plan discussion always included 
carbamazepine, lamotrigine, and antipsychotics as important considerations, if patients 
were clinically stable on these medications with manageable side effects, or if they had 
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a history of a favorable response to these medications.  It is important to note that the 
final decision regarding prophylaxis during pregnancy was always made by the patient, 
following a collaborative discussion to consider the risks and benefits of each pharmacologic 
treatment option, including the potential for teratogenicity and the risk of relapse.
 In those women receiving maintenance lithium treatment, we prescribed doses three 
times a day during pregnancy to avoid peak lithium levels.  After delivery, we reduced 
the numbers of doses to once a day (with a target minimum plasma level postpartum of 
0.8 mmol/L).  High-risk women who were medication-free at the time of evaluation were 
advised to start lithium prophylaxis immediately postpartum. For these women, lithium was 
started the first evening after delivery and given once daily according to the plasma level 
(target minimum, 0.8 mmol/L).  Plasma lithium levels were monitored twice weekly during 
the first week postpartum, once per week during weeks 2-3, and thereafter as clinically 
indicated. Lithium levels were individualized based upon clinical symptoms and side effects, 
incorporating preferences of each patient and their previous history, if any, of lithium 
therapy.
 We particularly emphasized the importance of sufficient sleep during the peripartum 
period, as sleep loss has been demonstrated to be a modifiable risk factor in bipolar 
disorder and postpartum psychosis (24-26).  Accordingly, all women were advised to spend 
the first week postpartum in a private room on the inpatient obstetric ward, where nurses 
performed the overnight newborn feedings to provide mothers with the opportunity to 
sleep throughout the night.  In addition we recommended standardized treatment with 
benzodiazepines (lorazepam 1 mg at bedtime), during the first week postpartum, during 
which subjective self-reports of sleep quality were evaluated daily through clinical interviews. 
Further, women were advised against breastfeeding given the current uncertainty regarding 
breastfeeding during maternal lithium treatment (21, 27).
 In summary, a comprehensive individualized perinatal treatment plan was defined based 
on the choices of each woman in collaboration with her clinician regarding the risks and 
benefits of each treatment option, including prophylaxis, breastfeeding, sleep hygiene, and 
postpartum inpatient obstetric care.  All women received follow-up evaluations every 4-6 
weeks throughout the peripartum period.  We defined the postpartum period according to 
the DSM-IV definition of the first four weeks postpartum.  Therefore, we followed all women 
for a minimum of four weeks postpartum.  The mean period of follow-up was 12.6 weeks 
postpartum (range=4-52 weeks).
 Each patients and her partner were encouraged to immediately contact their psychiatrist 
in case of affective instability, psychotic symptoms, or refractory insomnia.  We defined 
relapse as the occurrence of any psychiatric episode fulfilling DSM-IV criteria, including 
hypomanic episodes.  During the first week postpartum, all patients were screened daily for 
prodromal symptoms by a perinatal psychiatric nurse (J.V.) in order to provide the earliest 
possible intervention.
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Table 1. Demographic and Clinical Characteristics of Pregnant Women with Bipolar Disorder or a 
History of Postpartum Psychosis Only.
Characteristic
Bipolar Disorder
N=41
Postpartum Psychosis
Only N=29
Difference
Between groups
Demographic variables
Mean SD Mean SD Two-Sample t 
Test (p)
Age (years) 33.6 3.8 32.7 5.2 0.40
N % N % Fisher’s Exact 
Test (p)
  Caucasian 36 87.8 23 79.3 0.50
  High educational level 12 29.3 11 37.9 0.61
  Living with father child 38 92.7 29 100 0.26
Childbearing
  Previous pregnancy 30 73.2 29 100 a < 0.01
  Previous delivery 24 58.5 29 100 a < 0.01
  Unplanned pregnancy 14 34.1 4 13.8 0.09
  Smoking during pregnancy 5 12.2 4 13.8 1
  Elective caesarean section 2 4.8 3 10.3 0.64
  Emergency caesarean section 7 17.1 3 10.3 0.51
Bipolar characteristics
  Bipolar type I 27 65.8
  Number of nonpuerperal episodes
    < 5 21 51.2
    5-10 13 31.7
    > 10 7 17.1
  Previous puerperal episodes 8 19.5
Treatment 
  Prophylaxis during pregnancy 31 75.6
  Lithium prophylaxis 30 96.8 b
a  All of these women had at least one previous delivery, as required by the study’s inclusion criteria. 
b Based on the 31 receiving prophylactic treatment during pregnancy 
Statistical Analysis
All analyses were performed using SAS, version 9 (SAS Institute, Cary, NC).  For characteristics 
of the study group, categorical data were evaluated by means of Fisher’s exact test and 
continuous variables were examined with two-sample t-tests.  Categorical outcomes of 
relapse risks were examined using both Fisher’s exact test and odds ratios with corresponding 
95% Confidence Intervals (CIs).  All hypotheses were tested with an alpha of 0.05 (two-sided).
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Results
Table 1 shows demographic, obstetric, and psychiatric characteristics for the enrolled 
patients.  No significant differences were found in age, education, marital status, unplanned 
pregnancy, smoking during pregnancy, or the frequency of Caesarean section. 
Table 2. Characteristics of Women With Bipolar Disorder or a History of Postpartum Psychosis Only 
Who Had a Relapse During Pregnancy or the Postpartum Period
Pregnancy Postpartum
Patient
Age 
(years)
Parity Prophylaxis
Time of 
Relapse 
(weeks)
Morbidity Prophylaxis
Time of 
Relapse 
(days)
Morbidity
Bipolar
disorder
1 35 0 Lithium 6 Maniaa Lithium 8 Maniaa
2 28 0 Lithium 6 Maniaa Lithium
3 29 0 11 Hypomania Lithium
4b 34 1 Lithium 19 Maniaa Lithium plus 
antipsychotic
0c Hypomania
5d 32 4 22 Mixeda Lithium plus 
antipsychotic 
plus 
antidepressant
6b 28 2 Lithium 23 Maniaa Lithium 4 Depressiona
7 21 0 Lithium 23 Maniaa Lithium 0c Hypomania
8 40 0 23 Depression Lithium
9 32 2 29 Depression Carbamazepine 
plus 
antidepressant
0c Depression
10 29 0 Lithium 39 Mixeda Lithium 24 Mixeda
11 33 3 Lithium 4 Depressiona
12b 30 1 Lithium Lithium 7 Maniaa
13 33 1 Valproate 16 Maniaa
Postpartum 
psychosis
1 37 1 7 Depressiona
2 20 1 8 Maniaa
3 34 1 12 Mixed
4 24 3 23 Psychosisa
a Required inpatient psychiatric admission.
b Patient’s history included an additional diagnosis of  postpartum psychosis.
c During pregnancy.
d Patient’s history included an additional diagnosis of postpartum depression.
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Peripartum Relapse in Bipolar Disorder and Postpartum Psychosis Only
The timing of relapse was substantially different between the women with bipolar disorder 
and those with postpartum psychosis (Figure 2).  Remarkably, despite being medication-
free throughout the entire pregnancy, none of the 29 women with postpartum psychosis 
relapsed during pregnancy.  Postpartum, four of the 29 (13.7%) relapsed (Table 2).  Of these 
four women with previous postpartum psychosis, the current relapse was manifested as 
mania for one woman, psychosis for one, a mixed episode for one and depression for one. 
Three of these four women required postpartum inpatient admission.
Figure 2. Cumulative Incidence of Relapse During Pregnancy and the Postpartum Period in Women 
with Bipolar Disorder or a history of Postpartum Psychosis Only
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Bipolar disorder (N=41)
History of postpartum 
psychosis only (N=29)
In contrast to the women with a history of postpartum psychosis only, none of whom had a 
relapse during pregnancy, 24.4% of women with bipolar disorder (10 of 41) relapsed during 
pregnancy (p<0.01, Fisher’s exact test) (Table 2). Of these 10 women, five had a manic 
episode, two women had a mixed episode, two had a major depressive episode, and one 
developed hypomania. Those with a manic or mixed episode all required hospitalisation. 
Relapse postpartum occurred in 22.0% of the women with bipolar disorder (nine of 41), the 
majority of whom (six of nine) had also previously relapsed during pregnancy. Three out of 
these six women achieved full remission after the relapse in pregnancy, but relapsed again 
postpartum. The other three women experienced a postpartum worsening of an episode 
beginning in pregnancy (Table 2). Consequently, relapse during pregnancy was a significant 
risk factor for relapse postpartum (P<0.01, Fisher exacts test, odds ratio=14.0, 95% CI= 2.5-
80.0). Of all nine women with bipolar disorder and postpartum relapse, three had a manic 
episode, one had a mixed episode, three had depression, and two had hypomania. Overall, 
six bipolar women required postpartum inpatient admission (Table 2). 
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 Relapse in the bipolar women, both during pregnancy and postpartum, was especially 
common in women with a history of puerperal episodes (Table 2). Eight women with bipolar 
disorder reported a history of both puerperal and nonpuerperal episodes, of whom 50.0% 
(four of eight) had a peripartum relapse. In contrast, the peripartum relapse rate was 27.3% 
in the women with bipolar disorder with a history of only nonpuerperal episodes (nine of 33).
Table 3. Relation of Peripartum Prophylaxis to Relapse in Women With Bipolar Disorder or a History 
of Postpartum Psychosis Only
Bipolar disorder (N=41)
Postpartum psychosis Only 
(N=29)
Total Relapse Total Relapse
Time Period and Group N % N % N % N %
Pregnancy
Prophylaxis 31 75.6 6 19.4 0 0.0
No prophylaxis 10 24.4 4 40 29 100.0 0 0.0
Postpartum
Prophylaxis 
Stable pregnancy 26 63.4 2 7.7 20 69.0 0 0.0
Unstable pregnancy 10 24.4 6 60.0 0 0.0
No prophylaxis 5 12.2 1 a 20.0 9 31.0 4 44.4
a This patient used valproate , which has a demonstrated lack of efficacy, as shown by Wisner et al. (23)
Influence of Prophylactic Medication in Women with  Postpartum Psychosis Only
All 29 women with postpartum psychosis only were medication free during pregnancy. 
During this time, none of these women had symptoms of relapse, including any manic, 
psychotic, or depressive episodes (Table 3).
 Of the 29 patients with a history of postpartum psychosis only, 20 began prophylactic 
treatment within 24 hours of delivery. Of these 20, 17 used lithium and three used 
antipsychotics. Notably, there were no cases of relapse among the women with postpartum 
psychosis who initiated postpartum prophylaxis upon delivery. Nine of the 29 patients 
decided against prophylactic medication, with the majority citing their intention to breast-
feed. The relapse rate in the women without postpartum prophylaxis and a history of 
postpartum psychosis was 44.4% (four of nine). The difference in relapse rates between 
the patients with and without prophylaxis was significant (p<0.01, Fisher’s exact test). No 
differences were found in demographic variables between these two groups. One woman 
had two deliveries during the study inclusion period. She was medication free throughout 
the first of these pregnancies, used lithium for postpartum prophylaxis, and remained 
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clinically stable throughout the entire peripartum period. During the second pregnancy, she 
was medication free and clinically stable throughout pregnancy. Unfortunately, however, 
she relapsed without postpartum prophylaxis. 
Influence of Prophylactic Medication in Women with Bipolar Disorder
Of the 41 women with bipolar disorder, 31 (75.6%) received maintenance prophylaxis during 
pregnancy: 27 women used lithium monotherapy for mood stabilization, two women used 
lithium plus an antidepressant, one woman used lithium plus an antipsychotic, and one 
woman used haloperidol monotherapy as prophylaxis. Ten (24.4%) of the 41 bipolar women 
did not use prophylaxis continuously throughout pregnancy: three discontinued prophylaxis 
during the first trimester and seven were without prophylaxis during the entire pregnancy. 
No significant differences in demographic or baseline clinical characteristics were observed 
between the women with bipolar disorder who received prophylaxis and those who did not.
The relapse rate during the pregnancies of the women with bipolar disorder who used 
prophylaxis was 19.4% (six of 31), compared to 40.0% (four of 10) in women without 
prophylaxis. Relapse during pregnancy was treated as clinically necessary, after which mood 
stabilization was continued throughout pregnancy and the postpartum period. However, 
despite maintenance mood stabilization, 60.0% (six of 10) of the women who relapsed 
during pregnancy also experienced a postpartum relapse (p<0.01, Fisher’s exact test; odds 
ratio=14.0, 95% CI=2.5–80.0).
 Among women with bipolar disorder who remained stable throughout pregnancy, 83.9% 
(26 of 31) used prophylaxis postpartum.  Of these women, only 7.7% (two of 26) relapsed 
postpartum.  Further, five of the 31 women who were stable throughout pregnancy declined 
prophylaxis postpartum, of whom one woman (20.0%) relapsed. Five bipolar women had 
two deliveries each during the study inclusion period. Three women declined prophylaxis 
during both of their pregnancies: two of them were stable during both pregnancies, while 
the third woman relapsed during both pregnancies. Two women used lithium prophylaxis 
and were stable during both pregnancies: one woman used lithium continuously during 
both pregnancies, whereas the other woman used lithium prophylaxis postpartum after her 
first pregnancy and continuous prophylaxis during her second pregnancy.
 
Discussion
A major goal of peripartum psychiatric care is the development of an effective prophylaxis 
algorithm that optimally balances the risks and benefits for the mother and fetus (28-
30). With this goal in mind, we designed a peripartum prevention program using the best 
available evidence for pregnant women with the two strongest risk factors for postpartum 
psychosis: a previous postpartum psychosis and/or a history of bipolar disorder. Overall, we 
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confirmed that lithium is highly efficacious for peripartum prophylaxis. However, women 
with a history of postpartum psychosis only, compared to those with bipolar disorder, had 
substantial differences in their clinical outcomes and prophylaxis requirements. 
 First, all women with a history of psychosis limited to the postpartum period were stable 
throughout their entire pregnancy, despite using no prophylactic medication. In contrast, 
women with bipolar disorder had high rates of relapse during pregnancy. Second, initiation 
of prophylaxis with either lithium or an antipsychotic immediately postpartum in women 
with a history of postpartum psychosis was highly effective for preventing postpartum 
relapse. In contrast, the efficacy of postpartum prophylaxis in women with bipolar disorder 
was much lower. Together, our findings suggest that postpartum prophylaxis is highly 
efficacious in women at high risk for postpartum psychosis who do not have a diagnosis 
of bipolar disorder. Moreover, these findings suggest that in striking contrast to women 
with bipolar disorder, women with a history of postpartum psychosis but without manic 
or psychotic symptoms outside the postpartum period may not require prophylaxis during 
pregnancy, thereby offering a substantial risk reduction by entirely avoiding fetal exposure 
to medications.
 Our findings support a wide literature demonstrating that women with bipolar disorder 
have a substantial risk of relapse during pregnancy as well as in the postpartum period (31-
33). In contrast, women with a history of only postpartum psychosis have a vulnerability 
for mania or psychosis that is restricted to the postpartum period. Therefore, our data 
contribute to the emerging consensus that women with a history of psychosis limited to the 
postpartum period might have a distinct variant of bipolar disorder. Accordingly, we have 
described elsewhere the postpartum-onset psychosis and distinctive phenomenology in 
this group (34). Therefore, it will be interesting to explore the neurobiological mechanisms 
that are most highly sensitized in the postpartum period and responsible for this restricted 
window of vulnerability to psychosis. It is important to note that the bipolar women who 
were unstable during pregnancy showed the highest rates of postpartum relapse. In 
particular, we observed that prophylaxis during pregnancy in bipolar women is important not 
only to maintain mood stability during pregnancy but also to prevent episodes postpartum. 
However, the benefits of continuous lithium use for affective stability in the mother, both 
during pregnancy and postpartum, must be carefully weighed against the teratogenic 
effects of lithium during early pregnancy and the elevated rate of neonatal complications (4, 
20, 21).  Further, the benefits of postpartum prophylactic treatment with lithium must be 
considered in light of the relative risk to infants of breastfeeding exposure versus the loss of 
the benefits of breastfeeding.
 This study has some limitations. We have likely missed symptoms associated with 
transient instability as our study was principally designed to detect mood episodes fulfilling 
DSM-IV criteria.  Further, our study was naturalistic, leaving open the possibility that some 
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of the outcomes were influenced by patients’ preferences.  Conversely, a naturalistic study 
design more likely reflects the scenarios confronting women and their perinatal healthcare 
providers.
 Our primary pharmacologic treatment recommendation for high-risk women was 
lithium, based on the literature. In contrast, studies using other prophylactic postpartum 
treatment strategies in bipolar women either failed to show efficacy, as in the case of 
estrogen administration  (35, 36) and valproate (23), or were inconclusive as in the case 
of olanzapine (37).  Notably, the relapse rates in bipolar women on lithium prophylaxis in 
our study were consistent with previous reports (9-12).  To our knowledge, no previous 
prophylaxis studies have independently examined women with postpartum psychosis 
limited to the postpartum period.  Clearly, more studies are required to compare the efficacy 
of other potential prophylactic treatment options (e.g. antipsychotics, carbamazepine) with 
that of lithium, as well as their relative efficacy for prophylaxis in bipolar women and those 
with a history of psychosis limited to the postpartum period. 
 In conclusion, our study demonstrates a strong overall benefit of prophylaxis for the 
prevention of postpartum psychosis in high-risk women. Further, we have identified a 
clinically relevant algorithm that may prove useful in determining prophylaxis requirements. 
In bipolar women, prophylaxis during pregnancy appears critically important for maintaining 
mood stability during pregnancy and for minimizing the high risk of postpartum relapse.
In contrast, our findings suggest that women with a history of psychosis limited to the 
postpartum period should initiate prophylaxis immediately postpartum but remain 
medication free throughout pregnancy. Accordingly, this treatment algorithm may help 
reduce the fetal risk that can accompany in utero exposure to medications without 
compromising the efficacy of postpartum prophylaxis. 
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Introduction
Postpartum psychosis is a severe mood disorder with an acute onset of severe mood and 
psychotic symptoms within four weeks after delivery (1). Importantly, and in contrast to 
postpartum depression, life events and social stress are not implicated in the etiology 
of postpartum psychosis (2, 3). Consequently, many researchers have argued that 
neurobiological changes after delivery play a major role in the acute occurrence of affective 
psychosis immediately postpartum (4). Unfortunately, systematic investigations into the 
pathogenesis of postpartum psychosis have been hindered by the rare and unpredictable 
incidence of the disease.
 One of the most consistent findings in neurobiological research in postpartum psychosis 
over the last decades is the vulnerability for postpartum psychosis in women with bipolar 
disorder. Women with previously diagnosed bipolar disorder are at high risk for affective 
psychosis in the weeks following delivery (5, 6). In a major step toward causative etiological 
factors, Jones and Craddock identified the enrichment of specific genetic variants of the 
serotonin transporter gene (5HTT) and a genome-wide significant linkage signal at the 5HTT 
locus (chromosome 16p13) in bipolar patients with a history of postpartum psychosis (7, 8).
 Interestingly, the majority of women presenting with postpartum psychosis do not 
have a previous history of bipolar disorder. However following an episode of postpartum 
psychosis, some women will then begin to experience non-puerperal bipolar episodes, for 
which the postpartum psychosis could be considered as the first-onset of a bipolar mood 
disorder. The general assumption is that after an initial postpartum affective psychosis, a 
woman has between a 40-80% chance of developing a non-puerperal bipolar mood disorder 
(9). Accordingly, it is of major clinical interest to determine the risk factors for conversion 
to bipolar disorder after a first episode of affective psychosis in the postpartum period. 
Therefore, understanding the etiologic pathophysiology of postpartum psychosis will 
provide a more comprehensive understanding, and will likely provide novel clinical insights 
into the risk factors governing both an initial postpartum psychosis and the subsequent 
risk for bipolar disorder. In this chapter, we review previous neurobiological studies of 
postpartum psychosis, summarizing neuroendocrine hypotheses and the influence of sleep 
loss.
The sex-steroid withdrawal theory of postpartum psychosis
In the last few decades, neurobiological research in postpartum mood disorders has been 
most intensely focused on neurosteroid pathways because of the clear changes occurring 
in hormone levels following delivery.  After removal of the placenta following delivery, hCG, 
estrogen and progesterone levels drop dramatically during the first two weeks, which is the 
typical time-course for the onset of postpartum psychosis.
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In particular, the rapid fall in estrogen has been widely hypothesized to be a major trigger 
in postpartum psychosis. The “estrogen withdrawal-associated psychosis theory” can 
be found in several case reports, describing women within and outside the puerperium, 
with psychosis possibly related to estrogen withdrawal (10). Wieck et al hypothesized 
that the fall in estradiol could trigger increased dopamine receptor sensitivity leading to 
a postpartum psychotic episode in bipolar women (11). Indeed, the onset of affective 
psychosis after childbirth was associated with increased sensitivity of dopamine receptors 
in 15 high-risk women. However, Meakin et al could not replicate these findings (12).  If 
estrogen depletion is indeed the culprit trigger for postpartum psychosis, prophylactic 
administration of estrogens should prevent this psychosis. However, Kumar et al. showed in 
a study with a group of 28 women that the prophylactic administration of an estrogen could 
not prevent relapse in subjects at risk for postpartum affective psychosis (13).  In addition, 
an association could not be identified between polymorphisms in estrogen receptor genes 
and the prevalence of postpartum psychosis (14, 15).
 Rapidly declining progesterone levels have also been hypothesized as one of the possible 
causes of postpartum mood disorders. Unfortunately however, studies of progesterone 
have only been performed in postpartum depression, but not in postpartum psychosis (16). 
Higher progesterone levels were observed in postpartum depressed mothers compared to 
healthy controls (17, 18), however other studies could not confirm these findings (19-21). 
Thus far, the drop in hCG postpartum has not been linked to the onset of postpartum mood 
disorders, although data are lacking to make any definitive conclusions. 
 Together, clear evidence is very limited for a well-defined influence of pregnancy hormones 
(estradiol, progesterone and hCG) in the aetiology of postpartum psychosis. Furthermore, 
the pathophysiological background is undoubtedly complex, for which at-risk women might 
have differential sensitivity to the increase and/or withdrawal of these hormones rather 
than harboring significantly altered levels of the hormones themselves (22-24). Further 
research into the influence of pregnancy hormones should be focussed not only on sex-
steroid receptor candidate genes but also on a more comprehensive biochemical pathway 
analysis including sex-steroid receptor co-regulators and their enzymatic metabolism (25).  
Other endocrine dysregulation in women with postpartum psychosis
Postpartum dysregulation of non-steroid hormone systems has also been associated with 
the sudden onset of affective psychosis in the postpartum period. Therefore, we briefly 
discuss the potential influences of the hypothalamic-pituitary-adrenocortical (HPA) axis, the 
hypothalamic-pituitary-thyroid (HPT) axis, prolactin and oxytocin, on the development of 
postpartum psychosis. 
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The hypothalamic-pituitary-adrenocortical (HPA) axis
Dysregulation of the hypothalamic-pituitary-adrenocortical (HPA) axis is one of the most 
consistent biological findings in mood disorders. The HPA axis robustly changes the first weeks 
after delivery. Immediately postpartum, corticotrophin releasing hormone (CRH) receptors 
in the hypothalamus are down regulated, leading to a decreased adrenocorticotrophic 
hormone (ACTH) response and decreased cortisol release. This blunted stress response is 
restored to normal non-pregnant levels only after 6 weeks postpartum (26). 
 Remarkably, no alterations in the stress system have ever been conclusively reported 
for postpartum psychosis. Two studies in small samples reported similar non-suppression 
in the dexamethasone suppression test in patients with postpartum psychosis compared 
to healthy controls postpartum (27, 28). Furthermore, no evidence was observed for the 
enrichment of glucocorticoid receptor (GR) gene polymorphisms in bipolar patients with or 
without postpartum psychosis (29). 
 In postpartum depression, findings are inconsistent. Hyperactivity of the HPA axis has 
been reported in some studies (20, 30), although others have failed to replicate these findings 
(22, 31). Remarkably, other studies reported exactly the opposite: lower cortisol levels and 
excessive HPA axis suppression (32, 33). Together, findings in HPA axis abnormalities in both 
postpartum psychosis and depression have been inconclusive. 
The hypothalamic-pituitary-thyroid axis 
Considerable alterations to the hypothalamic-pituitary-thyroid axis are also observed in 
the normal postpartum period.  Notably, some women experience thyroid dysfunction, 
predominantly postpartum thyroiditis, in the initial few months following delivery.  Case 
reports have suggested a significant co-morbidity of postpartum autoimmune thyroiditis 
and postpartum psychosis (34). One study in puerperal psychotic inpatients with late onset 
showed no significant differences in thyroid function and thyroperoxidase antibodies (35). 
In contrast, our recent study found autoimmune thyroid dysfunction more prevalent in 
patients with early-onset postpartum psychosis (36). This finding is consistent with several 
studies in postpartum depression reporting a small but statistically significant association 
between depressive symptomatology postpartum and thyroperoxidase antibody positivity 
(37-40). Clearly, replication studies investigating thyroid function in postpartum psychosis 
are warranted.
Lactational hormones: Prolactin and oxytocin
The principle hormones involved in lactation, prolactin and oxytocin have not been 
measured in patients with postpartum psychosis, except for one case report of a women 
with postpartum mania and high levels of degraded products of oxytocin (41). In our recent 
clinical study, we reported a similar prevalence of breastfeeding in women with postpartum 
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psychosis compared to controls. However, this similar prevalence of breastfeeding does not 
preclude an influence of lactation on postpartum psychosis, as both prolactin and oxytocin 
have each been independently associated with disturbances in mental state. 
 Some studies have shown that anxiety and depressive symptoms in the postpartum 
period are correlated with low prolactin levels  (18, 22, 32, 42, 43), although other studies 
could not find such a correlation (44-46). The release of oxytocin during suckling is associated 
with feelings of well-being, relaxation and a lower responsiveness to stressors, providing 
a potential substrate protective for the occurrence of mood disorders (47, 48). Clearly 
endocrine lactational studies investigating these hormones and their receptors in women 
with postpartum psychosis are warranted.
Sleep loss as a culprit trigger
In clinical practice, sleep loss is a prominent symptom of postpartum psychosis. Sharma et 
al. described in a small chart review that insomnia is in fact the most common symptom 
in postpartum psychosis, which invariably preceeds the onset of the mood and psychotic 
symptoms (49). In this study, women in the postpartum psychosis group had a longer 
duration of labour and were more likely to have a night-time delivery (50). As expected, in 
a case series of 3 women with postpartum psychoses, sleep deprivation therapy worsened 
their psychosis, and all 3 patients improved after recovery sleep (51). Although these small 
studies suggest causality, sleep impairment could also be seen as one of the first symptoms 
of an impending postpartum psychosis instead of a causal factor. Indeed, a recent study 
could not find a difference in sleep/wake activity in women with a history of postpartum 
psychosis (52). Circadian genes are known to have a regulatory impact in mood disorders 
(53). In this respect, it would be very interesting to investigate whether circadian gene 
polymorphisms moderate the relationship between sleep-wake cycle disturbances and the 
incidence of postpartum psychosis.
Conclusion
The fundamental molecular and cellular mechanisms underlying postpartum psychosis 
remain elusive. Unfortunately, neurobiological studies in patients with postpartum psychosis 
are scarce, probably due to the low incidence of the disorder (1 - 2/1000) combined with 
the acute severity, making it difficult to collect large enough cohorts for a meaningful 
biological or clinical study. Thus far, research focused on endocrine systems has not led 
to clear etiological clues. In contrast to postpartum psychosis, neurobiological research of 
postpartum depression has been extensive, for which several biological mechanisms have 
been carefully explored. Unfortunately, research in this area has also been inconclusive, likely 
due to the heterogeneity of the disease, and complex physiology in the normal postpartum 
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period (54, 55). We believe that neurobiological research in more severe postpartum mood 
disorders, such as postpartum psychosis, has strong potential for future success guided by 
standardized and larger-scale designs. In the next chapters, we propose a novel hypothesis 
to view postpartum psychosis as an immune-related disorder. This perspective has led to the 
studies described in chapter 7 and 8. 
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Introduction
Women are at high risk for severe psychiatric episodes, such as postpartum psychosis, in 
the immediate postpartum period (1). For some women, this psychosis remains entirely 
limited to the postpartum period. Unfortunately however for many women (40-80%), 
postpartum psychosis is the incipient onset of a bipolar mood disorder (2). Genetic studies 
have confirmed the strong etiological link between severe postpartum episodes and 
vulnerability for bipolar disorder (3).  This relationship is further evidenced by high relapse 
rates immediately postpartum in women for whom a diagnosis of bipolar disorder was 
made already prior to pregnancy (1, 4).  Therefore, it is intriguing but unknown why bipolar 
disorder frequently has its onset (or an exacerbation) specifically in the early postpartum 
period. Furthermore, it is also unknown why some women exhibit only severe affective 
psychosis in the postpartum period without any non-puerperal episodes.
 Bipolar disorder has a lifetime prevalence of 2% and is characterized by episodic 
pathological disturbances in mood ranging from extreme elation (mania) to severe 
depression. Based on the most current studies, the heritability for bipolar disorder is 
estimated up to 80% (5).  Although the genetics of bipolar disorder is far from unravelled, the 
current findings support a concept of Immune-Brain Interaction in its pathogenesis (6, 7). 
We and others have reported immune dysfunction in patients with bipolar disorder. Immune 
activation in bipolar disorder encompasses an elevation of serum cytokines and chemokines 
(8-13), a higher prevalence of organ-specific auto-antibodies (14-16), T-cell activation (17, 
18) and inflammatory monocyte gene expression (7, 19). A recent Danish register study 
described a high co-occurrence of autoimmune diseases in patients with bipolar disorder. 
They conclude: “… the results suggest the possibility that the onset of psychosis - including 
bipolar disorder - in some cases arises in connection with a contemporary inflammatory 
process associated with these autoimmune diseases” (20). 
 Here, we hypothesize that the frequent onset (or exacerbation) of bipolar disorder in the 
postpartum period is associated with immune activation postpartum. To further elaborate 
this hypothesis, we will review some of the existing data on immune dysfunction in bipolar 
mood disorder, after a general introduction regarding the normal functions of the immune 
system. 
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The normal functions of the immune system.
Among the most fundamental challenges for the immune system is to provide defence 
against pathogens, by distinguishing pathogenic (foreign) antigens from physiological auto-
antigens. The immune system is broadly defined by two distinct components: innate and 
adaptive responses, each of which utilizes cellular and humoral mechanisms.
The innate immune system represents the evolutionarily more ancient component of 
the immune system, designed to mount an immediate, antigen-non-specific response 
following exposure to an invading microorganism. Innate defence mechanisms are mostly 
represented by the phagocytosis and destruction of microorganisms. The innate immune 
system prominently includes phagocytic cells of the Mononuclear Phagocyte System (see 
explanation below), natural killer cells and humoral proteins, such as complement and acute 
phase proteins (Figure 1). 
The adaptive immune response refers to antigen-specific defence mechanisms that 
require several days to become protective, as they are designed for the targeted clearance 
of identified antigens. It involves a remarkably specific process of antigen recognition 
mediated by high affinity receptors localized on T and B-cells. B-cells are responsible for the 
production of antibodies, which neutralize extracellular bacteria, viruses and toxins. T-cells 
are responsible for the cell-mediated immunity (see below and Figure 1).
Mononuclear Phagocyte system (MPS)
The cells of the MPS form a system of travelling surveillance cells, of which the monocyte 
is the representative in blood. These circulating monocytes are capable of infiltrating target 
tissues, where they differentiate into macrophages or dendritic cells. The classical function 
of MPS cells is to provide defence against foreign intruders via the recognition, uptake and 
full degradation of microorganisms in a process called phagocytosis (an “innate” immune 
process).  Importantly, cells of the MPS not only fully degrade foreign intruders but also 
degrade these to an array of antigenic peptides, which are subsequently presented to T 
and B-cells.  In this process, T-cells and B-cells are triggered and capable of mounting an 
antigen-specific immune response. While macrophages are examples of these antigen-
presenting cells, the most specialized antigen-presenting cells are dendritic cells. Aptly, the 
entire process of antigen presentation by dendritic cells, followed by stimulation of T and 
B-cells is called “immunization”.
 Dendritic cells are not only capable of stimulating antigen-specific T and B-cells to 
proliferate, but also capable of acting as the conductors of the T and B-cells. Under 
conditions of “danger” (e.g., foreign intruders, damaged tissues), a molecular program 
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is engaged within the dendritic cell, leading to proliferative expansion of dendritic cells, 
and followed by a cytotoxic T and B-cell attack on the intruders. Under “steady-state” (i.e., 
normal physiologic) conditions, a molecular program exists within dendritic cells to induce 
T and B-cell tolerance to self-antigens.  In autoimmune and allergic conditions, the steady-
state molecular program in MPS cells is disrupted by intrinsic abnormalities, driving MPS 
cells into an abnormally activated “danger” set-point.
T-cell system
T-cells form a heterogeneous group of cells comprising effector cells, regulatory cells and 
memory cells. T-cells are typically divided into CD4+ and CD8+ classes. Effector CD8+ cells 
are cytotoxic and important in killing endogenous cells infected with virus, intracellular 
bacteria or otherwise dysfunctional (e.g., malignancy). Effector CD4+ cells are important in 
providing help to other T-cells and are therefore called T-helper cells (Th). Upon stimulation 
by an antigen-presenting cell, naïve T-helper cells have four distinct potential cell fates 
of differentiation: Th1, Th2, Th17 and inducible T-regulatory cells. Th1 and Th17 cells are 
capable of macrophage activation, essential for defence against viruses and intracellular 
pathogens. Th2 cells play a central role in B cell activation and antibody production. 
Reactivity to self is primarily accomplished during fetal development through deletion by 
the thymus of auto-reactive T-cells, a process called central tolerance. However, this process 
is not perfect.  Occasionally, some low-affinity auto-reactive T-cells escape this mechanism. 
But, they are prevented from causing autoimmune disease by naturally occurring T-regulatory 
cells (T-reg) of the thymus (21). These T-reg cells represent 2–5% of all peripheral CD4+ 
T cells.  T-reg cells are believed to be important for immune tolerance via suppression of 
low-affinity auto-reactive T-cell clones. The best known subtype of the natural T-regulatory 
cell population is the CD4+CD25+FOXP3+ cell, defined by the high expression of CD25 and 
FOXP3. Progression towards autoimmune diseases, such as type 1 diabetes (T1D), has been 
linked to a decline in the capacity of T-reg to maintain functional antigenic tolerance (21).
Immune dysfunction in bipolar disorder
Clinicians have noticed for decades a high prevalence of autoimmune comorbidity in patients 
with bipolar disorder. In clinical studies, the strongest and most consistent evidence is for high 
co-occurrence of bipolar disorder with autoimmune thyroiditis and multiple sclerosis (20, 22-
24). Accordingly in serum of bipolar patients, there is a higher prevalence of organ-specific 
auto-antibodies (TPO-, H+/K+ATPase-, GAD65- and antiphospholipid antibodies). Importantly 
however, the majority of bipolar patients with antibody positivity do not have overt clinical 
symptoms of an autoimmune disorder (14-16). Rather, these findings are suggestive of an 
immune system dysregulation in a subgroup of patients with bipolar disorder.
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Figure 1. The cells of the immune system
The implication that activation of the immune system is associated with the occurrence 
of mood symptoms is based on the “Macrophage-T-cell theory of mood disorders”, 
formulated in the 1990s (25).  This theory states that chronically activated macrophages 
(and their counterparts in the brain, i.e. microglia) together with T-cells produce cytokines 
and inflammatory compounds impacting brain development, thereby exposing the brain 
to liability for precipitating mood symptoms determined by a given person’s genetic and 
environmental risk factors. 
 Indeed, numerous studies have reported elevated levels of inflammatory cytokines in 
the serum, plasma and cerebrospinal fluid of patients with major mood disorders (26). 
In bipolar disorder, there is evidence for increased cytokine production across all phases 
of illness, although acute exacerbations appear to be a particularly sensitive period in 
demonstrating accentuation of this pro-inflammatory state. During mania, there is evidence 
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for increased CRP, soluble Il-2 receptor, IL-6 and TNFα (27). In contrast, relatively few studies 
have examined immune markers during bipolar depression, for which the findings have 
partly overlapped with those observed during mania but with substantial inconsistence 
across different studies (28). Notably, normalization of the immune activation is observed 
upon clinical remission of bipolar episodes (29). 
 How could elevated serum levels of peripheral cytokines influence the brain? 
Cytokines are relatively large molecules, of which only a subset are capable of readily entering 
the brain through the blood-brain barrier.  However, several routes have been uncovered 
through which cytokines might enter and act in the brain (30).  For example, cytokines can 
enter the brain through parts where the blood-brain barrier is relatively permeable due 
to inflammation or acute stress (via the cerebral endothelium). After entering the brain, it 
has been shown that cytokines bind to their receptors on glial cells and neurons in multiple 
brain regions, where they can trigger dysregulation of major neurotransmitter systems (31).
 Notably, one must take into account that increased levels of pro-inflammatory cytokines 
are not only found in psychiatric disease, but also in cardiovascular disease, autoimmune 
disease and cancer. In addition, it is important to consider that cytokine levels in serum or 
plasma are strongly confounded by age, gender, socioeconomic status, metabolic syndrome, 
visceral obesity, smoking, exercise, poor-rated self-health and medication. Further 
complicating research efforts, cytokine measurements are known to be notoriously difficult 
to analyze in a standardized manner.  Accordingly, we have focused our investigations on 
the cellular producers of cytokines and proinflammatory compounds, namely MPS cells and 
T-cells (30).
 Supporting this approach, our group has identified an elevated number of circulating 
CD25+T cells in patients with bipolar disorder (17, 18). Further, T-cell activation was particularly 
evident within the regulatory arm, for which higher numbers of CD25+FOXP3+Tregulator cells 
were present (predominantly in younger patients). T-cell activation was further evidenced 
by elevated serum levels of IL2-R, a global indicator of T-cell activation. With regard to MPS 
cells, we also found enhanced expression of immune genes in circulating monocytes. These 
gene expression studies were carried out on purified monocytes of 56 bipolar patients and 
matched healthy controls using Affymetrix analyses followed by confirmatory quantitative 
real-time PCR. In total, aberrant expression of 34 mutually correlated genes was detected 
(7, 19). 
 Other groups have found evidence for dysregulated expression of inflammatory related 
genes in post-mortem brain samples of patients with bipolar disorder. In particular, changes 
in transcriptome profiles across multiple brain regions (the frontal cortex, the prefrontal 
cortex and the orbitofrontal cortex) were observed (32, 33).  Notably, while genes involved 
in energy metabolism and mitochondrial function were downregulated, genes involved in 
immune response and inflammation were found to be significantly upregulated, consistent 
with our immunological findings (34).
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Conclusion
Taken together, there is increasingly solid evidence to implicate a dysregulation in the immune 
system as a pathophysiological mechanism for bipolar disorder (35). Therefore, we intend to 
address the following primary research question: Is the frequent onset (or exacerbation) of 
bipolar disorder in the postpartum period associated with immune activation postpartum? 
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Abstract
Background: Postpartum psychosis is a life-threatening psychiatric emergency, which often 
occurs without significant premorbid symptoms.  Although many studies have hypothesized 
an involvement of the immune and endocrine systems in the onset of postpartum psychosis, 
the specific aetiologic factors have remained unknown.  
Aims: We examine the hypothesis that autoimmune thyroid dysfunction may be associated 
with the onset of postpartum psychosis.
Method: Thirty-one consecutive primiparous women with no prior psychiatric history 
were referred to our inpatient unit for postpartum psychosis (n=31).  The control group 
(n=117) compromised primiparous women with consecutive deliveries at a community 
practice.  Blood samples were obtained from all participants at 4 weeks and 9 months 
postpartum.  Thyroperoxidase antibody levels were quantified as immunological measures 
of autoimmune thyroid disease (AITD).  Thyroid stimulating hormone and free thyroxine 
levels were measured to assess clinical thyroid dysfunction.
Results: At 4 weeks postpartum and prior to the initiation of mood stabilizers, 19 % of women 
with postpartum psychosis had AITD compared with 5 % in the control group.  Women with 
both postpartum psychosis and AITD had a dramatically higher risk of progression to clinical 
thyroid dysfunction (67%) than control subjects with AITD (20%).  
Conclusion: Women with postpartum psychosis are at higher risk not only of AITD but also 
of clinical thyroid failure.  These data implicate thyroid function as an important clinical 
outcome in patients with postpartum psychosis.  Further, AITD represents a potentially 
strong aetiologic factor for the development of postpartum psychosis.  Therefore, screening 
for thyroperoxidase antibodies is warranted in patients with postpartum psychosis.
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Introduction
Postpartum psychosis is a severe disorder occurring in 0.1% of childbearing women. 
The clinical symptoms include fluctuations in mood accompanied by delusions and 
hallucinations, as well as agitation, insomnia, and cognitive impairment. Patients often 
require acute hospitalization with thoughts of suicide and infanticide (1-4).  Although there 
are no current treatment guidelines for postpartum psychosis, both antipsychotics and 
mood stabilizers are recommended and widely used (4, 5). Women with bipolar disorder 
are at very high risk of developing postpartum psychosis: up to half of women with bipolar 
disorder relapse in the early postpartum period, often with psychotic symptoms (6-8). 
However, most patients with a postpartum psychosis have no history of psychiatric disorder 
(9).  During the past century many possible determinants of postpartum psychosis have 
been proposed. In particular, many studies have focused on neurosteroid pathways, given 
the dramatic changes in hormone levels throughout pregnancy and the postpartum period. 
However, no specific mechanism has been conclusively identified as an aetiological factor in 
postpartum psychosis. 
 Postpartum autoimmune thyroid disease (AITD) is defined by autoimmune thyroid 
inflammation and elevated thyroid antibody titres, occurring within the first year after 
delivery. With a postpartum prevalence of 5–7% in the general population (10), AITD 
has been identified as a risk factor for postpartum depression (11-15).  In contrast to the 
emerging consensus regarding the link between AITD and postpartum depression, the lower 
incidence of postpartum psychosis has thus far precluded analogous studies.  Although case 
reports have documented the co-occurrence of postpartum psychosis and AITD (16, 17), 
the only previous systematic study found no evidence for an increase of AITD in patients 
with a late-onset presentation of postpartum psychosis (> 4 weeks after delivery) (18). 
Importantly however, no prior study has reported prospective AITD screening in patients 
with classic early-onset postpartum psychosis (≤ 4 weeks after delivery) before the start of 
medication.  Lithium, frequently used in the treatment of postpartum psychosis, has several 
deleterious effects on thyroid function (19). Our study was therefore designed to document 
the prevalence of serological and clinical evidence for autoimmune thyroid dysfunction 
in patients with early-onset postpartum psychosis during the initial 9 months following 
delivery.
Method
The study protocol was approved by the institutional review board of the Erasmus University 
Medical Centre, Rotterdam, The Netherlands. After receiving a complete description of the 
study, all patients and their authorised legal representatives provided written informed 
consent before participation. Between August 2005 and November 2008 we examined all 
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patients referred to the mother and baby in-patient unit of the department of psychiatry 
at the Erasmus Medical Centre for evidence of postpartum psychosis, using the Structural 
Clinical Interview for DSM–IV (SCID)(20). The catchment area for this unit includes the 
provinces of South Holland, Zeeland and North Brabant. Since ‘postpartum psychosis’ is not 
described as a separate disease entity in DSM–IV, we selected patients for whom the SCID 
interview generated the following DSM–IV diagnoses: psychotic disorder not otherwise 
specified, brief psychotic disorder or mood disorder (manic, mixed or major depressive 
episode) with psychotic features, all requiring the specifier ‘with postpartum onset’ (44 
weeks after delivery). Of the 123 patients examined, 55 fulfilled the criteria of postpartum 
psychosis. Twenty-one patients were excluded because of their psychiatric history (eight 
patients with bipolar disorder, five patients with psychosis not otherwise specified, five 
patients with a previous postpartum episode, two patients with schizoaffective disorder 
and one patient with chronic cannabis misuse). Thirty-four patients reported no previous 
psychiatric history. A parallel history was obtained to confirm the time course of symptoms 
for all patients examined. One patient declined to participate. All patients except two were 
primiparous. As parity is a potential risk factor for thyroid autoimmunity (21), data-analysis 
was restricted to the 31 primiparous women.
 Patients were referred by acute psychiatric services and the majority had been briefly 
treated with benzodiazepines (lorazepam, temazepam or oxazepam: 23 patients with a 
treatment duration of 3.5 days, s.d.= 0.6) and/or antipsychotics (haloperidol or olanzapine: 
19 patients, treatment duration 4.5 days, s.d.= 1.1). Of the 31 primiparous women with 
postpartum psychosis, 23 had a presentation of manic psychosis, 5 had a mixed episode 
and 3 presented with psychotic depression. During admission all 31 patients were treated 
with benzodiazepine anxiolytic medication and 29 patients required clinical treatment with 
an antipsychotic. In 25 of these 29 patients a trial of antipsychotic monotherapy provided 
suboptimal efficacy, with addition of lithium for improved mood stabilisation. Lithium dose 
was determined by plasma level (0.6–1.0 mmol/l). Importantly, no patient received lithium 
prior to the plasma sampling at admission.
 The control group was established by screening 291 women consecutively evaluated 
during pregnancy between 1994 and 1996 in the North Brabant province. Selection was 
based exclusively on primiparity, regardless of medical or psychiatric history. Each control 
group participant (n = 117) was followed during pregnancy and the first year after delivery 
to determine the incidence of postpartum thyroid dysfunction and postpartum depression. 
Laboratory thyroid function assays in both the postpartum psychosis and control groups 
were performed using the same immune assays in the same laboratory (Laboratory of 
Autoimmune Diseases, Department of Immunology, Erasmus Medical Centre, Rotterdam). 
Prevalence of autoimmune thyroid dysfunction in postpartum psychosis
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Laboratory assessments 
Blood samples were obtained from all participants 4 weeks and 9 months after delivery. 
In addition, patients with postpartum psychosis had blood samples taken at various times 
over the 9-month study period, as clinically indicated. Thyroperoxidase antibodies were 
measured using the Immulite human immunoassay (Siemens, Los Angeles, California, 
USA); values greater than 35 IU/ml were regarded as positive serological evidence of 
autoimmune thyroid disease. Thyroid-stimulating hormone and free thyroxine levels were 
measured in the clinical laboratory of the Erasmus Medical Centre using reference ranges 
(thyroidstimulating hormone 0.4–4.0mIU/l; free thyroxine 10–24 pmol/l) defined by the 
Centre’s validated standards. Clinical thyroid dysfunction was defined as the coexistence of 
abnormal levels of the two hormones.
Statistical analysis
All analyses were performed using SAS version 9 for Windows. For sample characteristics, 
categorical data were evaluated using Fisher’s exact test and continuous variables using 
a two-sample t-test. Continuous variables are expressed as the mean (standard error) 
unless otherwise indicated. Categorical outcomes were examined using odds ratios with 
corresponding 95% confidence intervals. Time to clinical thyroid dysfunction was evaluated 
using Kaplan–Meier methodology and the log-rank test. All hypotheses were tested with an 
alpha of 0.05 (two-sided).
Table 1. Sample characteristics of women with postpartum psychosis and a general population 
postpartum control group
Postpartum psychosis
Group (n=31)
Postpartum control 
group (n=117) P
Ethnicity, white, n (%) 29 (94) 117 (100)
Never smoked, n (%) 20 (65) 91 (78)
Smoked in pregnancy, n (%)   1 (3) 26 (22) < 0.05 a
Primigravida, n (%) 27 (87) 105 (90)
Caesarean section, n (%)   4 (13) 10 (9)
Preterm birth, n (%)   1 (3) 7 (6) 
History of thyroid disease, n (%)   0 (0) 0 (0)
History of other autoimmune 
disease, n (%)
  0 (0) 0 (0)
Age, years: mean (s.d) 31.2 3.8 28.0 3.3 < 0.0001 b
Birth weight of child, g: mean 3340 3314
a Fisher’s exact test
b Two-sided t-test 
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Results 
Participants with postpartum psychosis were 3.2 years older than the general population 
cohort (Table 1). Although a similar percentage of patients and controls had ever smoked 
in the past, a significantly higher percentage of the control group smoked during pregnancy 
(22%) compared with the patient cohort (3%). No difference was found in the frequency of 
Caesarean section, rate of primigravidity, birth weight of the child or incidence of preterm 
birth. None of the patients or controls had a history of thyroid or autoimmune disease. 
Prevalence of AITD in the early postpartum period
At 4 weeks postpartum, 5% of the control group had AITD, with no case of clinical thyroid 
dysfunction. In contrast, 19% of the patients with postpartum psychosis met criteria for AITD 
on admission to the hospital, before the start of antipsychotic or lithium pharmacotherapy 
(OR = 4.44, 95% CI 1.32–14.92; Table 2). Further, half of the patients with postpartum 
psychosis and AITD also demonstrated clinical thyroid dysfunction at the time of admission 
to the hospital. 
Table 2. Prevalence of autoimmune thyroid disease and clinical thyroid dysfunction 
Postpartum psychosis
group (n=31)
% (n/N)
Postpartum
control group 
(N=117) % (n/N)
Odds ratio (95% CI)
4 weeks postpartum (prior to 
treatment)
Autoimmune thyroid disease 
(AITD)
19 (6/31) 5 (6/117) 4.44 (1.32-14.92)
Clinical thyroid dysfunction 10 (3/31) 0 (0/117) NC a
Clinical thyroid dysfunction per 
AITD 50 (3/6) 0 (0/6) NC
 a
9-months postpartum
Autoimmune thyroid disease 
(AITD)
29 (9/31) 13 (15/117) 2.78 (1.08-7.17)
Clinical thyroid dysfunction 19 (6/31) 3 (3/117) 9.12 (2.14-38.96)
Clinical thyroid dysfunction per 
AITD 67 (6/9) 20 (3/15) 8.00 (1.23-52.25)
AITD, autoimmune thyroid disease; NC, not computed
a Odds ratio cannot be computed given the absence of clinical thyroid dysfunction in controls at 4 
weeks postpartum
Prevalence of autoimmune thyroid dysfunction in postpartum psychosis
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Follow-up
The 9-month prevalence of AITD was significantly higher in women with postpartum 
psychosis (29%) compared with controls (13%; OR= 2.78, 95% CI 1.08–7.17; Table 2). 
Further, clinical thyroid dysfunction occurred in 19% of patients compared with only 3% 
of controls (OR = 9.12, 95% CI 2.14–38.96). Patients with postpartum psychosis showed a 
significantly higher rate of progression from subclinical AITD to clinical thyroid dysfunction 
(log-rank P = 0.017; Fig. 1). Specifically, of the patients with AITD at the 9-month follow-up, 
67% had overt thyroid dysfunction compared with only 20% of the control group (OR = 
8.00, 95% CI 1.23–52.25). Importantly, as shown in both Fig. 1 and Table 2, the increased 
rate of clinical thyroid dysfunction in patients with postpartum psychosis was already 
evident at the time of hospital admission, prior to the administration of antipsychotic or 
lithium treatment. At 9 months, 23 patients remained on lithium monotherapy, 2 patients 
were taking antipsychotics and 2 patients required initiation of antidepressant medication 
(sertraline and citalopram). Notably, the 3 patients who developed AITD and clinical thyroid 
dysfunction during treatment with mood stabilisers were all taking lithium. In contrast, none 
of the 18 lithium-treated patients without AITD developed clinical thyroid dysfunction.
Figure 1. Survival curve of thyroid function during the 9 month study period in patients and controls 
with autoimmune thyroid disorder. 
Figure	2.	Survival	curve	of	thyroid	function	during	the 	
9	month	study	peri d	in	patients	and	controls	with	
AITD.	
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Discussion
To the best of our knowledge, this is the first observational study of primiparous women with 
first-onset postpartum psychosis and no previous psychiatric history. Our data show that 
autoimmune thyroid disease is much more prevalent in women with first-onset postpartum 
psychosis than in postpartum women from the general population. Further, clinical thyroid 
failure occurs significantly faster and in a greater percentage of patients with postpartum 
psychosis. Importantly, these differences appear to be independent of antipsychotic or 
lithium treatment in the early postpartum period. Taken together, the high prevalence 
of clinical thyroid dysfunction in patients with postpartum psychosis is an important 
consideration for both clinical management and pathophysiological understanding.
 Although one limitation of the current study is that the control group was not drawn 
from the identical population within The Netherlands, the 5% point prevalence of AITD in 
our control group at 4 weeks postpartum closely matches the mean prevalence of 5–7% 
determined from a review of over 20 studies on women from the general population (10, 22, 
23). Further, our findings in patients with postpartum psychosis are similar to the increased 
prevalence of AITD in women with bipolar disorder (24).  In addition, a twin study of people 
with bipolar disorder showed that AITD was not only related to the disorder itself but also 
to the genetic vulnerability to development of the disorder (25).  
 During pregnancy, changes in the maternal immune system are necessary to induce 
tolerance of the mother towards genetically different fetal tissue. From a clinical point of 
view, this state of tolerance is reflected by a substantial amelioration of symptoms in patients 
suffering from certain autoimmune diseases, such as rheumatoid arthritis or autoimmune 
thyroiditis (26).  Consistent with this model, substantial decreases of the relevant serum 
autoantibody concentrations are frequently observed during pregnancy (12).  After 
delivery, the immunosuppressive state of pregnancy is not only restored but shoots into 
overreaction (the “rebound phenomenon”).  In some women this results in exacerbation 
of pre-existing autoimmune disease or a first manifestation of an episode of autoimmune 
disease, reflected by increases in autoantibody concentrations (27). Postpartum immune 
activation is postulated to produce the clinical manifestations of both thyroid dysfunction 
and psychiatric illness (Figure 2).  In one scenario, the postpartum psychotic condition per se 
may exacerbate an underlying postpartum thyroiditis.  Conversely, in some cases postpartum 
thyroiditis may serve as an important aetiological factor, leading to either depression or 
mania, depending upon the patient’s neurobiological vulnerability.
Prevalence of autoimmune thyroid dysfunction in postpartum psychosis
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Figure 2.  Pathophysiological model for a shared vulnerability to autoimmune thyroid dysfunction 
and postpartum psychosis. 
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From a clinical point of view, it is evident that postpartum thyroid dysfunction needs to be 
diagnosed and treated early (22, 23).  Given our findings of a dramatically increased rate of 
autoimmune thyroid dysfunction in women with postpartum psychosis, we strongly suggest 
that thyroid function and autoantibody titers should be rigorously monitored in all women 
presenting with postpartum psychosis. Further, we believe that all women at high risk of 
developing postpartum psychosis should be screened for thyroperoxidase antibodies prior 
to delivery.  Clinically, a previous history of bipolar disorder and/or postpartum psychosis 
is the only known strong risk factor for developing a subsequent postpartum psychosis. 
Therefore, we recommend that any woman with a previous history of bipolar disorder and/
or postpartum psychosis should have thyroperoxidase antibody testing.  Importantly, for 
effective perinatal screening of this antibody, we recommend testing in early gestation or 
preferably before pregnancy because TPO antibody levels decrease significantly during 
pregnancy. Further, in these high risk groups we recommend testing thyroid function and 
autoantibody titers at both 4 weeks and 6 months postpartum, given the well-documented 
postpartum rebound of thyroid autoantibodies.
 Several studies have documented that in addition to female gender, elevated 
thyroperoxidase antibody titre and lithium treatment are both independent risk factors for 
the development of thyroid dysfunction (24, 28).  However, lithium has widespread clinical 
support as a highly effective mood stabilizer in postpartum psychosis (4, 29).  Although our 
study lacks the statistical power to determine the influence of lithium treatment on thyroid 
function, the risks and benefits of lithium should be weighed carefully in choosing the most 
appropriate pharmacologic regimen for treatment of postpartum psychosis, particularly for 
patients with elevated thyroperoxidase antibody titres.
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 Together, these data demonstrate compelling evidence for autoimmune thyroid 
dysfunction in patients with postpartum psychosis.  Further research is needed to confirm 
our findings and ascertain whether AITD is an aetiological factor in postpartum psychosis. 
Acknowledgements: We greatly appreciate Harm J. de Wit, Siska Verploegh, Jeroen 
Vervoort, and Andre Wierdsma for their assistance.
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Abstract
Background: Accumulating evidence suggests that dysregulation of the immune system 
represents an important vulnerability factor for mood disorders. Postpartum psychosis (PP) 
is a severe mood disorder occurring within 4 weeks after delivery, a period of heightened 
immune responsiveness and an altered endocrine set point. Therefore, the aim of this study 
was to examine immune activation in patients with first-onset PP at the level of monocytes, 
T-cells, and serum cytokines/chemokines.
Methods: We included 64 women consecutively admitted with first-onset postpartum 
psychosis (PP).  Control groups included healthy postpartum (n=43) and non-postpartum 
(n=37) women.  A quantitative-PCR monocyte gene expression analysis was performed 
using 45 genes previously identified as abnormally regulated in non-postpartum mood 
disorder patients including the isoforms of the glucocorticoid receptor.  T-cell percentages 
were measured by FACS analysis, while serum cytokines/chemokines were determined 
using a cytometric bead array.
Results: Compared to healthy non-postpartum women, monocyte gene expression and 
T-cell levels in the postpartum period were significantly elevated.  Among the postpartum 
women, PP patients had a significant up-regulation of monocyte genes not otherwise 
elevated in the normal postpartum period.   Further, the glucocorticoid receptor-β/α gene 
expression ratio was increased in monocytes of PP patients, strongly correlating with their 
immune activation.  Remarkably however, PP patients had significantly reduced levels of 
total T-cells and total T helper cells, as well as Th1 and Th17 subsets, compared to healthy 
postpartum controls.
Conclusion: This study demonstrates a robust dysregulation of the immuno-neuro-
endocrine set point in PP, with a notable over-activation of the monocyte/macrophage arm 
of the immune system.
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Introduction 
Postpartum psychosis is an acute psychiatric emergency and considered the most severe 
postpartum mood disorder. The acute onset of mood symptoms and psychosis occurs within 
the first four weeks postpartum (1).  Remarkably, the majority of patients admitted with 
postpartum psychosis have no prior diagnosis of a psychiatric disorder (2). While some 
patients experience symptoms only during the postpartum period, postpartum psychosis 
will often in retrospect be appreciated as the incipient presentation of bipolar disorder (3). 
 Thus far, neurobiological research in postpartum psychosis has been principally focused 
on neuro-steroid pathways because of the dramatic changes occurring in hormone levels 
in the early postpartum period. Further, sleep deprivation has been described as a possible 
causal trigger for postpartum psychosis (4). However, the precise underlying mechanisms 
have remained elusive (5-7).
 Although little is known about the biological mechanism underlying postpartum 
psychosis, there is accumulating evidence that an abnormal activation of the immune system 
might be central to the pathogenesis of bipolar disorder (8). This activation is reflected by an 
elevation of serum cytokines and chemokines (9-14), an activation of circulating monocytes 
demonstrated through profiling of inflammatory gene expression, as well as through an 
activation of the T-cell system (15, 16). Given the overlapping clinical characteristics with 
bipolar disorder, postpartum psychosis might also be characterized by immune activation, 
especially because the postpartum period is considered as a period of elevated immune 
responsiveness. During pregnancy, changes in the maternal immune system are necessary 
to induce tolerance of the mother towards the histo-incompatible fetus.  However, following 
delivery the relative immune suppressive state of pregnancy shows a rebound, during which 
many immune diseases are well-described to become clinically exacerbated or have their 
initial onset (17-24).
 Here we perform a detailed and comprehensive analysis of immune activation in a 
cohort of patients with first-onset postpartum psychosis and no prior psychiatric history. 
Further, we included both healthy postpartum and non-postpartum women as control 
groups, given that the healthy postpartum period is a period of immune activation.  We 
have investigated inflammatory gene expression in circulating monocytes, focusing on those 
genes previously found to be significantly up regulated in bipolar disorder, schizophrenia, 
and major depression (15, 16). We also included genes related to autoimmune thyroid 
disease and glucocorticoid receptor signalling, to specifically evaluate the hypothesis that 
postpartum psychosis is the psychopathological endpoint of a deregulated neuro-immuno-
endocrine axis (6, 25-27).  In addition to monocyte gene expression, we also determined the 
percentages of circulating lymphocytes, Th1, Th2, Th17, Treg, and of natural killer (NK) cells 
using detailed FACS analysis. Lastly, we determined the level of monocyte and T-cell related 
cytokines/chemokines in serum. 
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Methods and Materials
Participants
This study was approved by the medical ethical committee of the Erasmus MC Rotterdam. 
All subjects provided written informed consent. Sixty-four (n=64) patients with first-onset 
postpartum psychosis (PP) were recruited from the Mother-Baby Inpatient Unit of the 
Department of Psychiatry of the Erasmus University Medical Center in Rotterdam, the 
Netherlands between August 2005 and May 2011.  All patients were diagnosed according 
to DSM-IV-TR (28) using the Structural Clinical Interview for Disease (SCID – 1/P research 
version).  The clinical characteristics of this cohort have been described in detail (29).
 Briefly, we have included patients with any of the following diagnoses, including the 
specifier “onset postpartum”: depressive disorder with psychotic features, mania with 
psychotic features, mixed episode with psychotic features, or brief psychotic disorder. 
Importantly, the specifier “onset postpartum” requires that the onset of symptoms must 
occur within 4 weeks postpartum. Patients with a history of prior psychotic episodes and/
or bipolar disorder were excluded. Physical examination and routine laboratory screening 
were performed at the time of study enrolment to confirm the absence of infection. All our 
patients were in an acute disease state at moment of blood withdrawal.
 Monocyte gene expression was conducted in 2 distinct cohorts, to allow for independent 
replications of our analyses.  In the first cohort, we used a group of 23 healthy control women, 
with low levels of depressive symptoms as assessed by the Edinburgh Postnatal Depression 
Rating Scale (EPDS) score <10 at the time of 4 weeks postpartum blood sampling, collected 
between 1994-1996 (30) (31).  The monocyte gene expression replication cohort, for which 
all T-cell and cytokine tests were also performed, consisted of 43 healthy postpartum 
women recruited between 2008-2011 through the Department of Obstetrics & Gynaecology 
(Erasmus MC, Rotterdam), with an EPDS score <10 at the time of 4 week postpartum blood 
sampling. Thirty-seven (n=37) healthy age-matched non-postpartum women were recruited 
from the Rotterdam general population between 2005-2011. Inclusion criteria for both 
postpartum and non-postpartum controls included the absence of any medical, neurologic, 
psychiatric, autoimmune disorder or acute infections. 
Blood collection and preparation
Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in sodium-
heparin tubes for immune cell preparation. From the heparinized blood, peripheral blood 
mononuclear cell (PBMC) suspensions were prepared by low-density gradient centrifugation, 
as described previously in detail (32), within 8 hours to avoid activation of the monocytes 
(erythrophagy). PBMCs were frozen in 10% dimethylsulfoxide and stored in liquid nitrogen. 
This enabled us to test patient and control immune cells in the same series of experiments 
later.
Immune system dysregulation in first-onset postpartum psychosis 
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Gene expression of monocytes
Isolation of monocytes, RNA isolation and RT-qPCR.
CD14 positive monocytes were isolated from frozen PBMCs by magnetic cell sorting system 
(Miltenyi Biotec). The purity of monocytes was >95% (determined by morphological 
screening after Trypan Blue staining and FACS). RNA was isolated from purified monocytes 
using RNAeasy columns according to the manufacturer’s instructions (Qiagen, USA) (33).
 For the initial monocyte gene expression analysis, we included 15 consecutive PP 
patients, 23 controls postpartum (CP), and 17 healthy controls (HC). We used the BIOMED-1 
protocol (15). To obtain cDNA for RT-qPCR, 1 µg RNA was reversed-transcribed using 
Superscript-II (Invitrogen) and random hexamers (Amersham Biosciences, Roosendaal, 
The Netherlands) for 50 min at 42 C. RT-qPCR was performed with Taqman Universal PCR 
Mastermix (Applied Biosystems, Foster City, CA) as previously described (16). RT-qPCR 
conditions were 2 min at 50 C, 10 min at 95 C, followed by 40 cycles of 15 s at 95 C, and 
finally 1 min at 60 C. PCR amplification of the reference gene ABL was performed for each 
sample to allow normalization between the samples. Expression values were calculated 
using the comparative threshold cycle (CT) method.
 For the independent replication sample, we included 23 consecutive PP patients, 
17 controls postpartum (CP), and 9 healthy controls (HC), using a more advanced gene 
expression technique. One mg RNA was reversed-transcribed using High Capacity cDNA Kit 
(Applied Biosystems, Nieuwerkerk a/d Ijssel, The Netherlands) for 120 min at 37 C, while 
RT- qPCR was performed using a preloaded Taqman Low Density Array (TILDA) for real-
time amplification and relative mRNA qualification (Applied Biosystems, Foster City, CA). 
A TaqMan Low Density Array is an Array of 384 reaction wells for two-step RT-qPCR.  Each 
cDNA sample (40 µL) was added to 50 µL 2x TaqMan universal PCR master mix (Applied 
Biosystems) and 10 µLRNase free water was added to get an total volume of 100 µL. After 
gentle mixing and centrifugation, the sample was transferred on a TLDA card. The card 
was sealed and PCR amplification performed using an Applied Biosystems Prism 7900HT 
sequence detection system (equipped with a TaqMan low density array upgrade). Thermal 
cycler conditions were: 2 min at 50 C, 10 min at 94.5 C, 30 s at 97 C, and 1 min at 59.7 C 
for 40 cycles. Expression values were calculated using the comparative threshold cycle (CT) 
method. The next-generation assay for RNA expression analysis (TaqMan Low Density Array, 
TLDA) used in cohort 2 was extensively validated against the single RT-qPCR method used in 
cohort 1.
T-cell subsets
Intracellular staining and fluorescence-activated cell sorting (FACS) analysis
We determined the percentages of circulating T-cell subsets in 41 consecutive women with 
PP, 30 CP, and 31 HC using intracellular staining and fluorescence-activated cell sorting (FACS) 
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analysis, as described previously (34, 35) and in the legend of Table 3 in detail. Specifically, 
we determined the percentages of Natural Killer cells (CD3-CD56+ NK cells), total T-cells 
(CD3+ T-cells), cytotoxic T-cells (CD3+CD8+ T-cells) and T-helper cells (CD3+CD4+ T-cells). The 
latter group is not a homogeneous group but can be subdivided into three effector and one 
regulator subgroups. The effector subgroups are identifiable by the panel of cytokines they 
secrete. T-helper 1 cells (Th1) and T-helper 17 cells (Th17) are involved in the activation of 
macrophages and secrete IFN-γ and IL-17, respectively. T-helper 2 cells (Th2) cells secrete 
IL-4 and IL-5, involved in the activation of B-cells. The regulator subgroup is formed by the 
natural T-regulatory cells, which dampen the activity of Th1, Th2, and Th17 cells. Natural 
T-regulator cells can be identified by CD25 and FOXP3 expression. Membrane staining of 
CD3, CD4, and CD25 enabled us to determine the percentages of Th1, Th2, and Th17 cells, 
respectively, as well as the regulatory T-cell population, in combination with staining of the 
hallmark intracellular cytokines IFN-γ, IL-4, and IL-17A and transcription factor FoxP3.
Serum cytokine determination
Multiple serum cytokines were measured using an array approach: the Cytometric Bead Array 
kit (CBA, BenderMedSystems, California, USA) according to the manufacturer’s protocol. 
Samples were analyzed in a FACS flow cytometer (BD Biosciences, California, USA) with the 
FlowCytomix Pro 2.3 Software (BenderMedSystems, California, USA). Using subjects enrolled 
in the study exclusively within the previous 12 months, we determined serum levels of the 
monocyte/macrophage cytokines CCL2, IL-1β, IL-6, the pro-inflammatory T-cell cytokine IL-
22, and the anti-inflammatory cytokine IL-10. The T-cell growth factor receptor sIL-2 levels 
were measured using a commercially available serum ELISA (DIACLONE Besancon, France).
Statistical Analysis
All analyses were performed using SAS, version 17.0 (SAS Institute, Inc., Cary, NC).  For 
sample characteristics, categorical data were evaluated using Fisher’s exact test and 
continuous variables using a two-sample t-test.  Continuous variables are expressed as 
the mean ± standard error, unless otherwise indicated.  The Mann-Whitney U test was 
used to compare levels of nonparametric parameters (serum cytokines/chemokines and 
percentages of T-cells). Statistical analysis on the gene expression data in monocytes was 
performed using DataAssist version 3.0 (Applied Biosystems, Life Technologies Corporation). 
Correlations were determined via Spearman rank correlation coefficients. All hypotheses 
were tested with an alpha of 0.05 (two-sided).
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Results
Sample Characteristics
There were no significant differences in obstetric characteristics between women with 
postpartum psychosis (PP) and healthy postpartum women (CP) (Table 1). In the 1st  CP 
cohort women were significantly younger and weighted less compared to patients. There 
was no difference in age and weight between patients and controls in the 2nd CP cohort. 
Significantly more CP women in both control cohorts were breastfeeding at the time of blood 
withdrawal (P < 0.01), given that all women with postpartum psychosis were advised to stop 
breastfeeding upon admission. At the time of blood sampling , the majority of PP patients 
were being treated with benzodiazepines (51 patients; 6.5 ±1.5 days) and/or antipsychotics 
(39 patients; 6.8 ± 1.8 days). 
Table 1.  General and obstetric characteristics of healthy controls, healthy controls postpartum (2 
different cohorts) and patients with first onset postpartum psychosis.
Healthy 
Controls 
N=37
Controls 
Postpartum-I
N=23
Controls 
postpartum II 
N=43
Postpartum 
Psychosis
N=64
Difference 
between 
groups
Mean S.E.M Mean S.E.M Mean S.E.M P 1 P 2
Age (years) 32.4 
(1.1)
28.6 (0.6) 32.7 (0.6) 32.0 (0.6) < 0.01 0.50
Weight  62.5 (1.2) 71.8 (1.8) 71.6 (1.7) < 0.01 0.94
bloodwithdrawal, 
days postpartum 
28.0 (0.8) 28.1 (2.0) 33.6 (3.7) 0.36 0.25
N % N % N %
Primiparity 19/23 82.6 25/43 58.1 41/64 64.0 0.12 0.55
Primigravidity 19/23 82.6 28/43 65.1 51/64 79.6 1.0 0.11
Caeserian section 2/23 8.7 10/43 23.2 9/64 14.0 0.72 0.30
Vacuum extraction 3/23 13.0 4/43 9.3 7/64 10.9 0.72 1.0
Breastfeeding at time 
of bloodwithdrawal 
9/23 39.1 28/43 65.1 2/64 3.1 < 0.01 < 0.01
1  Significance versus Controls Postpartum cohort I
2 Significance versus Controls Postpartum cohort II
Activation state of monocytes 
In a first series of experiments, we determined the gene expression in monocytes in a sample 
of 15 consecutive first-onset PP patients, 23 CP women, and 17 healthy non-postpartum 
(HC) women. For this cohort we determined the monocyte expression of 25 genes which 
had been identified as strongly up regulated in bipolar disorder within 2 highly correlated 
gene clusters (15). The first cluster of genes predominantly consisted of pro-inflammatory 
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genes, while the second cluster consisted of adhesion, motility and, chemotactic factors.
A drawback of this series is the prolonged storage of the cells from CP women as compared 
to the PP and HC women. In order to overcome this drawback, we examined a second 
independent cohort of patients and controls that were collected in parallel over the same 
time period (2008-2011) in order to validate and further extend our findings.
We included a new group of 23 consecutive PP women, 17 CP women from the same hospital, 
and 9 HC women. We determined the monocyte gene expression of 43 genes, including the 
25 genes examined in the first cohort, plus an additional set of 5 genes identified as up 
regulated in schizophrenia (16), 6 genes identified in studies of major depressive disorder 
(36), 4 interferon-inducible genes (37), 1 gene from studies of autoimmune thyroid disorder 
(38), as well as the transcripts for both the active and inactive glucocorticoid receptor. 
Given the more extensive set of genes analysed in the replication cohort, we performed a 
new cluster analysis for postpartum psychosis (Figure 1). Two main clusters were identified 
and these clusters extensively overlapped with the previously identified monocyte gene 
cluster 1 and 2 from bipolar patients (15, 16).
Figure 1.  Heat map of gene correlation.  Correlation of expression of the various genes; data 
represent Spearman’s correlation coefficients, tested on the relative mRNA expression of the genes 
in 23 postpartum psychosis patients. The correlations of all tested genes to each other are shown. 
Significant positive correlations (p<0.05) are given by the red scale (darkest red are correlations >0.50), 
significant negative correlations are given by the green scale. Lighter fields are not significant. 
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Healthy postpartum women
Monocytes of CP women showed moderate upregulation of cluster 1 genes, compared to HC 
women (Table 2). In the 1st cohort, 6/13 cluster 1 genes were significantly upregulated; while 
in the 2nd cohort, expression levels for only 3/19 of the cluster 1 genes were significantly 
increased. In contrast to the upregulation of cluster 1 genes, the changes in the cluster 2 
genes were not consistent between the two study cohorts: in the initial cohort 4/13 were 
altered; while in the 2nd cohort, significant changes were not observed.
Postpartum psychosis 
In women with PP, monocyte gene expression was consistently and more robustly 
upregulated, compared to both the HC and CP women (Table 2). Compared to HC, all cluster 
1 genes upregulated in CP were also upregulated in PP within both the initial and replication 
cohorts. Of the remaining cluster 1 genes that were unchanged in CP monocytes, PP women 
showed upregulation of 4/6 genes in the initial cohort and 7/16 genes in the replication 
cohort as compared to the HC women (Table 2). Further, compared to the expression in 
the CP cohort, expression levels of 4/13 genes in the 1st cohort and 5/19 genes in the 2nd 
cohort were significantly increased. 
 In contrast to the more robust changes in cluster 1 gene expression, changes in cluster 
2 were more modest.  In the initial cohort, 2/11 cluster 2 genes in PP women had an 
altered expression level compared to HC, while just 1 gene was significantly different from 
CP women.  In the replication cohort, 7/16 cluster 2 genes were significantly upregulated 
compared to HC and 3/16 were significantly upregulated compared to CP women.
 
Figure 2.  Correlations of all tested genes to GR a and GR b expression in patients 
with postpartum psychosis (PP), healthy controls postpartum (CP) and healthy 
controls not postpartum (HC). Significant positive correlations (p < 0.05) are 
given by the red scale (darkest red are correlations > 0.50), significant negative 
correlations are given by the green scale.
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Together, all genes showing significant upregulation between postpartum psychosis 
and postpartum healthy controls were genes not otherwise upregulated in the normal 
postpartum period.
With regard to the GR expression we found the inactive GR-β up regulated in PP women as 
compared to HC and CP women, while the active GR-α expression was somewhat reduced. 
This resulted in a significantly higher GR-β/GR-α ratio in monocytes of women with PP as 
compared to those of both control groups (P = 0.02, Figure 2). The upregulation of the 
inactive GR-β correlated positively and significantly to the over expression of many of the 
monocyte activation genes (Figure 2). 
With regard to serum cytokine/chemokine levels, CP subjects showed significantly higher 
levels of the pro-inflammatory cytokine IL-1β compared to HC (p=0.026). Women with PP 
showed significant higher expression levels of CCL2 compared to both HC (p= 0.040) and CP 
(p=0.036). 
Table 2. RT-qPCR analysis of monocytes in two cohorts of patients with first onset postpartum 
psychosis (PP) compared to healthy controls (HC) and healthy controls postpartum (CP). 
Postpartum control 
group
n=23
Postpartum 
psychosis group 
n= 15
Postpartum control 
group n=17
Postpartum 
psychosis group
n=23
Cluster 1 mean P-Value mean P-Value mean P-Value mean P-Value
IL1A 0,49 0,54 2,04 0,32
IL1B 49,47 0,00 109,10 0,00 1,35 0,55 2,24 0,08
CCL20 192,18 0,00 936,13 0,00 1,18 0,90 5,59 0,01
IL6 557,96 0,00 1819,87 0,00 4,11 0,02 6,89 0,00
PTX3 3,85 0,11 10,53 0,14 0,93 0,83 1,39 0,18
IRAK2 1,07 0,91 1,53 0,22
TNF 16,86 0,00 11,63 0,02 0,62 0,38 0,83 0,60
BCL2A1 1,60 0,90 4,69 0,06 1,73 0,19 2,70 0,00
CXCL2 7,71 0,00 18,03 0,02 2,46 0,19 5,41 0,00
PTGS2 4,10 0,13 7,56 0,00 3,16 0,02 5,33 0,00
ADM 1,10 0,83 1,92 0,04
BTG3 1,08 0,83 1,68 0,06
SERPINB2 1,53 0,52 2,26 0,02
PDE4B 2,46 0,80 4,76 0,03 1,21 0,55 2,54 0,00
TNFAIP3 8,50 0,00 8,90 0,01 1,20 0,68 1,60 0,17
ATF3 1,29 0,49 3,18 0,06 2,59 0,04 3,28 0,00
CDC42 1,31 0,49 1,94 0,91 1,52 0,52 1,85 0,11
MAFF 2,66 0,52 5,22 0,06
DUSP2 3,13 0,40 3,59 0,07 2,05 0,41 3,27 0,02
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Postpartum control 
group
n=23
Postpartum 
psychosis group 
n= 15
Postpartum control 
group n=17
Postpartum 
psychosis group
n=23
Cluster 2 mean P-Value mean P-Value mean P-Value mean P-Value
CCL7 11,89 0,11 19,46 0,54 0,67 0,83 9,57 0,02
FCAR 0,72 0,01 1,42 0,59 1,17 0,55 1,81 0,00
PTPN7 0,84 0,02 0,73 0,01 0,91 0,83 1,11 0,64
THBD 1,20 0,52 1,86 0,00
RGC32 1,52 0,55 2,81 0,02
STX1A 1,61 0,18 1,15 0,22 1,09 0,91 2,29 0,12
EMP1 0,88 0,14 0,80 0,19 1,38 0,52 2,12 0,01
NAB2 0,40 0,00 0,55 0,00 0,83 0,80 1,44 0,27
MAPK6 1,08 0,39 1,50 0,90 0,88 0,55 1,13 0,38
DHRS3 3,87 0,00 1,97 0,22 1,26 0,52 1,24 0,34
MXD1 1,22 0,52 1,97 0,00
IL1R1 0,96 0,91 1,57 0,08
CCL2 1,82 0,11 3,95 0,52 1,23 0,80 1,93 0,07
EGR3 5,47 0,19 9,24 0,02
CD9 2,04 0,51 1,29 0,41 1,57 0,67 1,11 0,86
FABP5 1,61 0,17 1,41 0,94 1,01 0,91 0,98 0,85
IFN related cluster
IFI44 1,14 0,55 1,31 0,06
IFI44L 1,09 0,83 1,36 0,22
IFIT3 1,26 0,64 1,24 0,52
HSP70 1,77 0,00 1,69 0,01 1,40 0,52 1,03 0,92
ADAM17 1,13 0,52 1,03 0,85
IFI27 1,01 0,98 1,47 0,27
Glucocorticoid receptor genes
NR3C1-GR-alpha 0,99 0,93 0,88 0,18
NR3C1-GR-beta 1,04 0,91 1,54 0,06
beta/alpha *1000 1,09 0,67 1,63 0,02
Significant dysregulation compared to healthy controls (p<0.05, see table) is given in bold. Significant 
dysregulation in patients with postpartum psychosis compared to controls postpartum are highlighted 
in grey (p<0.05, p values not given). ND= Not Determined; these genes were only determined in cohort 2. 
The quantitative value obtained from qPCR is a cycle threshold (CT). The fold change values between 
different groups were determined from normalized CT values (CT gene- CT housekeeping gene), by 
the ΔΔCT method (2-ΔΔCT, User Bulletin 2, Applied Biosystems, Foster City, California). To correct for 
inter-assay variance, we set the mean of the studied genes found in the healthy control groups (HC) 
in the same assay for each gene to 1. The fold change values of the genes in patient monocytes were 
expressed relative to this set mean of 1. 
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Lymphocyte subsets
T cell counts and T-cell growth factor sIL2-R were measured in 41 consecutive patients with 
PP, 30 CP and 31 HC (Table 3).
Healthy postpartum women
Circulating Natural Killer cells were reduced in the postpartum period (P = 0.04), while 
percentages of circulating T-cells were elevated (P < 0.01, Table 3). This rise in T-cells was due 
to a significant rise in CD4+ T helper cells (P = 0.02). Within the CD4+ helper compartment, 
not only were the Th1 and Th17 cell percentages increased (P = 0.04 and P < 0.01), but also 
the percentages of T regulatory cells (P = 0.03), suggesting a balance between effector and 
regulator forces despite T-cell activation. The rise in T-cell numbers was not reflected by a 
rise in the levels of the sIL2-R in serum. 
Table 3 Percentage of different T-cell subsets in female healthy controls (HC), healthy controls 
postpartum (CP) and of patients with first onset postpartum psychosis (PP) using FACS analysis.
Healthy 
Controls N=31
Controls Postpartum
N=30
Postpartum psychosis
N=41
Mean SD Mean SD P 1 Mean SD P 1 P 2
NK cells: CD3-CD56+ (%) 14.19 (7.8) 9.93 (3.5) 0.04 11.43 (4.6) 0.31 0.32
T-cells: CD3+ (%) 73.15 (5.8) 79.56 (5.4) 0.00 73.46 (8.0) 0.67 0.01
Cytotoxic T-cells: CD3+/CD4- (%) 17.26 (10.7) 16.81 (7.6) 0.11 20.25 (8.1) 0.09 0.68
T helper cells: CD3+/CD4+(%) 46.11 (9.8) 52.00 (8.5) 0.02 47.49 (8.5) 0.92 0.04
Th1: CD4+IFNγ+  (%) 4,83 (2,4) 6,07 (2,3) 0.04 4,58 (2,5) 0.56 0.01
Th2: CD4+IL-4+ (%) 0,97 (0,4) 1,10 (0,5) 0.22 0,98 (0,4) 0.84 0.26
Th17: CD4+IL17A+ (%) 0,24 (0,2) 0,38 (0,2) 0.00 0,29 (0,2) 0.30 0.02
Treg:CD4+CD25+FoxP3+ (%) 2,10 (0,6) 2,62 (0,8) 0.03 2,18 (0,5) 0.40 0.06
IL-2R+ T-cells : CD25+ 14,63 (7,2) 16,32 (7,58) 0.39 16,86 (8,4) 0.29 0.82
1  Significance versus Healthy Controls  (Mann Whitney U test)
2 Significance versus Controls Postpartum (Mann Whitney U test), 
To obtain detectable cytokine levels within lymphocytes, PBMC samples were suspended in complete 
culture medium and stimulated with PMA and ionomycin (both from Sigma Aldrich, Missouri, USA) in 
the presence of transport inhibitor GolgiStop (Becton Dickinson, New Jersey, USA) for 4 hours in 37°C 
under a 5% CO2 environment. Cells were harvested and stained extra-cellularly with anti-CD4 APC and 
anti-CD45RO FITC (DAKO, Glostrup, Denmark). For determination of regulatory T-cells, non-stimulated 
PBMC samples were stained with anti-CD3 FITC, anti-CD4 PerCP-Cy5.5, anti-CD25 APC and anti-CD56 
PE-Cy7. Following extracellular staining, cell samples were fixed and permeabilized using the FoxP3 
staining buffer set (eBioscience, California, USA) according to the manufacturer’s instructions. Next, 
stimulated cell samples were stained intra-cellularly with anti-IL-4 PE-Cy7, anti-IFN-γ PerCP-Cy5.5 
(both from eBioscience, California, USA) and/or anti-IL-17A PE and non stimulated cell samples with 
anti-FoxP3 PE.  All antibodies were from Becton Dickinson, New Jersey, USA, unless stated otherwise. 
Stained cells were analyzed on a BD LSR II flow cytometer (BD Biosciences, California, USA) as described 
previously and analyzed using FlowJo (Tree Star Inc. Ashland, Oregon, USA) research software.
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Postpartum psychosis
Women with postpartum psychosis did not show the higher percentages of total T-cells, 
Th1, Th17 and T regulator cells observed in the healthy postpartum period.  Consequently, 
there were significantly reduced levels of T-cells (P = 0.01), T-helper (P = 0.04), Th1 (P = 
0.01), and Th17 (P = 0.02) cells compared to healthy postpartum control women (table 3). T 
regulatory cells were reduced at a significance level of P = 0.06. Serum levels of sIL2-R were 
in the range of both the healthy postpartum and non-postpartum control group. 
Relation of monocyte activation and T cell numbers to medication use, disease status, 
mode of delivery and breastfeeding
The majority of patients were on medication for just a few days at the time of bloodsampling. 
Antipsychotic and/or benzodiazepine use did not result in a significant change in gene 
expression in cohort 1. In the larger patient cohort 2, antipsychotics decreased the 
expression of 3/43 genes: DUSP2 (r=-0,45, p=0.03), PTX3 (r=-0,58 p=0.03), TNF (r=-0,49, 
p=0.02), while benzodiazepines decreased expression in 4/43 genes: IL1B (r=-0,43, p=0.04), 
PTX3 (r=-0,43, p=0.04), PTGS2 (r=-0,52, p=0.01), TNFAIP3 (r=-0,48, p=0.02). Benzodiazepine 
use was positively correlated with Th2 helper cells (r=0,34, p=0.03). Further, medication use 
was not related to significant changes in cytokine/chemokine levels.
  Patients with symptoms of psychotic depression showed lower gene expression for 3 
genes compared to patients with manic psychotic symptoms in cohort 1, but this finding was 
not replicated in the larger cohort 2 analyses. Further, there were no differences observed 
in T-cell subsets or cytokines/chemokine levels between patients with depressive or manic 
psychotic symptoms.
 There was no significant correlation between mode of delivery and any of the 
inflammatory genes in healthy controls or patient, in either cohort. However, there was 
a significant increase of the monocyte/macrophage chemokine CCL2 (r=0.27, p=0.04) in 
patients with a caesarean section. Further, CP with delivery by caesarean section showed 
higher percentages of Th1 helper cells (r=0.52, p=0.03). In contrast, there was no significant 
correlation between the duration of delivery and any of these immune parameters. 
 Although there was no significant correlation between breastfeeding and inflammatory 
gene expression in healthy controls from cohort 1, healthy controls from the larger replication 
cohort who were breastfeeding at time of blood withdrawal had a significant upregulation 
of FAB5 (r=0.63,  P=0.006). Further, we found no effect of breastfeeding on T-cell subsets or 
cytokine/chemokine levels. 
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Discussion
Our study confirms that the normal postpartum period is a time of immune system alteration. 
Our findings show a modest gene transcription activation of monocytes, an increase in 
serum IL-1β and circulating T-cell numbers across multiple T-cell subtypes, but a decrease 
in NK cell numbers. The fact that both the percentages of T-effector and T-regulatory cells 
were increased in the postpartum period confirms a previously hypothesized balance 
between inflammatory and anti-inflammatory T cell forces (39).  The observation of low NK 
cell numbers during the normal postpartum period is also consistent with previous reports 
(40). Therefore, our data support the concept that the immune system reaches a distinct 
activation set point in the postpartum period of the macrophage-T cell arm. It is therefore 
not surprising that across the lifespan of women, the risk of immune disease exacerbation is 
elevated during the postpartum period. (41-43). 
 There are several reports suggesting that the activated T-cell system is specifically 
responsible for many postpartum immune syndromes (e.g. postpartum thyroiditis) (18). 
Further, an activated T-cell system has also been associated with susceptibility for mood 
disorders (34, 44-46). Surprisingly however, we did not find evidence of T-cell activation in 
women with postpartum psychosis. On the contrary, the percentages of circulating T-cells 
and T cell subsets were even significantly decreased as compared to the normal postpartum 
period. Interestingly, a decrease in T helper cells has also been described in schizophrenia 
patients with acute psychosis and in patients with major depression (47, 48). 
 With regard to monocyte function we found that monocytes of women with postpartum 
psychosis show a gene expression profile more robustly up-regulated than normally in the 
postpartum period. A similar high transcription of immune genes has been described for 
bipolar disorder and schizophrenia (8). 
 The majority of our patients were using benzodiazepines and antipsychotics for just a 
few days at the time of blood sampling. Antipsychotics are generally anti-inflammatory in 
character and known to downregulate inflammatory gene expression (49, 50). Indeed, we 
found a significantly attenuated upregulation for a few genes in patients using medication 
compared to patients without medication. Therefore, based on these findings, we expect 
that monocyte immune activation in postpartum psychosis would be even more robust in 
an entirely medication-free cohort.
 In theory, alterations in the stress axis and lactational hormones of breastfeeding 
women have the potential to influence maternal immune status. However, studies 
showing clear immune differences between women choosing to breastfeed versus bottle 
feed are scarce. Groer et al reported that immune differences between breastfeeding and 
bottle feeding were relatively mild compared to the striking immune differences between 
postpartum women and non-postpartum controls (51). Accordingly, in our study, we found 
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no significant correlation between either monocyte or T-cell activation and breastfeeding 
in the postpartum period. Therefore, the robust increase in monocyte activation during 
postpartum psychosis does not seem to be significantly influenced by breastfeeding.
 The pregnancy and postpartum period are periods in which the HPA-axis undergoes 
substantial changes. Several reports suggest a causal relation between these HPA-axis 
disturbances and the occurrence of postpartum mood disorders (26, 52-57). We found 
that the ratio of the blocking GR-β to stimulating GR-α was not altered in monocytes of 
healthy postpartum women in comparison to that of non-postpartum women.  However, 
the blocking GR-β to stimulating GR-α ratio was elevated in monocytes of women with 
postpartum psychosis due to a specific increase in the level of the blocking GR-β. This 
pattern of GR-β up-regulation and the correlation patterns of GR-β to the expression level of 
inflammation related genes indicates that steroid resistance – due to a higher production of 
the inactive GR-β – is part of the monocyte activation state in postpartum psychosis. 
Our data thus clearly underscore the close link between a disturbed endocrine and immune 
system in postpartum psychosis. 
 We found that CCL2 was increased in the serum of PP patients compared to CP.  Notably, 
a higher serum level of CCL2 is consistent with previous reports in bipolar patients (11). 
CCL2 is produced by monocytes while infiltrating the tissues and this phenomenon may thus 
represent an ongoing mild inflammatory monocyte/macrophage response. 
 Collectively, our data highlight a model for postpartum psychosis by which an abnormal 
set point of the neuro-immuno-endocrine axis leads to increased activity of macrophages 
and a reduction in T cell numbers. Macrophages and their analogous cells in the brain, the 
microglia, are well-documented in animal models to regulate the growth, development, 
and function of neurons (58). Further, an activated immune set point of microglia has been 
detected in acute schizophrenia patients for which animal models have demonstrated 
robust causal influences of microglial function on psychopathology (59-61). Together, we 
hypothesize that an altered set point postpartum of the immune-endocrine system is the 
ultimate trigger for the acute onset of psychosis in women with an underlying genetic 
susceptibility for bipolar disorder or psychosis. In support of such a theory, our data showed 
an abnormal set point of the neuro-immuno-endocrine axis in women with postpartum 
psychosis, given their elevated macrophage activity and significant reduction of T cell 
numbers. 
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Conclusions
- Our data show that women with psychosis limited to the postpartum period have a 
unique risk profile and phenomenology, compared to bipolar patients with postpartum 
psychosis.  In particular, these patients demonstrate a significantly delayed postpartum 
onset and the absence of obstetric complications (Chapter 3). 
- We report adverse reactions on antidepressants in patients with postpartum psychosis 
with depressive features. In contrast, we demonstrate a more favourable treatment response 
when these patients are treated with lithium and antipsychotics (Chapters 2 and 3).
- We highlight the importance of distinguishing postpartum psychosis from bipolar 
disorder in the clinical care of women during subsequent pregnancies, as both groups 
optimally require distinct clinical treatment algorithms. In contrast to bipolar patients, there 
is no indication for pharmacological prophylaxis during pregnancy in patients with a history 
of psychosis limited to the postpartum period. Rather, prophylaxis should begin immediately 
postpartum in order to avoid the fetal risk of in utero medication exposure (Chapter 4). 
- Thyroid autoimmunity has a significantly elevated incidence during episodes of 
postpartum psychosis (Chapter 7).
- The normal postpartum period is characterized by both monocyte and T-cell activation. 
Patients with postpartum psychosis have exaggerated monocyte activation, but lower T cell 
counts, compared to the normal postpartum period (Chapter 8).
Postpartum psychosis, a separate diagnostic entity?
Postpartum psychosis is a phenotypically well-defined disease entity, even though its 
nosological status is not distinctly classified in DSM-IV or ICD-10. Previous studies have 
clearly described the unusual symptom presentation of patients with postpartum psychosis, 
as well as similarities to bipolar disorder (1, 2).  Although bipolar disorder is certainly an 
important risk factor for postpartum psychosis, a large proportion of postpartum psychosis 
patients have no history of prior manic or psychotic episodes (3). In our research we have 
particularly focused on this group: patients with first-onset psychosis postpartum. Together, 
our data contribute to the emerging consensus that women with a history of psychosis 
limited to the postpartum period might have a distinct variant of bipolar disorder (4). 
 For patients, clinicians and researchers, there are many advantages to give postpartum 
psychosis an official status as a discrete gender-specific diagnostic entity. First, it will aid 
in reducing stigma as women will not be categorized immediately as bipolar, a life-long 
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illness, but instead diagnosed with “a postpartum condition”. Women are now forced into 
current diagnostic criteria because ICD-10 and DSM-IV do not adequately recognize the 
syndrome. The result of these conceptual problems is an impression of confusion that has 
hindered research into this specific condition.  More research can lead to official treatment 
algorithms and distinct prevention plans for subsequent pregnancies.  Further, it would 
facilitate long-term prognosis and maintenance recommendations. Perhaps most notably, 
if not all psychotic episodes postpartum convert to bipolar disorder during lifetime, use of 
long-term mood stabilizers is not required for all women who experience a postpartum 
psychosis.
 Overall, we strongly believe that a classification of postpartum psychosis as distinct 
gender-specific diagnostic entity would be very beneficial for our patients. Here we 
summarize the most prominent arguments in favor of a distinct classification: 
1. Postpartum psychosis is the only psychiatric disease with an intrinsically defined onset, 
namely within 4 weeks postpartum. 
2. Clinical features do not fit with the current diagnostic criteria. Women suffering from 
postpartum psychosis do not always present with features typical of bipolar disorder 
(manic episode, mixed episode) or a psychotic disorder. Postpartum psychosis 
patients often show a prominence of mood-incongruent delusions, in the absence of 
schizophrenia-like criteria. Longitudinal studies have reported that for some women, 
affective psychosis remains exclusively limited to the postpartum period.
3. First-onset postpartum psychosis has markedly different characteristics compared to 
postpartum psychosis in bipolar patients. Postpartum psychosis patients demonstrate 
a significantly delayed postpartum onset compared to postpartum relapses in bipolar 
patients. Further, and in contrast to bipolar patients, obstetric complications are not a 
risk factor for patients with psychosis limited to the postpartum period.
4. The overwhelming majority of patients experience a complete symptom remission 
within 3 months postpartum after treatment.
5. In stark contrast to the high rates of relapse in bipolar disorder, women with psychosis 
limited to the postpartum period are not at elevated risk of psychiatric episodes during 
pregnancy.
Immune theory of postpartum psychosis
The pathogenesis of psychosis and mania is considered genetically complex and 
heterogeneous. Current theories suggest that an interaction between genetic factors and 
other stressors or external factors determine an individual’s risk of psychosis or mania. For 
example, the effect of cannabis may be stronger in those with a high genetic risk for the 
development of psychosis (5).  In addition to drugs, other common examples of external 
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factors leading to psychiatric disease in subjects with high genetic susceptibility are trauma, 
severe stress, infection, brain injury and severe sleep loss. It has been shown that childbirth 
has the highest relative risk of any factor heretofore identified in psychiatry (6). Several 
neurobiological pathways are highly sensitized in the immediate postpartum period, and 
could thus serve as a potential trigger. Thus far, most research in postpartum psychosis 
has been focused on endocrine pathways because of the dramatic postpartum hormonal 
changes (7, 8).  However despite extensive efforts, no consistent endocrinological aetiology 
for postpartum psychosis has been demonstrated.  We propose an alternative mechanism 
underlying the sudden onset of psychosis postpartum: an immune related trigger.  Moreover, 
we propose that the sharp increase in the occurrence of psychotic and manic symptoms 
after delivery could be associated to postpartum immune activation.  
 Most importantly supporting our immune hypothesis of postpartum psychosis: Every 
other known medical condition with a postpartum flare pattern has been demonstrated 
as originating from immune system dysfunction (9). Autoimmune diseases such as 
autoimmune thyroid dysfunction, rheumatoid arthritis, multiple sclerosis, autoimmune 
hepatitis, and myasthenia gravis classically remit during pregnancy, but have an exacerbation 
or initial onset during the postpartum period (10-17). Accordingly, there is consensus that 
immune activation in the peripartum period is a critical physiological trigger for the clinical 
manifestations of these autoimmune diseases. Intriguingly, the pathogenesis of another 
postpartum disease, peripartum cardiomyopathy, has only recently been elucidated. 
Although this is not a classical autoimmune disease, peripartum immune changes appear to 
function prominently in the disease pathogenesis (18), further supporting the notion that 
postpartum psychosis may be governed by a similar immunological mechanism. 
 Here, we provide 4 major lines of evidence in support of an autoimmune pathophysiology 
for postpartum psychosis:
1. Common characteristics of pregnancy-related autoimmune diseases include familial 
occurrence, progression from subclinical to clinical disease, a cyclical exacerbation-
remission pattern, and a high recurrence risk with subsequent pregnancies.  Remarkably, 
postpartum psychosis has been definitively shown to possess all of these clinical features. 
Postpartum psychosis is highly familial, frequently exhibits a bipolar-like exacerbation-
remission pattern after a first-onset postpartum psychosis, and has recurrence rates of 
approximately 50% with subsequent pregnancies. 
2. The co-occurrence with autoimmune thyroid dysfunction is suggestive of immune 
relatedness. It is well known that autoimmune diseases show associations with each 
other. As described in Chapter 7, there is high comorbidity between bipolar disorder and 
postpartum psychosis with autoimmune thyroid dysfunction (19-21).  
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3.  There is increasing evidence that immune activation postpartum is related to anxiety and 
mood symptoms (22). Postpartum depressive symptoms are significantly correlated with 
the increase of cytokines IL-1b, IL-6 and IL-8, an activation of a pro-inflammatory type-
1 T cell response and a deficiency of tryptophan (23-29). Further, differential immune 
activation was recently demonstrated through investigation of gene expression profiles 
in blood mononuclear cells of women with postpartum depression (30). 
4. There is emerging evidence that dysregulation in the immune system is central to 
the pathogenesis of bipolar disorder. Several studies have reported elevated serum 
cytokines and chemokines (31-36), a higher prevalence of organ-specific auto-antibodies 
(20, 37, 38), T cell activation (39, 40) and inflammatory monocyte gene expression (41, 
42) in patients with bipolar disorder. Furthermore, in this thesis, we have reported on 
alterations of monocyte activation in patients with first onset postpartum psychosis. 
Taken together, the robust combination of disease onset, clinical course, familial loading, co-
occurrence with AITD, monocyte activation and T-cell dysregulation are highly suggestive of 
an immunological etiology for postpartum psychosis. Importantly however, it remains a very 
open question of which immunological mechanism(s) are directly responsible for triggering 
affective instability and psychosis. Moreover, even for well-defined autoimmune disorders, 
such as AITD, MS and RA, the postpartum immune trigger is only partially understood (9, 
10, 17).
 During pregnancy, changes in the immune system are necessary for inducing tolerance 
of the mother towards the genetically distinct foetus. In general, there is a down-regulation 
of potentially dangerous T-cell mediated immune responses, in parallel with a coordinated 
activation of the innate immune system.  Further, endocrinological changes lead to a 
T helper 1 (Th1) suppression and Th2 up-regulation during pregnancy, for which there 
is a rapid reversal of this balance in the early postpartum period (43). Accordingly, this 
restoration of the Th1/Th2 balance postpartum has been widely hypothesized to model 
rheumatoid arthritis (RA) and autoimmune thyroid disease, as Th1-driven diseases often 
have their initial onset during the postpartum period (44). Importantly however, the precise 
immunological processes that are most highly influential during normal human pregnancy 
and the postpartum period remain under intense debate, given that the historical 
conceptualizations of T helper 1 (Th1) suppression and Th2 up-regulation during pregnancy, 
with postpartum restoration of this balance postpartum, appears to incompletely capture 
the full complexity of observed data. 
 An emerging alternative explanatory model for the high occurrence of autoimmune 
disorders postpartum regards the influence of T regulatory cells (45). T regulatory cells 
play a major role in pregnancy by inhibiting T cells. T regulatory cells increase early in 
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pregnancy, peak in the second trimester and then decline in the postpartum period (46). 
A decline T regulatory cells function has been linked to progression towards autoimmune 
diseases outside the postpartum period. Therefore, some investigators have suggested that 
disordered postpartum T regulatory cell function might lead to maternal autoimmunity (11). 
 Lastly, there is also reason to believe that several adaptations of the innate immune system 
during pregnancy and postpartum are highly relevant for autoimmunity in the peripartum 
period. In general, the innate immune system appears activated during pregnancy, in a 
“controlled state of inflammation” (47). Enhancement occurs in the numbers and activation 
state of circulating granulocytes and monocytes, leading to a more aggressive attack on 
invading bacteria. Besides a prominent function in host defense, monocytes participate in 
the maintenance of tolerance by displaying tolerogenic signals to T-cells (48). This state of 
innate immune activation during pregnancy appears to extend into the early post-partum 
period.  During the initial few days postpartum, serum levels of inflammatory cytokines such 
as IL-6 and IL-1β (23, 24) are typically increased. Unfortunately however, the differential 
rates of change in various aspects of postpartum innate immune function have hardly been 
investigated, for which possible links with autoimmunity remain largely unexplored.
 Taken together, the mother is protected from infection during pregnancy by an increased 
innate immunity. Adaptive immunity against fetal tissue is in a tolerogenic mode, likely due 
to increased T regulatory cells and tolerogenic dendritic cells. Postpartum, there is evidence 
for both monocyte and T cell activation with altered T regulatory subsets. The postpartum 
occurrence of autoimmunity might therefore be linked to this monocyte and T cell activation 
and/or the imbalance in T regulator cells. 
 A similar mechanism could hold true for the occurrence of mania and psychosis 
postpartum. We propose that the elevated set point of the monocyte/macrophage/T 
cell system in the normal postpartum period might critically alter a set point of the 
immune-endocrine system leading to the onset of bipolar disorder in vulnerable women. 
This “immune hypothesis of postpartum psychosis” could be seen as complementary to 
previous endocrine hypotheses. Several studies have shown bidirectional interactions 
between endocrine systems and the immune system. Accordingly, it is well established 
that glucocorticoid stress hormones have profound immune modulatory effects, and that 
sex hormones also modulate immune responses (49). A specific hormone of interest is 
prolactin, as this hormone is associated with acute disease exacerbations in autoimmune 
disorders (50, 51). 
 A combined endocrine-immune trigger postpartum could lead to disease in vulnerable 
women. An alternative model could be that different subtypes lead to the same phenotypes. 
Altered signaling mediated by immune molecules possibly underlies the biology of some 
subtypes of postpartum psychosis, whereas other subtypes might be caused by susceptibility 
for endocrine changes. Elucidating these immune-endocrine mechanisms might reveal new 
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insight into the onset of postpartum psychosis and bipolar disorder. Clearly, more research 
focused on immune dysfunction in bipolar women during pregnancy and the postpartum 
period is warranted.
Clinical Recommendations
•  Diagnostic efforts to distinguish between women with a first onset postpartum psychosis, 
versus women with postpartum psychosis and a history of bipolar disorder, will greatly 
enhance clinical prognosis and treatment.
•  We propose a treatment algorithm for postpartum psychosis based on our clinical 
experience, guided by the larger literature for treatment of bipolar patients.  We 
recommend using the sequential addition of benzodiazepines, antipsychotics, and finally 
lithium in those patients without a significant clinical response within 2 weeks. 
•  We recommend following the treatment guidelines for bipolar II depression in patients 
with acute onset during the postpartum period of depression with psychotic features. 
This recommendation is valid even in the absence of hypomanic symptoms in history or 
at the time of evaluation within the first 4 weeks postpartum. Further, we discourage the 
use of antidepressants (particularly in the absence of appropriate mood stabilization) 
during the postpartum period in patients with postpartum depression and psychotic 
features.
 •  Close monitoring of thyroid function is critically important for optimal clinical 
management. We suggest measuring TSH, f T4 and thyroperoxidase antibodies at the 
time of diagnosis and 6 months postpartum.
•  We recommend using a postpartum psychosis prevention plan in patients at high risk for 
postpartum psychosis: women with a history of postpartum psychosis and/or women 
with bipolar disorder. For specific guidelines, see Addendum 1.
•  In bipolar women, prophylaxis during pregnancy appears important for maintaining 
mood stability during pregnancy and to minimize the high risk of postpartum relapse. 
Importantly, use of medication during pregnancy should always be weighed against the 
risks for the fetus.
•  In women with a history of psychosis limited to the postpartum period, we recommend 
initiating prophylactic treatment immediately postpartum, thereby offering an important 
clinical advantage by avoiding in utero foetal exposure to prophylactic medication.  
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Future research
Replication and enlargement of the cohort 
The sample sizes of our studies in patients with postpartum psychosis are relatively small, 
so our results should be interpreted with caution. Therefore, we will not only try to replicate 
our findings in our ongoing OPPER study within the Erasmus MC, but we also intend to 
enlarge the cohort through inclusion of postpartum psychosis patients from other hospitals 
throughout the Netherlands. 
Long-term follow-up studies 
We are currently analyzing the nine-month and four-year follow-up data of our first onset 
postpartum psychosis patients. Through the nine-month postpartum follow-up dataset, we 
hope to obtain definitive rates of sustained remission. Furthermore, the four-year follow-
up data will provide increasing guidance for the necessary duration of treatment following 
full remission. In particular, we intend to quantify the risk for conversion to bipolar disorder 
over the four-year period following a first-onset postpartum psychosis. Clearly, it is of major 
interest to determine predictive characteristics and biological determinants of women who 
are particularly vulnerable for conversion to bipolar disorder, versus women who are only 
vulnerable for relapse immediately following delivery.
Prevention of postpartum psychosis 
While our recent work is a step forward in establishing standardized clinical guidelines for the 
prevention of postpartum psychosis, several key questions are outstanding. Specifically, the 
optimal duration of prophylactic treatment and the efficacy of antipsychotics for prophylaxis 
remain unclear.  Consequently, there is a need for a larger clinical data set that can evaluate 
the risks and benefits of specific antipsychotic and mood stabilization pharmacotherapies for 
moderating peripartum relapse risk and neonatal outcomes. Further, advancing the care of 
pregnant women at high risk for postpartum psychosis will involve the precise identification 
of the clinical and biological characteristics of women who are at risk for peripartum relapse, 
to allow individualized and maximally effective prophylaxis regimens while minimizing in 
utero fetal exposure.
Marker molecules 
In this thesis, we have discussed that disease onset, clinical course, familial loading, co-
occurrence with AITD and monocyte activation are in combination very suggestive of an 
immunological aetiology for postpartum psychosis. Therefore, we will not only evaluate 
clinical characteristics predictive for conversion to bipolar disorder versus a more favorable 
disease course, but also to search for immune and endocrine serum markers. In particular, 
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we are currently in the process of screening the serum of patients with postpartum psychosis 
for biomarkers of vascular function and angiogenesis, tryptophan metabolites, and auto-
antibodies with affinity for endogenous central nervous system (CNS) antigens. 
Genetics
Our model of postpartum psychosis hypothesizes that for any given woman in the postpartum 
period, acute immune-endocrine factors interact with underlying genetic factors to 
determine the risk of developing postpartum psychosis, with or without an ongoing bipolar 
disorder. Because our cohort is itself too small for independent genome-wide genetic 
studies, we plan to collaborate within an (inter)national consortia to identify differential 
genetic susceptibility for responsiveness to childbirth related neuro-immuno-endocrine 
triggers. In particular, we have established collaborations with the Danish reproduction and 
mental health studies (Aarhus), Perinatal Genetic Consortium (PACT, North Carolina), BIG 
consortium (Bipolar Genetics, Utrecht), PREDESIS (Tilburg), and Moodinflame (Rotterdam). 
Towards this goal, we have already designed and validated a standardized screening 
instrument for application in genetic studies, in order to accurately quantify childbirth-
associated severe psychiatric symptoms (Addendum 2).
Ideally, our current and future research will ultimately contribute to individualized, highly 
effective and minimally invasive strategies to prevent the development of chronic mental 
illness after a first onset postpartum psychosis.
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Addendum 1
Postpartum Psychose Preventie Behandelplan
Naam:
Gravida :      , Para :      
À terme datum:  
Psychiatrische diagnose: 
VOORBEELD: Postpartum psychose in de voorgeschiedenis, bipolaire stoornis.
Psychiatrische voorgeschiedenis: 
Vermeld ook of patiënte klachten had tijdens eerdere zwangerschap of na eerdere partus.
Somatische diagnose: 
Obstetrische voorgeschiedenis: 
Vermeld bijzonderheden eerdere bevallingen.
Huidige zwangerschap: 
Medische complicaties en of patiënte stabiel is tijdens deze zwangerschap.
Medicatie:  
Huidige medicatie inclusief start datum en spiegels. 
VOORBEELD 1: Wij adviseerden medicatie tijdens de zwangerschap te continueren, 
aangezien uit onderzoek blijkt dat afbouwen van medicatie tijdens de zwangerschap een 
hoog risico geeft op terugval. Wij informeerden patiënte over het risico op … [vul hier evt. 
gevolgen voor het (ongeboren) kind in afhankelijk van middel]. 
VOORBEELD 2: Wij adviseerden medicatie af te bouwen vanwege de mogelijke gevolgen 
voor het ongeboren kind.
Vermeld ook medicatie die voor de zwangerschap gebruikt werd en de stopdatum.
Bevalling: 
Vermeld als er een inleiding gepland is, sectio of pijnstilling en waar de bevalling gaat 
plaatsvinden. Vermeld ook de naam van de gynaecoloog.
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Handelingsplan rondom bevalling:
VOORBEELD:
-	 Mevrouw is geïndiceerd voor een klinisch kraambed (geplande duur 5 dagen) i.v.m. het 
risico op postpartum psychose. Wij adviseren opname op een alleenstaande kamer.
-	 Dagelijks wordt zij bezocht door haar behandelend arts (naam), sociaal psychiatrisch 
verpleegkundige (naam), of een dienstdoend arts-assistent psychiatrie.
-	 Mevrouw geeft geen borstvoeding. Lactatieremmers zijn gecontraïndiceerd.
-	 De eerste avond na de bevalling wordt om 20.00 Lithium verhoogd/gestart in een 
dosering van 1000 mg . De lithiumspiegel wordt bepaald op dag 2, 5 en 12 post partum. 
De streefspiegel is tussen 0.8-1.0 mmol/l. Op dag 12 tevens TSH en fT4 en thyroperoxidase 
antistoffen bepalen.
-	 Lorazepam 1 mg wordt standaard aangeboden voor de nacht en evt. opgehoogd bij 
slaapproblemen.
-	 De baby slaapt ‘s nachts op de babykamer. Verpleegkundigen nemen de nachtvoeding 
over. Na ontslag zal partner de eerste maand de nachtvoedingen op zich nemen.
-	 Indien medicatie gebruikt werd tijdens de zwangerschap gebruik de volgende 
zin; de baby zal direct na de bevalling door de kinderarts worden onderzocht 
i.v.m. psychofarmacagebruik en gedurende 48 uur geobserveerd worden op 
ontwenningsverschijnselen. In navelstrengbloed zal de lithiumspiegel, TSH, fT4, en TSI 
bepaald worden.
Signaleringsplan:
VOORBEELD: 
Eerste symptomen:
· Bij depressie: aanhoudende somberheid en vermoeidheid (enkele dagen), minder slapen 
en verminderde concentratie.
· Bij (hypo)manie: snel praten, druk gedrag, denken alles aan te kunnen. 
Wat kan ik zelf doen:
· Rust, regelmaat en reinheid.
· Met anderen emoties en klachten bespreken en signalen delen.
· Vooraf kraamafdeling zien.
· Vooraf afspraken maken over bezoek en mobiele telefoon.
Wat kan mijn omgeving doen:
· Hulp met huishouden en helpen dagstructuur aanbrengen/vasthouden.
· Vragen naar stemming/gevoel.
· Stimuleren en activeren, bijvoorbeeld samen buiten wandelen bij sombere stemming.
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· Laagdrempelig contact opnemen met de afdeling psychiatrie (telefoon polikliniek: 010-
7040139) of huisarts.
Nazorg: 
VOORBEELD: 
Wij adviseren lithium minimaal 3 maanden postpartum te continueren en vervolgens in 
overleg zeer geleidelijk af te bouwen.
……………  Mw…………..  
Psychiater (naam patiente, en handtekening) 
Kopie:
- Huisarts     
- Behandelend gynaecoloog
- Patiënte zelf    
- Behandelaren in de GGZ
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Addendum 2
Questionnaire Postpartum Mood Disorders (NL)
Patiëntnummer: ………………  Datum invulling: ………………..
Screeningsvraag: Bent u ooit zwanger geweest?
 Nee  → deze vragenlijst hoeft niet te worden afgenomen
 Ja     → vervolg deze vragenlijst
1 Heeft u kinderen? Vul de geboortedata van de kinderen in.
 
2 Heeft u ooit een miskraam/doodgeboren kind gehad? Vul het jaartal in.
3  Heeft u ooit een abortus ondergaan? Vul het jaartal in.
4 Heeft u na de geboorte van ......of miskraam of abortus een manische, psychotische of  
 depressieve periode doorgemaakt? 
	 ⇒	 Indien patiënte een manie of een gemengde episode heeft doorgemaakt vul ‘M’ in;
	 ⇒	 Indien een psychose: vul ‘P’  in; 
	 ⇒	 Indien een depressie vul ‘D’ in. 
 (psychose én manie en psychose én depressie kunnen beide ingevuld worden)
5 Wanneer is deze postpartum episode begonnen?
	 ⇒	 Indien tijdens de zwangerschap al begonnen, vul in ‘zw’. 
	 ⇒	 Indien begonnen binnen 4 weken postpartum, vul in ‘< 4 wk’. 
	 ⇒	 Indien begonnen tussen 4 en 8 weken postpartum, vul in ‘4-8 wk’.
	 ⇒	 Indien begonnen tussen 8 weken en 6 maanden postpartum, vul in ‘2-6mnd’.
Geboortedata kinderen
dd/mm/yyyy 
Postpartum episode?
Vul in:
Indien M, P of D: Aanvang episode
Vul in:
.. ../.. ../.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. ../.. ../.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. ../.. ../.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. ../.. ../.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. ../.. ../.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
Jaar miskraam yyyy 
.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
Jaar abortus yyyy 
.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
.. .. .. .. [  ] neen;  [  ] M;  [  ] P;  [  ] D [  ] zw; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 mnd
⇒	 Indien patiënte een manische, gemengde of psychotische episode postpartum heeft doorgemaakt 
vul dan sectie D van de MINI voor deze episode in. Indien patiënte meerdere episoden heeft 
doorgemaakt, neem dan de episode die binnen de kortste tijd na de bevalling begonnen is. 
⇒	 Indien patiënte een depressieve episode heeft doorgemaakt vul dan sectie A van de MINI voor deze 
episode in. Indien patiënte meerdere postpartum depressies heeft doorgemaakt, neem dan de episode 
die binnen de kortste tijd na de bevalling begonnen is. 
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Questionnaire Postpartum Mood Disorders
Patient number: ………………  Date: ………………..
Screenings question: Have you ever been pregnant?
 No  → please don’t fill in this questionnaire
 Yes  → continue this questionnaire
1 Do you have children? Please fill in dates of birth.
 
2 Did you ever experience a miscarriage or stillbirth? Please fill in the year.
3  Did you ever experience an abortion? Please fill in the year.
4 Did you suffer from a manic, psychotic or depressive episode after birth of …or miscarriage or  
 abortion? 
	 ⇒	 If patient suffered from a manic or, a mixed episode, please fill in  ‘M’;
	 ⇒	 If patient suffered from a psychotic episode, please fill in  ‘P’; 
	 ⇒	 If patient suffered from a depressive episode, please fill in ‘D’. 
 (Psychosis ánd mania and psychosis ánd depression can be filled in at the same time)
5 When did this episode start?
	 ⇒	 If started during pregnancy, please fill in ‘pr’. 
	 ⇒	 If started within 4 weeks postpartum, please fill in ‘< 4 wk’. 
	 ⇒	 If started between 4 and 8 weeks postpartum, please fill in ‘4-8 wk’.
	 ⇒	 If started between 8 weeks and 6 months postpartum, please fill in ‘2-6 m’.
Birhtdate Children
dd/mm/yyyy 
Postpartum episode?
Please fill in:
If M, P or D: Start episode
Please fill in:
.. ../.. ../.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. ../.. ../.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. ../.. ../.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. ../.. ../.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. ../.. ../.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
Year miscarriage yyyy 
.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
Year abortion yyyy 
.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
.. .. .. .. [  ] no;  [  ] M;  [  ] P;  [  ] D [  ] pr; [  ]<4 wk; [  ] 4-8 wk; [  ] 2-6 m
⇒	 If the patient suffered from a manic, mixed or psychotic episode postpartum, please fill in ‘section 
D from the MINI for this episode. If the patient suffered from more than one episode, please fill in the 
episode with earliest start postpartum.
 
⇒	 If the patient suffered from depressive episode postpartum, please fill in section A from the MINI 
for this episode. If the patient suffered from more than one episode, please fill in the episode with 
earliest start postpartum. 
© Bergink and Nolen
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Part I Clinical perspective
Chapter 2.
Postpartum psychosis is a severe disorder occurring in 0.1% of childbearing women.  The 
clinical symptoms include fluctuations in mood accompanied by delusions and hallucinations, 
as well as agitation, insomnia and cognitive impairment. Patients often require urgent 
hospital admission. At the Erasmus MC, patients can be admitted together with their baby. 
Although women are severely ill during this episode, the duration of postpartum psychosis 
is limited (weeks to months) and recovery is complete. At discharge, women experience 
minimal difficulties in bonding with their child. 
 At the Erasmus MC, patients are treated using a standardized algorithm consisting of the 
sequential addition of benzodiazepines, antipsychotics, and finally lithium. Our treatment 
algorithm was established based largely upon the treatment guidelines for bipolar patients, 
and guided by our specific clinical experiences in caring for patients with postpartum 
psychosis.  Importantly, this treatment algorithm includes patients with postpartum 
psychosis in the setting of depressive, manic, or mixed affective features. Over the last 4 
years, eight postpartum patients were referred to our clinic as a result of very unstable 
illness course after treatment with antidepressants. We suspect that antidepressant 
treatment without adequate mood stabilization places women with postpartum depression 
and psychotic features at an unacceptable risk for exacerbation of symptoms. Therefore we 
suggest treating these patients with antipsychotics and lithium.
 Although bipolar disorder is certainly an important risk factor for postpartum psychosis, 
a large proportion of postpartum psychosis patients have no prior history of manic or 
psychotic episodes. In our research, we have particularly focused on this group: those 
patients with first-onset psychosis in the postpartum period. We have investigated risk 
factors for postpartum psychosis, phenomenological characteristics, treatment response 
and prevention of further episodes.  Our studies demonstrate that women with psychosis 
limited to the postpartum period have distinct characteristics during their first episode 
(chapter 3), and a unique risk profile during subsequent pregnancy and postpartum period 
(chapter 4), compared to bipolar patients with postpartum psychosis. 
In chapter 3, we report the outcome of our prospective cohort study of patients with first-
onset postpartum psychosis. We included 51 women with postpartum psychosis and the 
absence of any previous manic or psychotic symptoms outside the postpartum period. We 
have investigated obstetric, neonatal, and lactational risk factors in these women, compared 
to a large population-based cohort. Furthermore, we documented their phenomenological 
characteristics and response to treatment. 
 Women with postpartum psychosis had a significantly higher incidence of primiparity, 
but no significant differences in delivery-related, lactational, or neonatal-related risk factors. 
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Further, our data show that patients with first-onset psychosis have a significantly delayed 
postpartum onset (median day 8) compared to bipolar patients, and a prominence of 
mood-incongruent psychosis. Encouragingly, a beneficial treatment response was observed 
in nearly all women. The median duration of episode was 40 days; prominent depressive 
features predicted a significantly longer duration of the postpartum psychosis episode. 
In chapter 4, we evaluated the outcome of lithium prophylaxis during pregnancy, compared 
to immediately postpartum, in 70 women at high risk for postpartum psychosis using 
standardized clinical guidelines. Specifically, we have investigated relapse rates both during 
pregnancy and in the postpartum period for 41 women with bipolar disorder and 29 women 
with a history of postpartum psychosis.  Women with postpartum psychosis, compared 
to those with bipolar disorder, had a substantial difference in their clinical outcomes and 
prophylaxis requirements.
 Notably, all women with a history of psychosis limited to the postpartum period 
were stable throughout their entire pregnancy despite using no prophylactic medication. 
In contrast, women with bipolar disorder had high rates of relapse during pregnancy. 
Furthermore, initiation of prophylaxis immediately postpartum in women with a history 
of postpartum psychosis with either lithium or antipsychotics was highly effective for 
preventing postpartum relapse. In contrast, the efficacy of postpartum prophylaxis in 
women with bipolar disorder was much lower. During the postpartum period, relapse was 
highest in women with bipolar disorder who experienced mood episodes during pregnancy. 
Therefore, we have proposed distinct clinical treatment algorithms for women with 
bipolar disorder versus women with a history of postpartum psychosis. In bipolar women, 
prophylaxis during pregnancy appears critically important for maintaining mood stability 
during pregnancy and to minimize the high risk of postpartum relapse. In contrast, we 
recommend initiating prophylactic treatment immediately postpartum in women with 
a history of psychosis limited to the postpartum period, offering an important clinical 
advantage by avoiding in utero fetal exposure to prophylactic medication.  
II. Pathophysiology of postpartum psychosis
Postpartum psychosis is widely hypothesized to be a disease with a strong neurobiological 
basis, however studies demonstrating robust biological influences have not yet been 
realized. Most neurobiological research has focused on endocrine pathways, given the 
dramatic changes in hormone levels after delivery, as summarised in chapter 5.
In chapter 6, we propose the novel hypothesis that postpartum immune dysregulation is a 
critical biological trigger for the onset of postpartum psychosis.
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In chapter 7, we examine the hypothesis that autoimmune thyroid dysfunction may be 
associated with the onset of postpartum psychosis. We investigated the prevalence of 
autoimmune thyroid dysfunction in a consecutive series of 31 primiparous women with 
postpartum psychosis, compared to postpartum women from the overlapping general 
population. Thyroperoxidase (TPO) antibody levels, Thyroid stimulating hormone (TSH), and 
free thyroxine (fT4) levels were measured at four weeks and nine months postpartum. 
Our data showed that autoimmune thyroid disease is much more prevalent in women 
with first-onset postpartum psychosis (19%) than in postpartum women from the general 
population (5%).  Furthermore, clinical thyroid failure occurs significantly faster and in a 
greater percentage of patients with postpartum psychosis.  Importantly, these differences 
appear to be independent of antipsychotic or lithium treatment in the early postpartum 
period.  
 Taken together, the high prevalence of clinical thyroid dysfunction in patients with 
postpartum psychosis is an important consideration for both clinical management and 
pathophysiological understanding. Therefore, screening for TPO antibodies is warranted 
in patients with postpartum psychosis. Of note, in our studies we used lithium as the 
final treatment option. While lithium has widespread clinical support as a highly effective 
mood stabilizer, lithium treatment is a risk factor for thyroid dysfunction. Therefore, the 
risks and benefits of lithium should be weighed carefully in choosing the most appropriate 
pharmacologic regimen for treatment of postpartum psychosis, particularly for patients 
with elevated TPO antibody titers.
In chapter 8 we examined immune activation in patients with first-onset postpartum psychosis 
at the level of monocytes, T-cells, and serum cytokines/chemokines. We included 64 women 
consecutively admitted with first-onset postpartum psychosis matched to postpartum and 
non-postpartum healthy controls, in order to control for confounding factors related to the 
normal postpartum period.  A quantitative-PCR case-control monocyte gene expression 
analysis was performed using 45 genes previously identified as abnormally regulated in non-
postpartum mood disorder patients including the activating and inactivating isoforms of the 
glucocorticoid receptor (GR–α and β).  T-cell percentages were measured by FACS analysis, 
while serum monocyte and T-cell related cytokines/chemokines were determined using a 
cytometric bead array.
 We found that monocytes of women with postpartum psychosis have a gene profile 
showing more robust immune activation than is normally present in the postpartum 
period, including genes that are not typically elevated in the normal postpartum period. 
Furthermore, the GR-β/α gene expression ratio was increased in monocytes of patients with 
postpartum psychosis, suggesting that steroid resistance is part of this monocyte immune 
activation state. Surprisingly however, we observed that most T-cell subsets were decreased 
Summary
136
in women with postpartum psychosis in comparison to the levels found in the normal 
postpartum period. 
 Taken together, we have demonstrated that postpartum psychosis is characterized by 
a robust dysregulation of the immuno-neuro-endocrine set point, including prominent 
monocyte/macrophage activation.
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Casus: een patiënte met postpartum psychose
Een 30 jarige vrouw, met een blanco psychiatrische voorgeschiedenis, bevalt bij een 
zwangerschapsduur van 39 weken poliklinisch van haar eerste kind: een gezonde dochter. 
De zwangerschap en de bevalling zijn ongecompliceerd verlopen. Tijdens de kraamtijd is de 
vrouw bezorgd of haar dochter wel voldoende borstvoeding krijgt. Als de kraamverzorgende 
weg is, voert zij de frequentie van het aantal voedingen op. Zij raakt gepreoccupeerd met 
de regel: “rust, reinheid en regelmaat” en drinkt daarom veel water. Daarnaast is zij tot 
diep in de nacht druk met het huishouden en vergeet zij soms te slapen. Er is sprake van 
toenemende agitatie, onder andere naar haar partner als hij haar maant rustiger aan te 
doen. Verder is zij toenemend achterdochtig ten aanzien van haar schoonzus die in huis is 
gekomen om patiënte na de kraamtijd extra te ondersteunen. Patiënte raakt in wisselende 
mate verward, heeft het idee dat haar dochter met hagedissenogen naar haar kijkt, herkent 
soms haar partner of andere familieleden niet, heeft het idee dat er een rollenspel wordt 
gespeeld en geeft speciale betekenissen aan kleuren die zij om zich heen ziet. Als de situatie 
uitmondt in een handgemeen, wordt de crisisdienst ingeschakeld en volgt opname. 
Het lezen van dit verhaal zal mogelijk een aantal vragen oproepen:
- Hoe kan het zijn dat iemand met een blanco psychiatrische voorgeschiedenis zo ziek   
 wordt vlak na de bevalling? 
- Wat is de oorzaak van deze ernstige psychiatrische ziekte?
- Wat voor behandeling heeft deze vrouw nodig? 
- Wordt deze vrouw weer helemaal beter?
- Wat gebeurt er na een eventuele volgende zwangerschap?
Deze vragen zijn voor ons in 2005 de reden geweest om te starten met de OPPER studie, 
Onderzoeksprogramma Postpartum Psychose Erasmus MC Rotterdam. De eerste resultaten 
van dit onderzoek hebben geleid tot dit proefschrift. In dit proefschrift wordt postpartum 
psychose vanuit verschillende invalshoeken benaderd. In het eerste deel beschrijven 
we postpartum psychose vanuit een klinisch perspectief. Na een beschrijving van de 
symptomatologie en de geschiedenis worden  risicofactoren en de behandeling onderzocht. 
Dit klinisch onderzoek richtte zich ook op het voorkómen van een volgende ziekteperiode. 
In het tweede deel worden mogelijke pathofysiologische oorzaken besproken. Na een 
overzicht van het onderzoek tot nu toe komen we tot een nieuwe hypothese: spelen de 
veranderingen in het immuunsysteem na de bevalling een oorzakelijke rol bij het ontstaan 
van postpartum psychose? We hebben verschillende immuunparameters onderzocht. 
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Deel I: Klinisch perspectief
In hoofdstuk 2 geven we een klinisch overzicht. 
In de periode na de bevalling, de postpartum periode, zijn vrouwen kwetsbaar voor het 
ontwikkelen van een psychiatrische aandoening of het verergeren van een al bestaande 
psychiatrische stoornis. Ook is bekend dat opname in de psychiatrie bij vrouwen vaker in de 
postpartum periode voorkomt dan op enig ander moment in hun leven.
 Postpartum psychose (kraambedpsychose) komt na 1 à 2 per 1000 bevallingen voor. Vaak 
zijn de eerste symptomen van een postpartum psychose al in de eerste week postpartum 
zichtbaar. Na enkele symptoomvrije dagen ontstaan er bijvoorbeeld slaapstoornissen, 
prikkelbaarheid, ontremming en achterdocht. Vervolgens worden na ongeveer een week 
psychotische verschijnselen waargenomen zoals verwardheid, hallucinaties, wanen, 
gestoorde realiteitsbeleving, maar ook een wisselend bewustzijn en symptomen van manie 
of depressie. De kans op agressie naar het kind en suïcide is toegenomen. 
 Opvallend aan het gepubliceerde onderzoek naar postpartum psychose is dat er veelal 
gebruik wordt gemaakt van slecht gedefinieerde termen en inconsistente classificaties. 
Dit komt omdat postpartum psychose niet als een op zichzelf staande aandoening wordt 
beschouwd binnen het huidige classificatie systeem, de DSM-IV. In de afgelopen eeuwen 
was dit anders, er zijn talrijke historische gevalsbeschrijvingen van postpartum psychose. 
In de 19e eeuw was iedere psychiater er van overtuigd dat postpartum psychose een apart 
ziektebeeld is. 
 Vrouwen met een bipolaire stoornis (manische depressiviteit) hebben een hoog risico 
op het krijgen van een postpartum psychose. De meeste patiënten die een postpartum 
psychose doormaken hebben echter een blanco psychiatrische voorgeschiedenis. Bij deze 
groep is de postpartum psychose soms de eerste manifestatie van een onderliggende 
bipolaire stoornis. In de literatuur wordt beschreven dat dit bij 40-80% van die vrouwen het 
geval is. 
 Vanwege de ernst van beeld is opname in het geval van postpartum psychose vrijwel 
altijd nodig. In Nederland zijn in het Erasmus MC te Rotterdam, het RPC Woerden en RGC 
Apeldoorn gespecialiseerde psychiatrische afdelingen waar moeders met psychiatrische 
problemen samen met hun kind tot de leeftijd van 6 maanden opgenomen kunnen worden. 
Zo snel mogelijk na opname dient algemeen lichamelijk onderzoek en bloedonderzoek 
gedaan te worden. Uitgesloten moet worden dat er geen sprake is van een psychose 
door een onderliggende somatische oorzaak, zoals schildklierlijden, elektrolyt- lever- en 
nierfunctiestoornissen, medicatie- of middelengebruik, immunologische afwijkingen, 
infecties of neurologische ziekten. Medicatie,  structuur, optimalisering van de moeder-kind 
interactie en aandacht voor de partner en de familie van de patiënte, zijn belangrijke peilers 
van de behandeling. Verder adviseren we de schildklierfunctie en autoantistoffen tegen de 
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schildklier tijdens de postpartum psychose en 6 maanden na de bevalling te controleren. 
Er bestaan geen specifieke richtlijnen voor de medicamenteuze behandeling van postpartum 
psychose. Vanwege de relatie tussen postpartum psychose en bipolaire stoornis, kan de 
richtlijn voor de behandeling van acute manie aangehouden worden in de acute fase van een 
postpartum psychose. In het Erasmus MC Rotterdam starten wij eerst met slaapmedicatie 
(benzodiazepinen), vervolgens antipsychotica en na 2 weken voegen we lithium toe, als er 
onvoldoende respons is.
 In de literatuur is niets bekend over de behandeling van postpartum depressie met 
psychotische kenmerken. Een depressie met psychotische kenmerken buiten de kraamtijd 
wordt volgens de richtlijnen behandeld met antidepressiva. Wij hebben echter de ervaring 
dat gebruik van antidepressiva in de postpartum periode bij sommige postpartum vrouwen 
kan leiden tot een verslechtering van het klinische beeld. Wij raden daarom gebruik van 
antidepressiva af bij patiënten met een postpartum depressie met psychotische kenmerken. 
We adviseren deze groep patiënten ook te behandelen met antipsychotica en/of lithium.
In hoofdstuk 3  beschrijven we onze zoektocht naar risicofactoren voor het krijgen van 
een postpartum psychose. In het Erasmus MC hebben we het enige prospectieve cohort 
van patiënten met een eerste postpartum psychose in de wereld. We hebben 51 vrouwen 
onderzocht met een postpartum psychose, zonder manische of psychotische symptomen 
voorafgaand aan de postpartum periode. We hebben gekeken naar fenomenologische 
karakteristieken en medicatie respons. Verder hebben we obstetrische-, neonatale- en 
aan borstvoeding gerelateerde risicofactoren in deze groep vergeleken met een groot 
bevolkingscohort, namelijk het “generation R cohort”. 
 Primipariteit (het krijgen van een eerste kind) bleek een belangrijke risicofactor voor 
het krijgen van postpartum psychose. We konden geen obstetrische-, neonatale- of aan 
borstvoeding gerelateerde risicofactoren vinden. We hebben verder gevonden dat klachten 
later beginnen bij vrouwen met een eerste postpartum psychose in vergelijking tot vrouwen 
met een bipolaire stoornis. Fenomenologisch valt op dat vrouwen met een postpartum 
psychose zonder voorgeschiedenis van manie of psychose vaak psychotische symptomen 
hebben die niet overeenkomen met de stemming (stemmingsincongruent).  Alle vrouwen 
behalve één reageerden goed op onze medicamenteuze behandeling (benzodiazepine-
antipsychotica-lithium). Vrouwen met depressieve symptomen hadden gemiddeld een 
langere ziekteduur vergeleken met vrouwen met manische kenmerken.
Hoofdstuk 4 behandelt het risico op terugval na een volgende zwangerschap. Vrouwen die 
eenmaal een postpartum psychose hebben gehad, lopen een groot risico op een nieuwe 
psychose na een volgende geboorte, net als vrouwen met bipolaire stoornis. Voor beide 
groepen is het risico op een nieuwe postpartum psychose tussen de 25 en 50%. Het was tot 
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nu toe onduidelijk wanneer men precies moest beginnen met medicatie om een psychose 
na de bevalling te voorkomen. 
 In dit onderzoek werden 70 vrouwen met een hoog risico op postpartum psychose 
behandeld in een speciaal programma om te voorkomen dat ze een postpartum psychose 
mee zouden maken. 29 vrouwen die een psychose hadden doorgemaakt na een bevalling 
(maar nooit een manie of psychose buiten de kraamtijd) bleven stabiel tijdens hun huidige 
zwangerschap, zonder medicatie. Vrouwen die meteen na de bevalling starten met lithium 
of antipsychotica kregen geen van allen een psychose na de bevalling. Vrouwen die geen 
preventieve medicatie gebruikten werden in 44% van de gevallen ziek.
 In tegenstelling tot de vorige groep waren 41 vrouwen met een bipolaire stoornis helaas 
wel vaak instabiel tijdens de zwangerschap, met name de vrouwen die geen medicatie 
gebruikten. Na de bevalling kregen juist de bipolaire vrouwen die instabiel waren tijdens de 
zwangerschap vaker een postpartum psychose.
 Deze bevindingen hebben geleid tot de volgende klinische adviezen: Vrouwen met een 
bipolaire stoornis kunnen het beste continue medicatie gebruiken, tijdens zwangerschap en 
in de postpartum periode om het risico op terugval zo laag mogelijk te houden. Het gebruik 
van deze medicatie dient echter te worden afgewogen tegen de risico’s voor het ongeboren 
kind. Vrouwen met een postpartum psychose in de voorgeschiedenis (en geen psychose of 
manie op andere tijden) kunnen medicatie het beste onmiddellijk na de bevalling starten 
om terugval te voorkomen. Belangrijk is dat vrouwen met een postpartum psychose in de 
voorgeschiedenis geen medicatie tijdens de zwangerschap nodig hebben, het ongeboren 
kind wordt dus niet aan medicatie blootgesteld.
Klinische aanbevelingen
•  Het is zinvol om in de diagnostiek onderscheid te maken tussen een eerste psychose of 
manie postpartum en een postpartum psychose in het kader van bipolaire stoornis. 
• We stellen voor om patiënten met postpartum psychose te behandelen met 
achtereenvolgend benzodiazepines, antipsychotica en lithium. 
•  We adviseren bij patiënten met een psychotische depressie postpartum de richtlijnen 
te volgen voor de behandeling van bipolaire depressie. Pas op met gebruik van 
antidepressiva in deze groep, er kan een verslechtering van het beeld optreden.
•  Controle van de schildklierfunctie is van groot belang. We stellen voor om TSH, f T4 en 
TPO abs tijdens opname en 6 maanden postpartum te bepalen.
•  Een postpartum psychose preventieplan is noodzakelijk voor vrouwen met een hoog 
risico op postpartum psychose. 
•   Vrouwen met postpartum psychose of manie in de voorgeschiedenis maar geen episodes 
buiten de kraamtijd kunnen wachten met medicatie tot direct na de bevalling; zo word 
het ongeboren kind niet aan medicatie blootgesteld. 
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Deel II, pathofysiologisch perspectief
Hoofdstuk 5
Hoewel vele onderzoekers een neurobiologische oorzaak veronderstellen voor het 
acute ontstaan van psychose postpartum, is er slechts weinig onderzoek verricht met 
teleurstellende resultaten. Dit komt omdat postpartum psychose relatief zeldzaam is en 
vrouwen zó ziek zijn dat ze moeilijk te includeren zijn in onderzoek. De neurobiologie van 
postpartum depressie is veel vaker onderzocht. Dit is echter een heterogeen ziektebeeld. 
De klachten beginnen vaak al tijdens de zwangerschap en psychosociale factoren spelen 
een grote rol. Onderzoek op dit gebied heeft dan ook niet geleid tot de ontdekking van een 
uitlokkende factor die postpartum leidt tot psychiatrische ziekte.
 Postpartum psychose is een fenotypisch goed gedefinieerd ziektebeeld. Een van de meest 
consistente bevindingen in het neurobiologisch onderzoek is de genetische kwetsbaarheid 
voor postpartum psychose bij vrouwen met een bipolaire stoornis. Verder is het onderzoek 
met name gericht op de hormonale veranderingen postpartum als mogelijke oorzaak. De 
geslachtshormonen (oestrogeen, progesteron en HCG) en de stress hormonen (ACTH en 
cortisol) dalen sterk na de bevalling, de “borstvoedingshormonen”(oxytocine en prolactine) 
stijgen juist. Helaas heeft geen enkel onderzoek een relatie kunnen aantonen tussen deze 
hormonale veranderingen en het ontstaan van postpartum psychose.
Dit is voor ons de reden geweest om een alternatieve hypothese te onderzoeken zoals 
beschreven in hoofdstuk 6. Als een ziekte in de geneeskunde vaker voorkomt of vaker 
ontstaat specifiek in de periode rondom de bevalling, dan is er een associatie met 
verstoorde autoimmuniteit. Schildklierziekten, reumatische ziekten, multiple sclerose zijn 
enkele voorbeelden van ziekten waarvan symptomen vaak zichtbaar worden of verergeren 
in de kraamtijd. Zou het kunnen zijn dat postpartum psychose ook te maken heeft met een 
verstoorde (auto) immuniteit? 
 Tijdens de zwangerschap ontstaat een selectieve rem op het immuunsysteem omdat 
vrouwen anders hun kind afstoten. Na de bevalling slaat die afweer aanvankelijk door en 
ontstaat een soort overreactie. Bij sommige vrouwen, die daar gevoelig voor zijn, leidt dat 
tot het ontstaan van een auto-immuunziekte. Het lichaam maakt dan antistoffen aan tegen 
eigen cellen. 
In hoofdstuk 7 onderzochten we de schildklierfunctie van vrouwen met postpartum 
psychose en ontdekten we dat zij kort na de bevalling ruim drie keer vaker dan gezonde 
kraamvrouwen antistoffen in het bloed hebben tegen hun schildklier (19 % thyroperoxidase 
antistoffen vergeleken met 5 % bij een postpartum controle groep). Ruim twee derde 
van de kraamvrouwen met een verhoogde concentratie antistoffen ontwikkelde later 
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een schildklierafwijking. Mogelijk speelt het gebruik van lithium, wat schadelijk voor de 
schildklier is, hierbij ook een rol. Het tegelijk voorkomen van postpartum psychose en 
auto immuun schildklier ziekte is een aanwijzing voor een mogelijke gemeenschappelijke 
afwijking in de immuun cellen.
Een tweede, belangerijk argument voor het onderzoeken van een immunhypothese voor 
postpartum psychose is de uitkomst van recent onderzoek naar de bipolaire stoornis 
(manische depressiviteit). Zoals eerder genoemd is er een sterke correlatie tussen 
postpartum psychose en bipolaire stoornis: Vrouwen met een bipolaire stoornis hebben 
een heel hoog risico op een postpartum psychose na zwangerschap en vice versa blijkt 
postpartum psychose vaak het begin te zijn van een bipolaire stoornis. 
 Er zijn diverse studies die afwijkingen in het immuunsysteem beschrijven bij bipolaire 
patienten. Ontstekingsmoleculen (cytokinen) komen vaker voor in het bloed dan bij controle 
patienten en hetzelfde geldt voor verschillende soorten autoantistoffen. Verder zijn er 
afwijkingen gevonden in de aantallen T cellen. Immuun gerelateerde genen en de expressie 
van deze genen in witte bloed cellen blijken bij sommige patienten af te wijken van gezonde 
controles. 
In hoofdstuk 8 zochten we naar immuunafwijkingen in het bloed van patienten met 
postpartum psychose. We vergeleken onze patienten met gezonde controles postpartum en 
niet postpartum. We hebben naar ontstekingsmediatoren in het bloed, aantallen T cellen en 
expressie van ontstekingsgerelateerde genen gekeken.
 We hebben in dit onderzoek, net als bij eerdere onderzoeken immuun activatie gevonden 
in de normale postpartum periode. Bij vrouwen met een postpartum psychose was er sprake 
van een dysregulatie van het immuunsysteem postpartum. We vonden in de monocyten van 
vrouwen met postpartum psychose meer expressie van immuungerelateerde genen dan 
aanwezig is in de normale postpartum periode. Het aantal T cellen was lager. 
Ons toekomstig onderzoek zal ook gericht zijn op de behandeling van postpartum psychose, 
de prognose en de preventie. We zullen het effect van onze behandeling van postpartum 
psychose evalueren 9 maanden na de bevalling. Na 4 jaar postpartum hopen we iets over 
de prognose te kunnen zeggen en voorspellers van terugval/ziekte te kunnen identificeren. 
Tenslotte zijn we van plan om in meerdere ziekenhuizen de uitkomsten van postpartum 
psychose preventie plannen te evalueren. We zijn benieuwd of antipsychotica net zo 
goed werken als lithium voor preventie van postpartum psychose. Verder verzamelen we 
gegevens over lithium en antipsychotica gebruik bij bipolaire zwangeren wat ons in staat 
stelt het effect van de medicatie op moeder en kind te onderzoeken. 
 We hopen in toekomstig onderzoek beter te kunnen voorspellen welke vrouwen een 
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eenmalige postpartum psychose doormaken en welke vrouwen meerdere manische, 
psychotische of depressieve episodes gaan doormaken.  Bij deze laatste groep is de 
postpartum psychose, achteraf gezien het begin geweest van een bipolaire stoornis.
 We zullen daarom niet alleen naar klinische karakteristieken zoeken die beloop 
voorspellen maar ook naar verschillende merkers in het bloed. We zullen ook genetisch 
onderzoek doen omdat we denken dat immunologische of hormonale mechanisme alleen 
tot ziekte leidt bij vrouwen die daar genetisch gevoelig voor zijn. Genetisch onderzoek is 
alleen zinvol bij grote groepen patienten (of bij families). Dit genetisch onderzoek zullen we 
dan ook in samenwerking doen anderen. Uiteindelijk hopen we dat dit type onderzoek leidt 
tot een manier om de start van bipolaire stoornis in de kraamtijd te voorkomen, dan wel het 
ziektebeloop gunstig te beinvloeden. 
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Het krijgen van een kind, zeker voor de eerste keer, is een ingrijpende gebeurtenis. Vrouwen 
die in deze tumulteuze periode ook nog eens ernstig psychiatrisch ziek worden hebben wel 
wat anders aan hun hoofd dan meedoen aan onderzoek. Daarom vind ik het heel bijzonder 
dat er zoveel vrouwen hebben meegedaan aan het onderzoek en wil ik jullie als eerste 
bedanken.
Mijn promotoren wil ik graag bedanken. Hemmo Drexhage, het vernieuwende onderzoek 
van jouw groep naar de immunologie van de bipolaire stoornis is de basis geweest van 
de “immuun hypothese van postpartum psychose”. Je hebt me meteen opgenomen in 
je onderzoeksgroep en me later de verantwoordelijkheid gegeven voor het postpartum 
gedeelte van “Moodinflame”. Jij hebt me veel geleerd over immunologie. Ik hoop de prettige 
samenwerking nog lang te continueren. 
 Michiel Hengeveld, je hebt me als jonge psychiater aangenomen en me de vrijheid 
gegeven om onderzoek op te zetten. Onze samenwerking was prima maar toch heb je het 
stokje overgegeven aan Steven, omdat je wilde investeren in het onderzoek op de lange 
termijn. Je bent gelukkig nog steeds erg betrokken en geïnteresseerd in het reilen en zeilen 
van onze afdeling en in de ontwikkelingen in de zwangerschapsgerelateerde psychiatrie.
 Steven Kushner, jij bent halverwege ingestapt als promotor en je hebt meteen 
geïnvesteerd in tijd, energie en menskracht. Verbazingwekkend hoe snel je was ingelezen 
en ingewerkt in zowel de perinatale psychiatrie als de relevante delen van de immunologie, 
zodat je inhoudelijk snel mee kon denken. Ik leer veel van je zorgvuldige manier van werken, 
schrijven, wetenschap bedrijven en je creatieve ideeën. Ik verheug me op een langdurige 
samenwerking.
 Witte Hoogendijk, als afdelingshoofd gaf je direct je vertrouwen in “Womens Mental 
Health” (jij hebt deze term geïntroduceerd). Ik ben heel blij met jouw ambitie om onze 
zwangerschapsgerelateerde zorg en het OPPER onderzoek uit te breiden en ik kijk uit naar 
onze samenwerking.
 Psychiaters Mijke van den Berg, Annemarie van Hulst, Monique Raats en Esther Knijff, 
jullie hebben me enorm geholpen bij de opzet van het onderzoek. Mijke, jou wil ik bedanken 
voor je hulp bij het design en de logistiek, Annemarie, je hebt jarenlange klinische expertise 
overgedragen, Monique, je zorgt voor de goede samenwerking met de afdeling gynaecologie 
en Esther, je hebt me de translationele weg gewezen naar de immunologie. Kathelijne 
Koorengevel, het is een groot genoegen om dagelijks met je te mogen samenwerken in 
de kliniek en aan onderzoek. Paul Bouvy, dank voor je hulp als vliegende keep in de kliniek 
en de opzet van de preventiestudie. Robert-Jan Osse, Tom Birkenhäger, Walter van den 
Broek, Esther Pluijms, Christian Röder, Sabine Roza, Marjolein Bannink en Nico van Beveren, 
bedankt voor jullie collegialiteit, relativeringsvermogen en gevoel voor humor. 
Goed klinisch psychiatrisch onderzoek is alleen mogelijk als de klinische zorg uitstekend 
is. Dit is het geval dankzij een heel goed en sterk team. Elly, Yolanda, Ans, Alex, Brenda, 
Bianca, Diana, Esther, Jolanda, Maaike, Mabel, Marja, Mariëlle, Marjolein, Mirjam, Nelly, 
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Martin, Norma, Nicola, Remco, Saskia, Vera, Walter, Monica, Ruud, Christina, John en Joke, 
de studenten op de babykamer en de psychiaters in opleiding wil ik van harte bedanken.
 Een aantal studies uit dit proefschrift kon uitsluitend tot stand komen dankzij de expertise 
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